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Abstract
Particle-mediated DNA delivery (PMDD) is a technique that uses compressed helium gas 
to accelerate microscopic gold beads coated with DNA into the skin. As a vaccination tool, 
it provides an attractive approach for generating antigen specific immunotherapy. As the 
number of applications for this technology in pre-clinical disease models grows, the need 
for in vitro surrogate models, which in part, can replace in vivo testing, is becoming 
increasingly important. Additionally, before it can be utilised successfully in man, a 
number of critical parameters which contribute to overall efficacy in vivo need to be more 
fully evaluated. To these ends, an in vitro model which featured PMDD as the means of 
plasmid delivery was developed. The relationship between the efficiency of PMDD to 
stimulate antigen specific CD8+ T cell responses in vitro and in vivo under conditions of 
single and dual plasmid immunisation was explored. Important aspects of the technology 
such as the association between antigen dose and resulting response were investigated. It 
was found that the in vitro model correlated well with the early stage primary response in 
vivo but this correlation deteriorated post boost. In addition, the relative contribution of 
antigenic competition and co-operation in shaping the resulting response was assessed after 
co-immunising with two independent antigens. Under the experimental conditions 
investigated, the dominant type of interaction was found to be competitive. Results 
suggested that competition occurred at the level of the T cell. Competition was most 
pronounced when both antigens were delivered in a linked manner and when both antigens 
were presented on the same APC. These results highlight the requirement for optimising 
key technical parameters in PMDD. Additionally, it demonstrates that interclonal T cell 
competition is a functionally relevant phenomenon and that it can occur when standard 
DNA vaccination strategies are employed.
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Chapter 1: General introduction
1.1. Introduction
The physiological function of the immune system is protection against infectious agents. In 
order to achieve this, the immune system has evolved sophisticated methods of recognising 
and eliminating these agents. The product of the immune system is termed the immune 
response and is broadly divided into two categories; the innate immune response and the 
adaptive or acquired immune response. They consist of uniquely different components and 
as separate mechanisms of defence, are extremely effective. The type and severity of 
invading pathogen dictates the most suitable type of response launched. More often than 
not, an effective immune response incorporates elements from both systems which interact 
in a co-ordinated and synchronised manner to remove the pathogen and restore health.
Vaccination provides a powerful tool to amplify and integrate aspects of both the innate and 
adaptive immune response in order to eliminate pathogens. In this regard, the emerging 
field of DNA vaccination employs a broad and varied number of strategies in order to elicit 
appropriate immune responses in prophylactic and therapeutic settings. Here, the 
contribution of one form of DNA vaccination; particle-mediated DNA delivery (PMDD) is 
discussed.
1.2. Innate immune response
Innate immunity is the phylogenetically oldest mechanism of defence against foreign 
pathogens. Through the last number of decades, it was widely believed to be relatively non­
specific in its recognition and effector functions. However, recent evidence suggests that 
innate immunity is much more specific and well defined than first imagined (Janeway and 
Medzhitov, 2002). It is most important in the early stages of infection and is primarily 
mediated by sub-populations of leukocytes, particularly monocytes, macrophages and 
natural killer (NK) cells.
21
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1.2.1. Innate recognition
Mononuclear and polymorphonuclear phagocytes possess a certain number of receptors 
which are dedicated to recognising conserved microbial molecules common to many 
microbial species (Kimbrell and Beutler, 2001). These molecules are usually indispensable 
components of the microbe which are not prone to alteration or mutation and thus constitute 
preserved targets for the innate response. The receptors used to recognise these targets are 
referred to as pattern recognition receptors (PRRs) and the structural features of the 
microbe which are recognised are the pathogen associated microbial patterns (PAMPs) 
(Werling and Jungi, 2003). One of the most well-known groups of proteins which act as 
PRRs are the Toll-like receptors (TLRs). These are type I integral membrane glycoproteins 
with ectodomains consisting of leucine rich repeats which form the PAMPS and a 
cytoplasmic tail sharing homology with the signalling domain of the IL-1 family (O’Neill, 
2002). To date, the TLR family consists of 13 members, 10 of which (TLR1-TLR10) have 
been identified in humans (Chuang and Ulevitch, 2001). Of these, TLR1-TLR6 are cell 
surface expressed while TLR7-TLR9 are found intra-cellularly. They bind to a wide range 
of ligands such as peptidoglycan (TLR2), unmethylated DNA (TLR9), dsRNA (TLR3), 
ssRNA (TLR7), bacterial flagellin (TLR5) lipopolysaccharide (TLR4) and lipoteichoic acid 
(TLR2) (Netea et al., 2004). While some of these receptors operate on their own, others 
combine with each other to form heterodimeric complexes. Examples of such complexes 
are those formed by TLR1/2 (Wetzler, 2003), TLR2/6 (Hajjar et al., 2001) and TLR4/5 
(Mizel et al., 2003) which serve to extend the repertoire of specificities of molecules 
recognised.
Once activated, the predominant signalling pathway used by TLRs involves recmitment of 
cytoplasmic adapter proteins like myeloid differentiation primary-response protein 88 
(MyD88), IL-1R-associated kinases (ERAKs) and TNF-receptor-associated factor 6 
(TRAF6) (Takeda and Akira, 2004). The activated signalling cascade causes the 
phosphorylation and degradation of IkB resulting in the nuclear translocation and activation 
of NF-kB. The genes that are expressed in response to TLR activation are cell line 
dependent but include anti-viral cytokines such as type I interferons, the inflammatory
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cytokines EL-1, IL-12 and TNF-a as well as adhesion molecules (E-selectin) and proteins 
involved in microbial killing (reactive oxygen intermediates such as nitric oxide) (Ozato et 
al., 2002).
Another family of proteins which recognise PAMPs are the nucleotide binding 
oligomerization domain (NOD) proteins. These are cytosolically localised proteins which 
recognise peptidoglycan structures that are not ligands for TLRs (Girardin et al., 2003). 
Signalling events for these receptors are mediated by members of the caspases family and 
also result in activation of NF-kB (Martinon and Tschopp, 2004). Other PRRs include 
mannose receptors which specifically recognise glycoproteins with terminal mannose or 
fucose residues and scavenger receptors which bind to oxidised or acetylated low density 
lipoproteins (Linehan et al., 1999). Different types of G protein coupled receptors (also 
called seven transmembrane a-helical receptors) are expressed on leukocytes and bind to 
ligands containing A-formylmethionyl residues. Some G protein coupled receptors also 
bind to proteins of the complement cascade such as C5a (Vanek et al., 1994), the neutrophil 
attractant IL-8 (Holmes et al, 1991) and a range of inflammatory mediators including 
prostaglandin E (Fujino and Regan, 2003), leukotriene B4 (Schepers and McLeish, 1993) 
and platelet activating factor (Lukashova et al., 2001).
1.2.2. Innate effector function
Innate effector function is mediated by a number of components which may be broadly 
divided into two different categories. First is the cellular arm which includes the 
mononuclear/polymorphonuclear and NK cells. Once activated, neutrophils and 
macrophages kill the ingested microbes by the co-operative activity of synthesised reactive 
oxygen and nitrogen intermediates (Alvaraz-Dominguez et al., 2000; Akaki et al., 1997). 
These cell types also produce several proteolytic enzymes such as elastase which function 
to kill ingested microbes (Ribeiro-Gomez et al., 2004). Macrophages fulfil the additional 
duties of recruiting other myeloid cells to the site of infection by release of TNF-a and IL-1 
(Gao and Tsan, 2004) and activating NK and T cells by secretion of IL-12 (Xing et al., 
2000). NK cell activation is regulated by the balance of expression of stimulatory and
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inhibitory receptors on its surface. Following activation, these cells destroy infected or 
malignant cells by interacting with the adaptive immune response in a process known as 
antibody dependant cellular cytotoxicity (ADCC) or by the sequential release of perforin 
and granzymes which create pores in the membrane of the target cell and induce apoptosis, 
respectively (Jie and Sarvetnick, 2004).
Second are the soluble mediators of the innate response which include plasma proteins and 
the complement system. These include the mannose binding proteins which opsonise 
carbohydrates with terminal mannose or fucose residues and activate the complement 
cascade via the lectin pathway (Super and Ezekowitz, 1992). The C reactive proteins bind 
to phospholipids of pneumococcal bacteria and activate the classical complement pathway 
via Clq ligation or may bind directly to Fc-y receptors (Mortenson, 2001). Another 
important component of innate immunity which serves to remove foreign pathogens is a 
group of plasma (and cell surface) proteins collectively known as the complement system. 
There are three major pathways of complement activation all of which lead to the 
congregation of C6, C7, C8 and C9 proteins at the surface of the invading micro-organism. 
These proteins form a membrane attack complex (MAC) and result in lysis of the target 
micro-organism (Fujita et al., 2004).
13. The adaptive immune response
While innate immunity is primarily characterised by lack of immunologic memory and to a 
lesser extent lack of specificity, these attributes are the signature of the adaptive response. It 
is mediated by lymphocytes (i.e. B and T cells), initiated by interaction with antigen 
presented to these cells by professional APCs such as DCs and improves with each and 
every antigenic encounter.
Specifically, this review focuses on the role of DCs in the adaptive immune response 
(Section 1.3.1), the activation of CD8+ and CD4+ T cells in the secondary lymphoid organs 
and the effector functions of these cells once activated (Sections 1.3.2 and 1.3.3, 
respectively). Additionally, the dichotomous relationship between CD8+ and CD4+ T cells
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during the primary and memory phases of the immune response is discussed in Section 
1.3.5 with particular emphasis on PMDD.
1.3.1. Dendritic cells
DCs represent a heterogeneous population of cells with different phenotypes and functions 
and are located in different anatomical locations (Shortman and Liu, 2002). In humans, they 
develop from bone marrow derived CD34+ hematopoietic cells and differentiate along 
different pathways into myeloid or plasmocytoid (lymphoid) DC (Ardavin et a l, 2001; 
Banchereau et al., 2000). The myeloid subset are phenotypically defined as CD14- or 
CD14iow, CDllc+, CDla+ cells and include the monocyte-derived interstitial and 
Langerhans type DCs (Liu et a l, 2001). Of particular importance in PMDD are the 
Langerhans cells. These cells are defined by the expression of Langerin (Henri et a l, 2001) 
and are involved in the presentation of antigens that enter the body through the skin 
(Lappin et a l, 1996; Romani et al, 2001). The plasmocytoid subset is found in the thymus, 
blood and tonsils and is characterised by expression of CD 123, CD45RA and absence of 
the CDllc marker (Celia et a l, 1999). Human myeloid and plasmocytoid are also referred 
to as DC1 and DC2 since they were once believed to direct Thl and Th2 differentiation, 
respectively (Rissoan et a l, 1999). Both subsets express high levels of MHC class II and 
are thus considered potent antigen presenting cells (Mellman et al, 1998). Similar DC 
subsets exist in the mouse but the myeloid subset may be further subdivided based on the 
expression of CD8a (Kamath et al, 2000). However, this means of delineation requires 
further clarity as there is evidence suggesting that CD8a is a marker of maturation status 
and not lineage (Martinez del Hoyo et a l, 2002).
1.3.1.1. Dendritic cell activation, maturation and migration
In the non-lymphoid tissues, DCs predominately exist in the immature form where they are 
highly phagocytic but are inefficient in their antigen processing and T cell activation ability 
(Celia et al, 1997). They are activated by exogenous and endogenous danger signals such 
as pathogen related products or inflammatory cytokines (Ulevitch, 2000; Schnurr et al,
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2000). For example, DCs express a wide range of TLRs (see Section 1.2.1) which when 
bound to their cognate ligands signal cell maturation (Akira, 2003). Immature DC expresses 
other receptors such as macrophage receptor with collagenous structure (MARCO) and 
DEC205 (CD205) (Swiggard et al., 1995; Kraal et al., 2000) which interact with 
microbially derived structures. In this respect, DCs form a vital link between innate and 
adaptive immunity. The source of the pathogenic stimulus impacts on the type of resulting 
response, with E.coli derived LPS (interacts with TLR4) inducing a Thl-type response 
while S.aureus derived peptidoglycan (interacts with TLR2) provoking a Th2-type 
response (Pulendran et al., 2001; Re and Strominger, 2001). Bystander cells resident at the 
site of infection also influence the resulting response. NK cells secrete EFN-y which 
promotes Thl differentiation via IL-12 production in maturing DC while EL-10 released by 
macrophages can lead to the suppression of IL-12 and results in Th2 differentiation 
(Mailliard et al., 2003; Moore et al., 2001).
Immature DC moving into sites of infection are characterised by expression of a number of 
chemokines receptors including CCR2 and CCR6 (which bind to monocyte chemotactic 
protein (MCP) and macrophage inflammatory protein (MEP-3a), respectively (Vanbervliet 
et al., 2002). They also express CCR1, CCR5 and CXCR1 which bind to number of 
chemokines released by macrophages after activation with microbial products such as MEP- 
la , CCL5 and EL-8 (Dieu et al., 1998; Stumbles et ah, 2001; Sallusto et al., 1998). 
Subsequent encounters with antigen lead to down regulation of the inflammatory 
chemokines receptors and a down regulation of phagocytic activity (Celia et al., 1997). 
During the course of maturation, the DCs become more responsive to chemokines produced 
in the secondary lymphoid tissue such as CCL19 and CCL21 (Saeki et al., 1999) as well as 
up-regulating cell surface expression of CCR7 which mediates homing of T cells to the 
secondary lymphoid organs (Willimann et al., 1998). The maturation process and the 
subsequent migration through the afferent lymphatics to the T cell areas of the local 
lymphoid tissue brings about an increase in cell surface expression of co-stimulatory 
molecules CD80 and CD86 as well as up-regulation of MHC class I and II which fine tunes 
the DC for antigen processing and presentation (Banchereau et al., 2000).
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1.3.1.2. Antigen processing pathways
Once resident in the paracortical regions of the draining lymph node, the primary 
responsibility of DCs is the activation of the appropriate response. This is determined in 
part by the route of antigenic processing within the DC and consequently, by the context in 
which the resulting peptides are presented. For MHC I restricted presentation, 
biosynthesised protein is primarily degraded into smaller peptides by the proteasome which 
are transported by the antigen associated with antigen processing (TAP) into the lumen of 
the endoplasmic reticulum (ER) (Lankat-Buttgereit et al., 2002). There, TAP associates 
with the MHC I-P2 dimer through interactions with the ER resident chaperones calnexin, 
calreticulin and tapasin (Cresswell et al, 1999) and the stable class I complex is transferred 
to the cell surface via the Golgi. Class II peptide presentation is predominately associated 
with peptides derived from exogenous proteins acquired by endocytosis or from 
internalised plasma membrane proteins (Watts, 2004). MHC II a  and (3 dimers combine 
with invariant chain (Ii) in the rough ER and pass through the Golgi to endosomal and 
lysosomal compartments. The Ii is degraded by several proteolytic enzymes of the 
cathespin family (Villadangos et al., 1999), allowing the MHC class II molecules to bind to 
antigenic peptides and get transported to the plasma membrane.
An alternative mechanism for class I antigenic presentation is cross-presentation (Bevan, 
1976). The two main intracellular pathways involved in cross-presentation result in ER or 
endocytic peptide loading and are TAP dependent and independent, respectively (Yewdell 
et al., 1999). The TAP dependent pathway appears to be the dominant route in DC 
(Regnault et al., 1999; Norbury et al, 1997) while TAP independent cross-presentation has 
been reported in macrophages (Castellino et al., 2000). In addition to class I and II 
presentation, DC express CD1 proteins which are capable of presenting antigen to T cells 
(Porcelli and Modlin, 1999). Surface expressed CD1 molecules are internalised and 
directed to the endocytic pathway where they associate with glycolipidic antigens of 
endogenous and exogenous origin (Jayawardena-Wolf and Bendelac, 2001). CD1 
molecules resident on the DC cell surface are also capable of antigen association (Briken et 
al., 2000).
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1.3.1.3. Lymphocyte activation begins at the immunological synapse
Before T cell activation occurs, naive T cells interrogate the surface of the DC for the 
MHC/peptide complex specific for its TcR. This interrogation requires the assembly of 
clusters of receptors on both cell types in very close proximity at an interaction site referred 
to as the immunological synapse (IS) (see Figure 1). This is a dynamically active structure 
characterised by a central region of interaction called the central supramolecular activating 
complex (c-SMAC) surrounded by a peripheral zone or p-SMAC (Monks et al, 1998). The 
components of the IS are dependent on the synaptic partners involved but typically, the c- 
SMAC consists of one or more clusters of CD3/TcR/co-receptor-MHC/peptide and CD28- 
CD80/CD86 complexes while a number of integrins and their ligands such as lymphocyte 
function associated molecule-1 (LFA-l)-intracellular adhesion molecule 1 (ICAM-1) 
occupy the p-SMAC (Grakoui et al., 1999). Larger molecules such as the sialoglycoprotein 
CD43 and the protein tyrosine phosphatase CD45 (both important for lymphocyte 
differentiation) are sterically excluded from the central activation zone (Leupin et al., 2000; 
Roumeir et al., 2001). The duration of the synapse is also dependent on the interaction 
partners and can last for many hours (-10-12) or just minutes (-2-20) for Th and CTL cells, 
respectively (Iezzi et a l, 1998; Stinchcombe et al, 2001b).
Intuitively, one would expect that the primary function of the IS is to provide a suitable 
environment for TcR signalling and T cell activation. However, its exact function is 
unresolved. There is evidence suggesting that it is not involved in initiating TcR signalling 
with TcR signalling events happening before mature IS formation (Lee et al, 2002). 
Postulated alternative roles include the polarisation of cytokines specific to the type of 
activated T cell (Stinchcombe et al, 2001a), facilitating the transfer of APC derived MHC- 
peptide complexes to CTL (Huang et a l, 1999) and in the case of DC-T cell interaction, 
conditioning the T cell for activation upon recognition of the appropriate MHC/peptide 
complex. The latter idea is supported by the finding that DC is the only immunologic cell 
type that can maintain the IS in the absence of specific antigen (Revy et al, 2001).
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Initially, association of TcR/CD3, CD4/CD8 and CD28 with their respective binding 
partners is accompanied by internal cytoskeletal activity such as the movement of the 
microtubule organising centre to a position close to the synapse in the activating T cell 
(Kupfer et al., 1991) and in the DC (Al-Alwan et al., 2003). Rearrangement of the T cell 
cytoskeleton facilitates recruitment of further TcR/CD3 and CD28 complexes into the 
synapse from other areas on the cell surface (Moss et al., 2002). Cell to cell dialogue 
instructs the DC to direct recently processed antigen to the antigen specific IS reinforcing 
the original stimulus and maintaining the synaptic structure (Chow et al., 2002). CD28 
ligation contributes to T cell activation by lowering the threshold of stimulated TcR 
required for a given response (Viola and Lanzavecchia, 1996) and by converting a weak 
MHC/peptide signal into a strong one (Manickasingham et al., 1998). Furthermore, it is 
important for stimulating IL-2 and IL-12 receptor expression (Schweitzer et al, 1998). 
Other receptors are recruited to the IS at later time-points such as negative regulator of 
activation, cytotoxic T lymphocyte associated antigen-4 (CTLA-4) (Carreno et a l, 2000) 
and members of the TNF receptor family such as 0X40 (CD134), 4-1BB (CD137) and 
CD27 (Paterson et al., 1987; Kwon et al., 1989; Bigler et al, 1988, respectively). In 
particular, the induction of 0X40 and 4-IBB on T cells after synaptic formation (-24 
hours) corresponds with their primary functions of maintaining cell division initially 
regulated by CD28 and preventing cell death in the late primary response of activated 
CD4+ and CD8+ T cells, respectively (Rogers et al., 2001; Cooper et al., 2002).
1.3.1.4. Initiation of T cell signalling
Ligation of the TcR activates the lymphocyte-specific protein tyrosine kinase p56Lck 
which phosphorylates specific residues within immunoreceptor-based tyrosine activation 
motifs (ITAMs) on CD3 and TCR£ chains (Sunder-Plassmann et al., 1997). This results in 
the phosphorylation and recruitment of zeta associated protein-70 (ZAP-70) to the TcR/Lck 
complex (Weiss and Littman, 1994) where it subsequently phosphorylates a number of 
adaptor proteins such as linker for activation of T-cell signalling (LAT) and SH2-domain- 
containing leukocyte protein of 76 kDa (SLP-76) amongst others (Jordan et al., 2003). The 
end result is calcium mobilisation which activates several transcription factors including
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nuclear factor of activated T cells (NF-AT) (Rooney et al., 1994) and NF-kB (Jmieson et 
al., 1991). These signalling pathways result in the activation of genes required for T-cell 
proliferation and differentiation as well as the synthesis of important cytokines and 
chemokines (Kuo and Leiden, 1999). In addition to these shared signalling pathways, type 
specific transcription factors are activated such as T-bet and GAT A binding protein-3 
(GATA-3) which play a role in the onset of Thl and Th2 type immunity, respectively 
(Szabo et al., 2000; Zheng and Flavell, 1997). Furthermore, thymopoeisis studies have 
identified that duration of signalling events also serve to differentiate between various T 
cell subsets (Yasutomo et al., 2000). The differentiation of naive T cells into CD8+ and 
CD4+ effectors is represented in Figure 1.
1.3.2. Activation of CD8+ T cells
Once activated, CD8+ naive lymphocytes develop into effector CTL and central and 
effector memory cells. The pathways of differentiation that create these populations are 
unclear with evidence for both “linear” (antigen induced differentiation of naive T cells into 
cytotoxic effectors followed by survival of a specific subset to form memory cells) and 
‘branched” (antigen induced differentiation leads to the separate induction of effector and 
pre-memory lineages) differentiation models (Kaech et al., 2002a).
1.3.2.L Tel andTc2 CD8+ effectors
CD8+ effectors are characterised by their ability to induce target cell apoptosis via specific 
effector mechanisms (i.e. effector CTL) and/or cytokine secretion (Figure 1). During a 
vigorous response to virus, a large effector response is established (Whitmire et al., 2000). 
Several cell divisions are required (>8-10) before a naive CD8+ T cell can become a 
functionally active CTL with each division cycle occurring approximately every 6-8 hrs 
(Opferman et al., 1999). The two main pathways responsible for effector activity in 
functional CTL are the perforin dependent granule exocytosis and the Fas ligand (FasL)/Fas 
pathway (Russell and Ley, 2002). In the former mechanism, perforin and granzymes stored 
in lysosomal secretory granules are secreted at the centre of the immunological synapse in a
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process regulated by the GTP binding protein rab27a (Stinchcombe et a l, 2001a). Death of 
the target cell requires perforin dependent plasma membrane permeabilization followed by 
granzyme A and B proteolysis of key cytoplasmic proteins (Beresford et al., 1999; Darmon 
et al., 1995). For the latter, TcR ligation results in FasL expression on the surface of CTL 
which bind to target cell expressed Fas molecules and activate enzymes that lead to 
apoptosis of the infected cell by destmction of its structural cytoskeleton proteins and by 
chromosomal degradation (Sharma et al., 2000). Analogous to CD4+ T cells, CD8+ 
effector subsets may be characterised by their cytokine secretion patterns. These include 
Tel cells which are defined by production of EFN-y and Tc2 cells which predominately 
secrete IL-4 and IL-5 (Mosmann et al, 1997). Naive CD8+ cells exhibit a preference for 
Tel differentiation especially in the presence of EL-12 and IFN-y. However, Tc2 
development can occur when IL-4 is available in large amounts (Sad et a l, 1995; Noble et 
al, 2001; Croft et a l, 1994). The latter population provides B cell help albeit at lower 
levels than that provided by Th2 cells (Maggi et al, 1994; Cronin et a l, 1995). In humans, 
CD8+ effectors may also be defined by CD45RA expression coupled with the absence of 
CD27 expression (Hamann et al, 1997).
1.3.2.2. Linear or branched differentiation?
Two different models are used to explain the relationship between CD8+ effector and 
memory populations. The most popular hypotheses is the linear model in which naive T 
cells, in response to antigen differentiate into CD8+ effectors followed by a subsequent 
progression of a specific subset into memory cells (Kaech et al, 2002b). By following the 
transcriptional and functional profile of effector and memory cells, Kaech and colleagues 
(2002a) obtained heterogeneous gene expression patterns demonstrating a dynamic and 
progressive shift from an effector phenotype toward the memory phenotype over the course 
of an immune response. The progression of CD8+ effectors into memory cells is reflected 
in the observation that both populations have a similar spectrum of TcR specificities 
coupled with similar patterns of cytokine secretion (Liu et a l, 1997). These data are further 
supported by findings of Jacob and Baltimore (1999), Opferman et a l  (1999) and Wherry 
et a l  (2003) all of whom suggest memory development as the product of a progressive
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differentiation programme. In contrast, others have demonstrated that CD8+CD62Liow and 
CD8+CD62Lhigh CD45RO+ memory populations were dissimilar suggesting that effector 
and memory populations are independently derived and are not inter-convertible (Baron et 
al, 2003).
1.3.2.3. CD8+ Tcm and/or TEm phenotypes
Following the effector phase, a memory CD8+ population forms which is maintained in the 
absence of antigen (Lau et al., 1994; Murali-krishna et al., 1999). Typically, these cells are 
divided into central memory (TCm) and effector memory (TEm) cells, characterised by the 
differential expression of CCR7 and different homing molecules as well as presence or 
absence of effector function (Sallusto et al., 1999). Tcm cells predominately reside in the 
lymphoid tissues and are CCR7+CD62LHigh while TEm cells circulate in non-lymphoid 
tissues, have lost expression of CCR7 and are heterogeneous for CD62L expression. In 
humans, memory is additionally distinguished by expression of CD45RA with TCm and TEM 
cells expressing low and no levels of this cell surface marker, respectively (Urbani et al., 
2002). There is evidence for and against Tcm effector function in both human (Hislop et al., 
2001; Rakov et al., 2003) and in mouse (Unsoeld et al, 2002; Masopust et al., 2001). In 
contrast, human and murine TEM cells exhibit consistent levels of cytotoxic effector activity 
(Hamann et a l, 1997; Sallusto et al., 1999). The latter memory subset expresses adhesion 
molecules and chemokine receptors which target these cells to specific tissues. These 
include cutaneous associated lymphocyte antigen (CLA) and CCR4 which direct TEm cells 
to the skin (Campbell et a l, 1999) and a4|37 and CCR9 (Zabel et a l, 1999) which identify 
gut homing TEm cells.
Whether the Tcm and TEm subsets are mutually exclusive memory subpopulations is 
unclear. Data from a murine LCMV model suggest a reciprocal conversion between subsets 
which was dependent on the physiological conditions encountered (Wherry et al., 2003) 
while others report that TEm cells are the end product of memory (Champagne et a l, 2001; 
Migueles et al, 2002). In apparent contradiction, analysis of CD8+ T cells in human
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peripheral blood led Baron et al. (2003) to suggest that T cm  and T em  are largely 
independent subpopulations.
1.3.2.4. Regulating differentiation and maintenance of memory
There are a number of factors which determine the fate of CD8+ memory cells including 
those which regulate the differentiation of CTL into memory and those which maintain the 
memory subpopulations. CD4+ help through CD40/CD40L ligation is important for 
promoting differentiation into memory cells (Bennett et al., 1998; Whitmire et al., 1996; 
Johansen et al., 2004) and maintaining memory (Cardin et al., 1996; Janssen et al., 2003). 
The pro-survival proteins B-cell lymphoma 2/3 (bcl-3, bcl-2) have been implicated as 
possible regulators of a prolonged effector response and in the induction of memory 
(Grayson et al., 2000; Mitchell et al., 2001). The generation of effectors and maintenance 
of memory are also influenced by various factors including the strength (i.e. antigen 
concentration) and duration of TcR signalling (Tanchot et al., 1997; Iezzi et al., 1998), low 
DC/T cell ratios during activation (Langenkamp et al., 2002) and co-stimulatory molecules 
like 4-1BB (Diehl et al., 2002; Shedlock et al., 2003). Cytokines such as IL-7 are extremely 
important survival factors for memory CD8+ cells (Goldrath et al., 2002; Schluns et al., 
2000) while IL-15 is critical for survival and proliferation of these cells (Fehniger et al., 
2001; Ku et al., 2000; Schluns et al., 2002). Furthermore, IL-21 has been implicated in the 
induction of the T cm  phenotype (Eberl et al., 2002). Finally, as a negative regulation 
mechanism of memory, IFN-a mediated cell death of existing CD8+ memory cells can 
occur when new CTL responses of different antigen specificity emerge (Varga et al., 2001; 
McNally et al., 2001).
1.3.3. Activation of CD4+ T cells
Presentation of peptide-MHC II complexes to naive CD4+ T cells by APCs triggers a cell 
proliferation and differentiation programme leading to the development of either Thl or 
Th2 effectors, defined on the basis of the cytokines they produce and by their immuno­
modulatory behaviour (Murphy et al., 2000). The Thl phenotype predominately produces
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EFN-y but also secretes lymphotoxin and is a key component of cell-mediated immunity 
(Mosmann et al., 1986; Mosmann and Coffman, 1989). Th2 cells secrete IL-4, IL-5, IL-10 
and IL-13 which mediate B cell immunity and antibody production (O’Garra, 1998; 
Romagnani, 1994). Typecasting the effector response in this way may be an over­
simplification however as others have demonstrated heterogeneity of effector CD4+ cells 
even within polarised effector populations (Kelso et al, 1999; Openshaw et al., 1995). This 
heterogeneity is a result of the complex interactions of different cytokines (O’Garra, 1998), 
cell-signalling proteins (Murphy et al., 2000) and transcription factor and chromatin 
remodelling events (Agarwal and Rao, 1998) which occur during the activation process. 
Proliferation is also influenced by other factors including the type and maturity of the APC 
(Celia etal., 2000), antigen dose, (Ruedl et a l, 2000), presence of co-stimulatory molecules 
(Corry et al., 1994) and the requirement for DNA replication (Richter et al., 1999; Laouar 
and Crispe, 2000). Within a population of activated CD4+ cells, a certain proportion 
secretes EL-2 and possesses the ability to differentiate into either Thl or Th2 depending on 
the conditions of subsequent stimulation (ThO) (Openshaw et al., 1995). Others have 
mRNA expression of markers denoting Thl or Th2 cells and are committed to either 
lineage after subsequent stimulation while some cells can secrete Thl/Th2 specific 
cytokines immediately after activation (Wu et al., 2002; Wang and Mosmann, 2001; 
Lanzavecchia and Sallusto, 2000). Currently, there is an ongoing debate on whether naive 
CD4+ cells are instructed or selected to mature into polarised Thl or Th2 effector cells 
(Reiner and Seder 1999). Here, the CD4+ helper response is discussed in terms of the 
classical Thl/Th2 paradigm.
1.3.3.1. Thl commitment
Thl cells produce IFN-y and play an important role in cell mediated immunity by activating 
macrophages to release pro-inflammatory cytokines and to eliminate intracellular 
pathogens (Bogdan et al., 1991). The central cytokine associated with Thl cell 
development is IL-12 (Manetti et al., 1993). It is a heterodimeric cytokine composed of p35 
and p40 subunits (Trinchieri and Scott, 1999) and is produced by a wide range of DC after 
appropriate stimulation (e.g. interaction of myeloid DC expressed TLR2 and TLR4 with
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peptidoglycan and LPS, respectively) (Boonstra et al., 2003). It binds to the EL-12(31 and 
IL-12(32 receptor on CD4+ T cells and activates the Signal Transducer and Activator of 
Transcription (STAT) pathways (Rogge et al., 1997; Szabo et al., 1995). Indeed, 
expression of the IL-12(32 receptor is considered a marker for Thl differentiation as Th2 
cells do not express this receptor due to direct activity of IL-4 (Sinigaglia et al., 1999). 
Mice deficient in IL-12 (Magram et al., 1996) and STAT-4 (Thierfelder et al., 1996) have 
substantially reduced EFN-y production and Thl responses. IL-18 augments the activity of 
EL-12 in Thl development and can work together with EL-12 to induce EFN-y production in 
differentiating and effector Thl cells. Indeed in fully committed Thl cells, no TcR-CD4 
activation signal is required when EL-12/EL-18 are present (Robinson et al., 1997).
Other important cytokines include the type 1 EFNs which play a role in promoting Thl 
differentiation by working together with TcR activation (Nguyen et al., 2002) and EFN-y 
itself which up-regulates the Thl transcription factor, T-bet which in turn activates EL-12(32 
and EFN-y (Afkarian et al., 2002). More recently, EL-23 and IL-27 have been implicated in 
Thl development (Oppmann et al, 2000; Pflanz et al., 2002). EL-23 preferentially induces 
IFN-y production and proliferation of the memory subset of T cells (Belladonna et al., 
2002). EL-27 induces naive CD4+ T cells to proliferate into Thl cells in an IL-12 
independent manner and also synergises with EL-12 to activate EFN-y production and Thl 
polarisation (Pflanz et al., 2002). In contrast, Thl development is negatively influenced by 
IL-10 (Fiorentino et al., 1989) by inhibiting APC maturation (Buelens et al., 1997) and EL- 
12 production (Murphy et al, 1994). Thl immunity is also influenced by chemokines such 
as CXCR3 and CCR5 (Qin et al., 1998) as well as adhesion molecules such as E- and P- 
selectin (Syrbe etal., 1999; Austrup et al., 1997).
At a transcriptional level, T-bet is the critical transcription factor linked with Thl 
development (Szabo et al., 2000). It is up-regulated via the STAT-1 pathway which is 
activated through the EFN-y receptor and operates independently of the IL-12 induced 
STAT-4 pathway (Mullen et al., 2001). Ectopic expression of T-bet in ST AT7' mice can 
induce EFN-y production in cells cultured under Th2 conditions (Mullen et al., 2001).
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Furthermore, CD4+ T cells from T-bet'7' mice have severe defects in Thl polarising ability 
(Szabo et al., 2002). Expression of T-bet induces DNAse I hypersensitivity in the IFN-y 
gene locus suggesting a role in epigenetic Thl regulation (Mullen et al, 2001). The STAT- 
4 pathway is also important in Thl immunity operating in an IL-12 induced manner (Bacon 
et a l, 1995) possibly by activating directly the IFN-y promoter (Xu et a l, 1996). In 
contrast, GATA-3 inhibits the development of Thl cells by down-regulation of the IL-12(32 
receptor (Ouyang et a l, 1998).
1.3.3.2. Th2 commitment
Th2 immunity is characterised by production of its signature cytokine EL-4 and is 
associated with the humoral immune response (Bird et al, 1998). These cells also secrete 
IL-5, IL-6, EL-9, EL-10 and IL-13 (Abbas et al, 1996). IL-4 plays a central role in the 
development of Th2 phenotype and naive CD4+ T cells stimulated by TcR activation in the 
presence of EL-4 leads to Th2 effectors capable of producing EL-4, EL-5 and IL-13 
(O’Garra, 1998). It also suppresses IFN-y production from Thl cells (Hsieh et a l, 1992). It 
binds to one of two different types of IL-4 receptors, both of which contain the IL-4Ra 
subunit (Lai et a l, 1996). Other important cytokines include IL-6 which induces Th2 cell 
differentiation by up-regulation of IL-4 while suppressing Thl development via the 
suppressor of cytokine signalling-1 (SOCS1), a STAT-1 phosphorylation inhibitor (Diehl et 
al, 2000) and EL-11 which promotes IL-4 and IL-5 production and inhibits EL-12 release 
from macrophages (Curti et a l, 2001). Additionally, EL-21 is preferentially expressed on 
Th2 cells and also serves to inhibit IFN-y production in Thl cells (Wurster et a l, 2002). 
Th2 type immunity may also characterised by expression of the chemokine receptor CCR3 
which is regulated by IL-4 and IL-13 and leads to production of eotaxin by endothelial and 
epithelial cells in response to allergic inflammation (Li et al, 1999). Other chemokine 
receptors preferentially expressed on Th2 cells are CCR4 and CCR8 (Randolph et al., 
1999; Sozzani et al., 1998).
Several Th2 related transcription factors have been identified. The most prominent ones 
include GATA-3, STAT-6 and c-MAf (Zheng and Flavell, 1997). Of these, GATA-3 is
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considered the master regulator of the Th2 phenotype. Indeed, ectopic expression of 
GATA-3 under Thl polarising conditions can cause Th2 development while down 
regulating IFN-y production (Ferber et a l, 1999). Furthermore, expression of this 
transcription factor in fully differentiated Thl clones results in EL-4 and EL-5 production 
(Ouyang et al, 2000). A number of GATA-3 binding sites have been identified on the IL-4 
and IL-13 genes indicating that it plays an important role in Th2 specific epigenetic 
regulation (Takemoto et al., 1998). It has the capacity to induce other Th2 transcription 
factors such as c-MAF as well as auto-inducing further GATA-3 production (Ouyang et al., 
2000) and it down regulates the IL-12 (32 receptor using an IL-4 independent mechanism 
(Ouyang et a l, 1998).
1.3.3.3. Fate of CD4+ effector cells
Memory CD4+ T cells display many functional differences to the nai've and effector cells 
from which they are generated including induction by lower amounts of antigen, rapid 
secretion of increased levels of cytokines, decreased susceptibility to activation-induced 
cell death and persistence in the absence of class II re-stimulation (Swain, 2000). Whether 
the transition from effector to memory happens through a linear differentiation pathway is 
unclear. Th2 effectors give rise to memory cells without further differentiation supporting a 
linear default pathway from effector to memory (Hu et al., 2001). This is also supported by 
the finding that the phenotype of polarised memory cells reflects the phenotype of 
adoptively transferred polarised effectors (Swain et al. 1999). In contrast, results from Wu 
et al. (2002) suggest that Thl effectors may not follow a similar differentiation pathway. 
Within the memory population itself, there is evidence for progressive differentiation from 
Tcm to Tem with increased signal strength suggesting that both memory subpopulations are 
inter-related (van de Merwe, 2001). Furthermore, memory CD4+ cells formed from 
polarised Thl and Th2 effectors can alter their cytokine profile after re-stimulation 
suggesting a degree of flexibility in the memory phase (Messi et al., 2003). CD4+ memory
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cells are maintained by IL-7 (Seddon et al., 2003) but unlike CD8+ memory T cells, they 
do not respond to IL-15 (Zhang et al., 1998).
1.3.4. Regulatory T cells
Specific T cell populations with regulatory/suppressive functions also exist in vivo and 
these cells are involved in important immune functions such as self-tolerance, anti-tumour 
immunity and control of infection (Sakaguchi, 2000; Shevach, 2002). Fundamentally, 
regulatory T cells ( T reg ) may be divided into naturally occurring CD4+ CD25+ T cells and 
induced T reg  cells (Bluestone and Abbas, 2003). CD4+ CD25+ cells are selected in the 
thymus in response to intermediate levels of TcR signalling from MHC-II-antigenic peptide 
complexes (Jordan et al., 2001). They may be characterised by low expression of CD45RB 
as well as 0X40, L-selectin (CD62L) and glucocorticoid-induced TNF receptor family- 
related gene (GITR) (McGuirk and Mills, 2002; McHugh et al., 2002; Lepault and 
Gagnerault, 2000; Shimizu et al., 2002, respectively). However, as these cell surface 
molecules are not exclusive to T reg cells, these subsets are more accurately defined by the 
expression of the transcription factor FoxP3 (Fontenot et a l, 2003). Once activated by 
antigen, T reg  cells mediate suppression in a cell contact, antigen independent manner 
leading to inhibition of IL-2 production in the target cell (CD4+CD25- T cells or DC) 
(Thornton and Shevach, 1998). The second category of T REg cells are referred to as induced 
T reg  cells and may be further subdivided into Trl and Th3 cells on the basis of IL-10 and 
TGF-|3 production, respectively (Roncarolo et a l, 2001; Weiner, 2001). They are derived 
from normal CD4+ CD25- cells and may represent an altered state of differentiation 
(Bluestone and Abbas, 2003). Both subsets suppress Thl and Th2 responses in a cell 
independent, antigen non-specific, cytokine mediated manner (Weiner, 2001; Groux, 2003). 
Both naturally occurring and induced T reg  cells cooperate in vivo and there is evidence that 
suggests that sub-populations of the naturally occurring CD4+CD25+ T reg  cells have the 
ability to induce Trl or Th3 T reg  cells of different antigen specificity (Jonuleit et al, 2002; 
Dieckmann et al., 2002).
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1.3.5. CD8-CD4 interactions
1.3.5.1. T cell co-operation
Synergistic interactions between antigen specific CD8+ and CD4+ responses are required 
for control of many viruses (Cardin et a l, 1996; Matloubian et a l, 1994). Indeed, in many 
viral infections, there is a reliance on CD4+ T cells for the development of the CD8+ 
response (Jennings et a l, 1991; Zajac et a l, 1998). In instances where CTL precursor 
frequencies are high (Mintem et a l, 2002) or when viral infection leads to direct up- 
regulation of co-stimulatory molecules such as B7-1/B7-2 on dendritic cells (Wu and Liu,
1994), CD4+ cells are not required for initial activation of the CD8+ response. However, 
optimal generation, differentiation and maintenance of memory CD8+ T cells requires the 
presence of CD4+ T cells during the initial CTL activation phase (Riberdy et a l, 2000; 
Belz et al, 2002; Johansen et al, 2004). The CD4+ response provides help by secretion of 
cytokines such as EL-2 which promote the expansion of the CD8+ response (Matloubian et 
al, 1994). A second mechanism of help involves activation of DCs by ligation of CD4+ T 
cell expressed CD40L with DC expressed CD40 (CD4-APC-CD8 pathway). This in turn 
leads to up-regulation of co-stimulatory molecules such as B7-1/B7-2 licensing the DC to 
induce CD8+ T cell activation through CD40 ligation (Schoenberger et al, 1998; Ridge et 
al, 1998) and to secrete cytokines important to CTL induction such as IL-12 (Curtsinger et 
al, 1999). There is also evidence for direct CD4-CD8 T cell help as activated CD8+ T cells 
transiently express CD40 after activation (Bourgeois et a l, 2002).
Using mathematical modelling, Wodarz and Jansen (2001) postulate a role for both 
mechanisms of help with each mechanism showing prominence at different stages of viral 
infection. They argue that in the primary phase of infection when vims load is high, the 
quickest and most efficient way to activate the CD8+ response is firstly the generation of 
CD8+ self-help through production of autocrine IL-2 and after a number of cell divisions, 
the secretion of IL-2 by CD4+ helpers (Deeths et a l, 1999). Subsequent phases of infection 
may favour the CD4-APC-CD8 pathway which promotes viral clearance at low vims loads. 
Other investigators have also demonstrated CD8-CD4 (Zhong et a l, 2001), CD8-CD8
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(Sherritt et al., 2000) and CD4-CD4 (Gerloni et al., 2000) T cell co-operation. From a 
DNA vaccination perspective, there is much evidence for co-operative CD4-CD8 T cell 
interactions (Maecker et al., 1998; Kursar et al., 2002; Ren et al., 2003). Furthermore, 
Creusot and colleagues demonstrated co-operation between CD4+ T cells of different 
specificity following PMDD (2003a; 2003b). Consistent with the view of Behrens et al. 
(2004) that linked recognition is a requirement for the provision of help, Creusot et al. 
observed that the CD4-CD4 helper effect was greatest when both antigens were delivered 
to the same dendritic cell.
1.3.5.2. T cell competition
There is also much evidence for competition between T cells. Competition between CD8+ 
T cells of same or different specificity (Probst et al, 2002; Palmowski et al., 2002; Lawson 
et a l, 2001; Grossmann et al, 2001) has been most commonly observed although CD4- 
CD4 T cell competition has also been noted (Smith et al, 2000). For CD8+ T cells, it is 
generally agreed that intraclonal competition (i.e. antigen specific competition) occurs 
(Kedl et al., 2000; Wolpert et al., 1998; Sandberg et al., 1998). These reports suggest that 
competition for antigen occurs at the level of the APC and that the competitive effects may 
be alleviated by increasing the number of available APCs (Butz et al., 1998a; Grufman et 
al., 1999a). Other factors that contribute to intraclonal competition are high precursor 
frequency and TcR affinity for antigen. Support for the former stems from the observations 
that competition is most prevalent following a number of immunisations (Kedl et al., 2002; 
Palmowski et al., 2002) and that pre-immunity to a subdominant antigen reduces the 
response to a more dominant antigen in subsequent immunisations against both antigens 
(Chen et al., 2000c). The link between TcR affinity for antigen and T cell competition was 
demonstrated by Kedl et al. (2002) who transferred high and low affinity anti-ovalbumin 
CD8+ T cells to a previously primed host and observed that the high affinity T cells out- 
competed the lower affinity T cells after antigenic challenge. Some groups have suggested 
that high affinity T cells compete by APC killing (Grufman et al., 1999b; Matloubian et al, 
1999; Ludewig et al., 2001) which would serve to reduce access to antigen by lower
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affinity T cells. Others implicate an antigen extraction mechanism whereby high affinity T 
cells induce antigen loss from the surface of the APC (Kedl et al. 2002).
Whether interclonal T cell competition occurs is less definite as there is evidence for 
(Wolpert et al., 1998; Kedl et a l , 2000) and against (Smith et al., 2000) this phenomenon. 
Indeed, the findings of Probst et al. (2002) led to the suggestion that interclonal 
competition does not play a functionally important role in the development of T cell 
responses. However, where it has occurred, there is a requirement for presentation of both 
antigens on the same APC (Sandberg et al., 1998). This type of competition is much less 
efficient than antigen-specific competition (Kedl et al., 2000). Ge et al. (2004) observed 
that CD8+ T cells with different TcRs compete only for cytokine factors surrounding the 
DC-T cell cluster such as IL-7 and EL-15. Furthermore, Rodriguez et al. (2002) showed that 
CD8+ T cells against an immunodominant epitope inhibit responses to subdominant 
epitopes by the suppressive effects of IFN-y secreted by the immunodominant T cell 
population.
The co-operative and competitive interactions between T cells of different specificities (i.e. 
following PMDD of influenza nucleoprotein and Ovalbumin encoding plasmid DNA) are 
investigated further in chapters 6 and 7.
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1.4. DNA vaccination
The ability of the adaptive immune system to develop memory is the foundation for the 
successful application of vaccines in modem medicine. Over the past century, many 
vaccines strategies have been so successful that infectious diseases such as smallpox, polio 
and diphtheria have either been totally eliminated or are on the verge of extinction. 
Development of these “conventional” vaccines centred on the whole disease-causing 
organism itself, either in the attenuated or killed form. Other standard approaches used to 
confer protective immunity included using sub-cellular units of organisms (sub-unit 
vaccines) and inactivated toxins from these organisms. Further developments in 
recombinant DNA technology and molecular biology saw the use of attenuated bacteria and 
vims vectors for gene delivery, but pre-existing immunity to these vectors dominated the 
immune response to the delivered antigen. Issues surrounding vaccine preparation, safety 
and pre-existing immunity together with the onset of diseases such as HIV and cancer 
which prove somewhat refractory to conventional vaccine strategies have precipitated the 
requirement for alternative approaches to vaccine development. One of these approaches is 
DNA vaccination.
DNA vaccination (also referred to as nucleic acid vaccination) is a vaccination method 
whereby the host is inoculated with a eukaryotic expression plasmid encoding antigen 
(Ulmer et al., 1993). Interest in this area was first initiated when Dubensky et al. (1984) 
demonstrated replication of viral and recombinant plasmid DNA in mouse liver and spleen. 
The findings of Wolff et al. (1990) who reported that P-galactosidase protein expression 
was obtained following injection of naked plasmid DNA into mouse and Tang et al. (1992) 
who demonstrated that gene gun vaccination (PMDD) successfully stimulated antibody 
production to the encoded gene product suggested DNA vaccination as a viable alternative 
to conventional vaccination. The simplicity of the composition of plasmid DNA has many 
immunological advantages over recombinant and viral vaccines. Once delivered in vivo, 
plasmid DNA becomes transcriptionally active, harnessing the cells cytoplasmic machinery 
to produce antigen. Unlike immunisation with protein, intracellular synthesis of the
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encoded antigen enables it to fold in its native conformation with normal post-translational 
modifications closely mimicking natural infection (Chattergoon et a l , 1997).
Absence of an associated viral coat allows it to escape the presence of neutralising 
antibodies and eliminates a potentially immunodominant response to coat surface proteins 
(Robertson and Griffiths, 2001). Furthermore, recombinant viruses risk mutation or 
reversion to more pathogenic forms and may suffer from pre-existing immunity (Restifo 
and Rosenberg, 1999). Studies addressing the risks associated with DNA inoculation have 
shown safe and well tolerated administration with no local or systemic reactions and 
absence of anti-DNA antibodies (Boyer et a l , 1999; MacGregor et a l, 1998). In other 
studies, mice immunised with DNA developed anti-DNA antibodies (Griffiths, 1995). 
However, antibody titres in that particular study were so low that they failed to induce auto­
immunity. Kanellos et a l  (1999) confirmed immunity without initiation of chromosome 
integration and nucleic acid auto-immunity. Moreover, the frequency of integration of 
foreign DNA into the host chromosome was estimated to be much lower than spontaneous 
mutation (Nichols e ta l, 1995).
DNA vaccination encompasses a wide range of delivery mechanisms including 
electroporation, jet-injection and liposomes (Clark and Johnson, 2001). The most widely 
used methods include needle injection of naked DNA into the muscle (Wolff et a l, 1990) 
or skin (Raz et al, 1994) and PMDD to the skin (Williams et al, 1991; Torres et a l, 1997). 
Less invasive means of introducing DNA involve topical application of plasmid to the skin 
or mucosal surfaces. Examples of these are intranasal (Klavinskis et a l, 1999), oral 
(Etchart et al, 1997) and intravaginal (Wang et al, 1997) administration all of which lead 
to the induction of antigen specific responses. DNA vaccination by PMDD is mainly 
focused on here.
1.4.1. Particle-mediated DNA delivery
Particle-mediated DNA delivery is a technique that uses compressed helium gas to 
accelerate microscopic beads coated with DNA into the skin. This method is very effective
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at delivering plasmid DNA to the cells of the epidermis and requires only nanogram 
quantities of DNA (Pertmer et al., 1995). Since it was first used to deliver DNA into plant 
cells (Klein et al., 1987), it has found applications in many different areas including gene 
therapy (Yang et al, 2004) and DNA vaccine delivery (Fuller et al., 2002). The potential of 
PMDD as a vaccination tool was first highlighted by Tang et al. (1992) who observed 
antigen specific antibody responses in semm of inoculated mice following intra-dermal 
DNA administration. Because PMDD is dependent on the physical nature of the delivery 
process, it has found a logical application in epidermal delivery (Haynes et al., 1996). 
Additionally, the epidermal layers of the skin are home to the myeloid DC, the Langerhans 
cells. These professional APC which are present in the skin at a density of 500-1000 
cells/mm2 (Chen and Payne, 2002) present a valuable target for plasmid DNA delivered by 
PMDD providing ready access to the adaptive immune response of the host.
1.4.1.1. Intra-dermal injection versus gene gun
DNA vaccines are most commonly delivered to the dermal and epidermal layers of the skin 
by needle injection or by PMDD. Comparative analysis of the two methods indicates that 
PMDD is more effective than intra-dermal needle injection as it possesses the ability to 
elicit equivalent CTL and antibody responses with substantially less DNA (Pertmer et al., 
1995; Degano et al., 1998). Indeed, Pertmer and colleagues demonstrated that only 16 ng 
DNA/immunisation was required to elicit significant antibody titres and CTL activity, 5000 
fold less than the amount needed if the DNA was administered by needle injection. 
Furthermore, the optimal doses of DNA eliciting an immune response in mice for intra- 
dermal needle injection is -10-100 fig compared with -0.1-1 fig for PMDD. For humans, 
-200-2500 and -1-4 fig of DNA are required to generate immune responses using DNA 
injection and PMDD, respectively (Payne et al., 2002).
This difference may be because intra-dermal injection delivers the DNA to the extracellular 
space in the skin where it is susceptible to degradation by nucleases (Levy et al., 1996). 
Alternatively, the differential requirements for DNA in both methods may also be due to 
the “danger signal” phenomenon which is important in stimulating the innate response
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(Porgador et al., 1998). The damage caused by the physical impact of gold particles 
delivered at high pressure may function as a danger signal that effectively recruits and 
activated DCs (Culley and Olszewska, 2003). Porgador et al. suggested that the danger 
signal effect was responsible for the influx of 20-30,000 non-transfected CDllc+ DCs in 
the local draining lymph node 24 hours after PMDD. This represented a two fold increase 
in the number of DC normally resident there. Furthermore, they demonstrated that PMDD 
of gold particles alone resulted in an increase in DC trafficking to the local draining lymph 
node suggesting the adjuvant effect of ballistic bombardment itself. Additionally, one 
important advantage of PMDD over intra-dermal DNA injection is that it is provides a 
simple way of introducing multiple genes and adjuvants such as GM-CSF (Xiang and Ertl,
1995) to the same antigen presenting cell, thereby improving the quality and quantity of the 
resulting immune response.
1.4.1.2. Gene gun modulates type 1/2 immunity?
The ability of a DNA vaccine delivered by PMDD to elicit a Thl or Th2 response is 
dependent on a number of factors including delivery mode, nature of antigen synthesised, 
and immunisation regimen used (i.e. number and time intervals between immunisations). 
Some of the earlier studies suggest that gene gun mode of delivery preferentially elicits a 
Th2 response characterised by the production of IL-4, IL-5 and an IgGl antibody response. 
In contrast, administration of naked DNA (especially intramuscular inoculation) leads to a 
predominantly Thl response (Feltquate et al., 1997; Pertmer et al., 1996). However, more 
recent data argues against this with Yoshida et al. (2000) and Frelin et al. (2003) 
demonstrating strong CTL responses and type 1 immunity against the respective antigens. 
Furthermore, Fuller and colleagues (2002) demonstrated significant CTL activity and a low 
antibody response against SIV antigens in rhesus macaques following multiple 
immunisations by PMDD. Whether the synthesised antigen is secreted or retained in the 
cytoplasm may also influence the nature of the resulting response. Torres et al. (1999) 
reported predominately IgGl antibody responses to influenza and measles virus 
hemagglutinins (HAs) following PMDD delivery. Increasing the time intervals between 
successive immunisations resulted in increased type 1 activity (characterised by IFN-y
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secretion) against HIV-1 gpl20 in mice and rhesus macaques using PMDD (Prayaga et al., 
1997; Fuller et al., 1996, respectively).
1.4.1.3. Plasmid design
A DNA plasmid in its simplest form usually consists of a bacterial plasmid that contains a 
gene-encoding antigen and poly-adenylation sequence under the control of a strong 
eukaryotic promoter. An antibiotic resistance gene and a bacterial origin of replication are 
also included for amplification in bacteria (Gurunathan et al., 2000). One of the more 
important factors to consider when generating such plasmids is the optimisation of plasmid 
design in order to generate plasmids which produce more antigen and are more stimulatory 
to the host immune system. To this end, a number of different promoters, enhancers and 
poly-adenylation sequences have been tested in DNA vaccines (Kwissa et al., 2000; Xu et 
al., 2001). Investigations from Lee et al. (1997) using the chloramphenicol 
acetyltransferase (CAT) gene as an indicator demonstrated that, of several different 
promoters, the cytomegalovirus immediate early enhancer-promoter (CMV-IE) was the 
most effective at inducing antibody responses following intra-muscular DNA plasmid 
inoculation. These findings were supported by Zhang and colleagues (2002) who reported a 
similar outcome in human prostate cancer cell lines transfected by PMDD. Others however 
have reported down regulation of antigen production in vivo in vectors containing viral 
promoters such as CMV due to inhibitory effects of cytokines such as IFN-y and TNF-a 
(Qin et al., 1997). Where there is a requirement for localised antigen production, promoters 
such as the desmin promoter (Kwissa et a l, 2000) or the creatine kinase promoter (Gebhard 
et al., 2000) which specifically target expression in muscle cells may be employed. 
Likewise, the dectin-2 promoter (Takashima and Morita, 1999) or the scavenger receptor 
gene promoter (Xiang et al., 1997) is preferentially active in DC.
Further expression optimisation is achieved through insertion of the “Kozak” consensus 
sequence in front of the start codon of the opening reading frame (Kozak, 1987) as well as 
through mammalian codon optimisation techniques. Indeed, Nagata et a l, (1999) 
demonstrated that codon optimisation correlated well with protein production levels in
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mammalian cells. Additional regulatory elements shown to enhance antigen expression 
include intron A (Niwa etal., 1990; Chapman etal., 1991) and exon-1 (Simari etal., 1998). 
The beneficial effects of intron A are attributed to increased levels of RNA polyadenylation 
(Huang and Gorman, 1990) or by acting as an enhancer (Buchman and Berg, 1988). The 
latter two components are compared for their effect on driving antigen expression in 
chapter 5.
An important attribute of plasmid DNA is its ability to stimulate the innate response 
through immuno-stimulatory sequences (ISSs). These sequences are present in the 
backbone of bacterial plasmids in the form of cytidine-phosphate-guanosine (CpG) motifs 
(Krieg et al., 1995). Because bacterial DNA has a much higher level of unmethylated CpG 
motifs compared with mammalian DNA, it possesses the ability to stimulate the 
mammalian innate immune system (Krieg et al., 1996). It binds to TLR9 which is 
expressed in the endosomal compartment of DCs and B cells (Ahmad-Nejad et al., 2002) 
and causes these cells to produce pro-inflammatory cytokines such as IL-12 and DFN-y, 
promoting Thl development (Klinman et al., 1996). As such, it behaves as an adjuvant to 
the adaptive immune response. Indeed, ISSs have been successfully used to improve the 
efficacy of DNA vaccines when present in the bacterial plasmid backbone (Sato et al.,
1996) or when co-delivered as an adjuvant (Cho e ta l, 2000). However, this adjuvant effect 
is species specific and so optimisation is required for each intended host system (Balias et 
al, 1996).
1.4.1.4. Mechanisms of antigen presentation
Following delivery, DNA vaccines engage both MHC I and II antigen processing pathways 
provoking cellular and humoral immunity, respectively (Chattergoon et al., 1997). There is 
much evidence supporting direct transfection of DC following DNA vaccination (Raz et al., 
1994; Timares et al., 2003). Using electron microscopic analysis and fluorescence 
microscopy, Condon et al. (1996) demonstrated the presence of LCs containing 1 /xm gold 
beads expressing green fluorescent protein in draining lymph nodes after PMDD indicating 
direct DC transfection. Iwasaki and colleagues (1997) showed that the induction of a CTL
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response was restricted to the MHC haplotype of transfected bone marrow derived DC and 
not to the haplotype of transfected somatic cells following PMDD. Skin ablation and 
grafting experiments demonstrated that T and B cell activation occurred in mice whose 
vaccination sites remained intact for 24 hrs after PMDD (Klinman et al., 1998). This 
together with the finding that skin grafts transferred to naive recipients within that time 
interval were capable of launching a response in those animals suggested that immunity 
was induced by cells which migrated quickly from the vaccination site to the draining 
lymph node. Further support for direct DC transfection as the predominant mechanism of 
antigen presentation was provided by Timares et al. (2003) who used a drug inducible 
system to switch on transgene expression within transferred LCs in recipient mice. Upon 
induction, antigen synthesised within the transferred LCs led to a cellular response which 
was equal in magnitude to that observed in the donor animals after vaccination. In contrast, 
the humoral response was 10-fold lower.
From a quantitative perspective, Porgador et al. (1998) attempted to elucidate the number 
of directly transfected DC following PMDD. They demonstrated that after five intra-dermal 
gene gun immunisations, only 50-100 directly transfected DC were recovered from an 
individual draining lymph node. However more recently, Garg and colleagues (2003) who 
used a sensitive genetic tagging technique observed that this number was -100 fold higher 
than that calculated by Porgador and colleagues.
Synthesised antigen may also access the class I pathway through cross presentation (Bevan, 
1976). Support for the contribution of this presentation pathway to the development of 
CD8+ immunity following PMDD comes from the studies of Cho et al. (2001). Using a 
tissue specific promoter system, significant CD8+ responses were obtained as a result of 
non-APC specific antigen expression. MHC II restricted presentation of antigen plays an 
important role in the induction of the humoral response following PMDD (Torres et al, 
1997). Further support for this antigen presentation pathway comes from Loirat and 
colleagues (1999) who demonstrated that antigen produced exclusively in muscle myocytes 
under the control of the muscle specific desmin gene promoter resulted in a qualitatively 
and quantitatively similar cellular response to that obtained with a non-specific CMV
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promoter was used. DCs can take up secreted vaccine antigen expressed in transfected 
bystander cells such as skin keratinocytes or myocytes. In this context, these somatic cells 
act as antigen depots supplying small amounts of secreted antigen and contribute to the 
induction and maintenance of the antibody response (Eisenbraun et al., 1993; Torres et al, 
1997). It is likely that direct DC transfection, cross-presentation and MHC II presentation 
play important roles both individually and collectively in the induction of protective 
immunity following gene gun immunisation.
1.4.1.5. Enhancing the efficacy of DNA vaccines
A large number of approaches have been employed to enhance the potency of DNA 
vaccines. Some of these strategies have been tested in PMDD models while others have 
been investigated following needle injection of DNA. Generally, these approaches may be 
divided into those which result in improved antigen uptake in DC and DC maturation, 
increased antigen degradation and presentation and the improvement of the DC-T cell 
interaction.
As discussed previously, unmethylated CpG motifs present in the plasmid backbone 
enables targeting of DNA to DC and stimulates maturation by binding to TLR9 (Klinman 
et al., 1996). Gene gun delivery of genes encoding the apoptosis inducing proteins, murine 
caspase 2 and a chimera of murine 2 prodomain and human caspase 3 enhanced the T cell 
responses to influenza hemagglutinin by preferentially directing the contents of apoptosed 
somatic cells to DC (Sasaki et al., 2001; Sasaki et al., 2002). In a similar fashion, Leitner 
and colleagues (2003) successfully broke tolerance to a tumour antigen by co-delivering a 
DNA vaccine encoding an alphavirus replicon. This provided a source of double stranded 
RNA which induced caspase-dependant apoptosis and stimulated the innate response 
through DC uptake. You et al. (2001) showed that a DNA vaccine for hepatitis B antigen e 
fused to an IgG Fc fragment was efficiently captured and processed by DC while Boyle and 
colleagues (1998) successfully used CTLA-4 as means to target antigen to DC. Chen et al. 
(2000a) demonstrated that linkage of the gene encoding heat shock protein (HSP)-70 
targeted the model antigen (HPV type 16 E7) to DC and increased the CD8+ T cell
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response in a CD4+ independent manner. An alternative approach to increasing the number 
of antigen containing DC is the use of protein transduction domains (PTDs) from 
translocatory proteins. Such proteins include VP22 from herpes simplex virus type 1 (HSV- 
1) and the HIV protein tat (Prochiantz, 2000). Hung et al. (2001a) demonstrated that HSV- 
1 VP22 enhanced the intracellular spreading of the linked HPV-16 E7 antigen to 
surrounding cells thereby increasing the E7 specific CTL response. Other strategies used to 
direct antigen to and mature DC include the delivery of constmcts expressing antigen fused 
to chemokines such as interferon inducible protein 10 (HP-10) and monocyte chemotactic 
protein 3 (MCP-3) (Biragyn et al., 1999) and the extra-cellular domain of the cytokine 
Fms-like tyrosine kinase 3 (Flt-3) (Hung et al., 2001c). Delivery of the cytokine GM-CSF 
has also proved effective at recruiting and maturing DC (Xiang and Ertl, 1995).
Increasing the level of antigenic degradation and improving the efficiency of presentation 
within the DC provides another way of increasing vaccine potency. DNA vaccines may be 
constructed which express only the immuno-dominant epitopes from a targeted antigen. 
These vaccines, termed mini gene or mini tope vaccines have been shown to induce CTL 
efficiently (Uchijima et al., 1998; Blaney et al., 1998). Intracellular targeting strategies to 
enhance MHC I restricted presentation include addition of leader sequences which localises 
the target peptide in the ER (Ciemik et al., 1996) and insertion of sequences which increase 
antigen ubiquitination and degradation (Wu and Kipps, 1997). Additionally, Rodriguez and 
colleagues (1998) demonstrated that the strategy of antigen ubiquitination results in 
enhanced CTL immunity. Antigen fused to a protein of foreign origin (i.e. influenza 
nucleoprotein366-374-green fluorescent protein conjugate) resulted in efficient CTL 
induction through increased CD4+ T cell help (Wolkers et al., 2002). Antigens fused to 
other proteins such as bacterial toxin translocation domains (Hung et a l, 2001b), 
calreticulin (Cheng et al., 2001), centrosomal y-tubulin (Anton et al., 1999) and heat shock 
proteins (Trimble et al, 2003) have also been demonstrated to augment the antigen specific 
CTL response through increased MHC I presentation. Arrington et al. (2002) reported a 
strong enhancement of the CTL response to multiple viral antigens when vectors encoding 
cholera toxin and E coli heat-labile enterotoxin were co-delivered by PMDD.
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Equally, many strategies have been used to augment MHC II restricted CD4+ T cell 
responses. DNA vaccines have utilized signals which target the class II processing pathway 
in the lysosome and late endosome. Ji et al. (1999) targeted HPV-16 E7 antigen to these 
sub-cellular compartments by co-delivery of the gene encoding the lysosome-associated 
membranous protein-1 (LAMP-1). Likewise, the lysosomal integral membrane protein-II 
(LIMP-II) was successfully used to induce antigen specific CD4+ T cell induction 
(Rodriguez et a l, 2001). Van Tienhoven and colleagues (2001) used an Ii construct (with 
class II associated invariant chain peptide (CLIP) replaced by a HSP-60 derived epitope) to 
induce HSP-60 CD4+ T cell responses.
In addition to enhanced processing and presentation, improving the quality and the 
longevity of the DC-T cell interaction is important for increased vaccine potency. This was 
well illustrated by Kim et al. (2003) who used anti-apoptotic factors such as BCL-xL and 
BCL-2 amongst others to prolong the survival of transfected DC. Although this strategy is 
in direct contrast with the pro-apoptotic approach adopted by Sasaki and colleagues (2002), 
it resulted in enhanced antigen specific CD8+ T cell responses. Other groups have co­
delivered cytokines such as IL-12 and the co-stimulatory molecule B7 which amplified T 
cell activation and augmented cell mediated and humoral immunity (Kim et al., 1997).
The microenvironment in which the antigen is presented may be manipulated to steer the 
activity of the antigen specific immune response. Numerous studies have reported that co­
administration of vaccine antigen with genetic adjuvants can alter the immune response to 
the antigen (Maecker et al., 1997; Chow et al., 1998). Inclusion of genes encoding IL-18 
(Zhu et al., 2003), IL-2, IL-12 and IL-15 (Moore et al., 2002) increased the magnitude of 
the response to the antigens of interest. Positive results were obtained in PMDD studies 
when IL-12 (Prayaga et al., 1997) and IFN-y (Siegel et al., 2001) were co-delivered.
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1.4.1.6. Prime-boost strategies
Because of the relatively small quantity of protein produced in vivo following DNA 
immunisation, this regimen by itself is limited in its ability to elicit a long lasting and 
potent immune response. To overcome this shortcoming, many groups have adopted 
heterologous prime-boost strategies whereby the immune system is primed to the target 
antigen delivered in one vector and boosted by delivery of the same antigen in the presence 
of a second but different vector (Ramshaw and Ramsey, 2000). In such approaches, DNA 
appears to be more effective at priming the immune response while a whole range of 
different viruses are preferentially used for priming. Priming with DNA avoids anti-viral 
vector host responses (Xiang et al., 1999) while viral boosting provides more antigen and a 
broader spectrum of antigen related targets (Estcourt et al, 2002). There is much evidence 
supporting the use of heterologous prime-boosting strategies of which DNA immunisation 
by PMDD is one component (Fuller et al., 1997a; Fuller et al., 1997b). Regimes in which a 
DNA prime is followed by a poxvirus boost have proved effective as demonstrated by the 
findings of Hanke et al. (1999) and Degano et al. (1999) who, compared with DNA 
immunisation only, reported increased CTL responses to HIV and malaria epitopes, 
respectively. Doria-Rose et al. (2003) demonstrated protection from CD4+ T cell depletion 
in a simian-HIV model (SHIV89.6P) using a DNA prime/vaccinia vims boost. Others have 
demonstrated complete protection against plasmodium berghei sporozoite challenge in 
mice using a DNA/modified vaccinia vims Ankara (MVA) regime (Degano et al, 1999).
1.4.1.7. Mucosal immunity
As the vast majority of infectious pathogens enter the body through the mucosae, adequate 
protection requires local immunity. A strong mucosal response is characterised by the 
presence of antigen specific mucosal CD8+ T cells and secretory IgA antibodies. As such, 
the challenges facing mucosal and systemic DNA vaccination are different (Lajeunesse et 
al, 2004). DNA vaccines delivered to mucosal sites by PMDD have demonstrated 
protective immunity or enhanced protection compared with systemic routes of 
administration (Loehr et a l, 2000; Wang et al, 2003). In most instances, greatest efficacy
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was obtained when PMDD was used as the priming component of a heterologous prime- 
boost regime. Livingston and colleagues (1998) demonstrated protective anti-human 
growth hormone IgA and IgG antibody responses following PMDD via the vaginal mucosa 
in mice. Furthermore, delivery of DNA to Peyers patches followed by a systemic boost (i.e. 
intra-dermal PMDD) in rabbits also resulted in high anti-HIV glycoprotein 120 IgG and 
IgA responses (Winchell et al., 1998). Although the preponderance of information on 
heterologous prime-boost strategies indicate better results when DNA is used as the 
priming component, Eo et al. (2001) observed optimal mucosal responses when vaccinia 
vims was used as the priming vector and DNA administered mucosally was used as boost. 
Additionally, that mucosal prime-boost strategy also induced good systemic responses.
1.4.1.8. PMDD efficacy in humans
Translating protective and therapeutic activity from mice to humans is the major goal for 
DNA vaccines. There are a number of studies demonstrating partial protection in non­
human primate models (Doria-Rose et al., 2003; Puaux et a l, 2004) but very few of these 
have been tested in clininal settings. As described in section 1.4.1.6, most of these 
approaches involve a DNA prime and fowlpox vims boost (Degano et al, 1999; Schnedier 
et al, 1998; Kent et al, 1998). In the first published PMDD human trial, Roy et a l (2000) 
demonstrated total sero-conversion with 12/12 individuals developing protective antibody 
responses against hepatitis B surface antigen (HBsAg). These antibody responses compared 
favourably with those obtained in other human studies which employed intra-muscular 
delivery of much higher amounts of DNA (up to 1000 fold more) (MacGregor et a l, 2000; 
MacGregor et a l, 2002). In a separate study, Rottinghaus and colleagues (2003) 
demonstrated protective immunity against HBsAg in 12/16 individuals, all of whom were 
previously unresponsive to conventional hepatitis B vaccination. Finally, McConkey et a l 
(2003) investigated the effect of a heterologous prime-boost regime (i.e. PMDD or intra­
muscular injection DNA prime/MVA boost) on the induction of protective immunity 
against pre-erythrocytic malaria thrombospondin-related adhesion protein (TRAP). 
Although the results indicated partial immunity, the prime-boost regime yielded antigen 
specific T cell responses that were 10 fold higher than those obtained by either PMDD or
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MVA alone. Furthermore, PMDD proved much more potent than intra-muscular injection 
for priming with several fold higher post boost T cell responses obtained.
1.5. Particle-mediated DNA delivery in vitro
The efficacy of transfection of mammalian cell lines in vitro is an important aspect to 
consider in the creation of potent DNA vaccines. This is especially relevant to PMDD 
where the in vitro and in vivo transfection processes are similar. Due to this close 
association, many studies have centred on PMDD as a transfection tool.
PMDD was pioneered by Klein and colleagues (1987) to introduce DNA into 
monocotyledonous plants. Since it was first used by Zelenin et al. (1989) to transfect 
mammalian cells, it has been employed successfully to transfect a wide variety of isolated 
tissue explants and the primary cultures derived from these explants as well as a number of 
cultured mammalian cells (see Table 1.1). It provides a fast and simple method for 
transfection with a requirement for only small quantities of DNA. Because it depends on 
the physical process of penetrating the cell membrane, it does not have a necessity for a 
particular type of receptor or biochemical structure on the cell type been transfected. For 
this reason, it has been used in cells types such as neuronal cells which have proved 
refractory to transfection by conventional techniques (Klimaschewski et al., 2002).
Quantitative assessment of PMDD efficiency in vitro is varied. The transfection rate is 
dependent on the type of device used and the origin of cells transfected (Biewenga et al.,
1997). Zhang and colleagues (2002) reported transfection rates of up to 35 % in human 
prostate tumour cell lines while other investigators observed transfection levels of ~ 1-5 % 
in murine cell lines (Kitagawa et al., 2003). In some instances, the technique compares well 
with other transfection techniques with Thompson et al. (1993) and Jiao et al. (1993) 
reporting ~5 and 100 fold increases in transfection efficiency compared with other 
transfection methods, respectively. In other cell lines, the technique does not compare well 
(Smith et a l, 2001). There are a number of ballistic parameters which are important to
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Transfection
Reference Device Force Cell type efficiency
(p s i)  ( % )
Kitagawa e ta l ,  2003 Powdeiject 300 MCA205: mouse fibrosarcoma 4.1
Accell NIH-3T3: mouse fibroblast 1
Novakovic e ta l ,  1999 Bio-Rad Helios 100 B - l6: mouse B -16 melanoma 9.6
MCF-7: human adenocarcinoma 10.5
L929: mouse fibroblast 3.9
Murphy and Messer, 2001 Bio-Rad PDS- 1350 Mouse cerebellum organotypic 34
1000 cultures
Schilthuis et al., 1993 Dupont PDS- 450 B1H1: Newt blastemal cells 10
1000
Klimaschewski et al., 2002 Bio-Rad Helios 120 Rat sympathetic neuron 10
Wellmann etal.,  1999 Bio-Rad Helios 120 PC12: rat pheochromocytoma > 5
100 Dog cerebellar granule cells > 10
Smith et al., 2001 Bio-Rad Helios 150 Human PBMC derived dendritic 0
cells
Timares etal.,  1998 Rumsey-Loomis 950 XS106 DC: mouseLC cell line 0.25
1000 NS46 FB: mouse fibroblast 2
O’Brien etal.,  2001 Bio-Rad Helios 175 HeLa: human cervical -2 6 -2 8
(modified) carcinoma
Hek293: human embryo kidney -  26-28
Fitzpatrick-McElligott, 1992 Bio-Rad PDS- 1300 CHO: Chinese hamster ovary 1.5
1000 ELA: mouse lymphocyte 0.6
Zhong et al. 2002 Bio-Rad Helios 150 DU145, PC-3, LNCaP: all - 3 5
human prostate cell lines
Heiser, 1994 Bio-Rad PDS- 1100 CHO: Chinese hamster ovary 4
1000
Table 1.1: A partial list of cultured cell lines and primary cultures transfected by PMDD.
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optimise such as the amount of DNA loaded on gold beads and the acceleration force 
required for DNA delivery (Heiser, 1994). For the hand held delivery system with the 
helium propulsion system (e.g. Helios and PowderJect XR1 gene gun devices), the latter 
parameter appears to be critically important but very variable. Some investigators have 
reported optimal transfection using delivery pressures as high as 1300 psi (Fitzpatrick- 
McElligiot, 1992) while others have optimised the process using pressures as low as 100 
psi (Novakovic et al., 1999). Indeed, many of the parameters involved in transfection have 
been demonstrated to be inter-dependent (Klein et al., 1987) highlighting the requirement 
for process optimisation for the combination of each device used and each cell line 
transfected.
An important application of PMDD is the transfection of DCs, either ex vivo or in vitro. For 
human DCs, transfection efficiency appears to be dependent on DC precursor type. DCs 
which develop from bone marrow derived CD34+ hematopoietic cells and which divide in 
culture have been shown to be resistant to transfection by PMDD (Lundqvist et a l, 2002). 
For non-dividing monocyte derived DC, there are both successful and unsuccessful 
transfection reports (Tuting et al., 1998; Smith et a l, 2001, respectively). To date, 
successful transfection of murine DC has not been reported. The efficiency of PMDD to a 
number of cell lines, including somatic and murine bone marrow derived DC is explored in 
chapters 3 and 4.
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1.6. Introduction to this PhD project
This research project has two main aims. The first is to explore the relationships between 
the efficiency of PMDD when used to stimulate immune responses in vitro with the more 
usual in vivo models. The development of in vitro surrogate models which can, at least in 
part, replace in vivo testing is becoming increasingly important in many areas of 
pharmaceutical research. In addition, these studies may identify some of the critical 
parameters which ultimately regulate and limit the overall in vivo immune response. Thus 
the first main aim is the development of an in vitro system featuring gene gun as the means 
of plasmid delivery. A number of cell lines are investigated for their capacity to become 
transfected by PMDD including a number of cultured mammalian cells lines as well as 
more immunologically relevant cell types like bone marrow derived DCs. Using this in 
vitro system, various different aspects of PMDD technology are examined. The effect of 
parameters such as immunising dose and the effect of single versus dual plasmid 
immunisation on the resulting immune response are investigated. Additionally, other facets 
of this technology which contribute to overall efficacy in vivo including the role of 
intracellular competition and intracellular targeting are addressed.
In the second part, the responses obtained by co-immunising with two independent antigens 
delivered together by PMDD are investigated in more detail. Following co-immunisation, 
the immune responses to both antigens may interact negatively (i.e. compete) or positively 
(i.e. co-operate) with each other. The final immune response reflects the balance between 
these opposing immune forces. The relative contribution of antigenic competition and co­
operation on the resulting immune response and the mechanisms involved are investigated. 
The effect of pre-existing immunity, antigen dose and antigen linkage are examined.
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2.1. Mice
BALB/c and C57BL/6 mice were obtained from Charles River U.K. RAG1/F5 mice 
(C57BL/10 background, H-2b haplotype), transgenic for TcR to nucleoprotein of influenza 
A/NT/60/68 residues 366-374 (Mamalaki et al., 1993) were obtained from the National 
Institute of Medical Research, Mill Hill, London, U.K. DO. 11.10 mice (BALB/c 
background, H-2d haplotype), transgenic for TcR to chicken ovalbumin peptide residues 
323-339 (Murphy et al., 1990), were obtained from Dr Ken Murphy (Washington 
University School of medicine, St. Louis, MO, U.S.A.). Colonies of DO. 11.10 and 
RAG1/F5 mice were kept at Bury Green Farm, GSK, U.K. All breeding, husbandry and 
experiments were carried out in accordance with U.K. animal experimental legislation.
2.2. Cell lines
The RAW and J774 macrophage cell lines and the EL4 T cell lymphoma cell line were 
cultured in complete RPMI 1640 (i.e. supplemented with 10% heat inactivated FCS, 2 mM 
L-glutamine, 100 IU/ml penicillin, 100 jag/ml streptomycin and 5 x 10'5 M (3- 
mercaptoethanol). The DAP-3/ICAM cell line is a mouse fibroblast cell line stably 
transfected with I-Ad and ICAM-1. This was cultured in complete IMDM containing the 
selection markers for ICAM-1 and I-Ad, 666 /-ig/ml geneticin and HAT (3.3 x 10'5 M 
hypoxyanthine, 3 x 10'5 M aminopterin and 5.33 x 10'5 M thymidine) (all Sigma), 
respectively. The MC57 fibrosarcoma cell line was cultured in DMEM supplemented with 
10% heat inactivated FCS, 2 mM L-glutamine, 100 IU/ml penicillin and 100 /xg/ml 
streptomycin. All tissue culture reagents were purchased from Gibco BRL unless otherwise 
stated. All cell lines were obtained from GSK, U.K. and tested negative for Mycoplasma 
contamination.
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23. Plasmids
2.3.1. Reporter gene studies
Plasmids pGL3-CMV-luciferase (Promega), pCIneo-CMV-p-GFP and pCIneo-CMV-p- 
galactosidase (Invitrogen) were used in reporter gene studies.
2.3.2. pVACl vectors
All pVACl vectors (Table 2.1, vector with no insert; see Figure 2.1) were kindly supplied 
by Dr Ian Catchpole, GSK, U.K. pVACl vectors are derived from the pCI vector 
(Promega), contain the CMV immediate early promoter, intron A, the SV40 
polyadenylation sequence and the ampicillin resistance gene. The pVACl.OVAc vector 
encoding cytoplasmically localised chicken ovalbumin protein was made by cutting the 
HindlU cDNA insert of pVACl.OVAs vector with Sstl (method by Tabe et al., 1984).
2.3.3. p7313.NT plasmid synthesis
Four p7313.NT plasmids (encoding nucleoprotein of influenza strain A/NT/60/68) with 
different promoter configurations were constructed (Figure 2.2). The p7313 vectors and the 
pspCl vector were kindly supplied by Dr Peter Ertl, GSK, U.K. The p7313 vectors contain 
the rabbit globin polyadenylation sequence and the kanamycin resistance gene. The pspCl 
vector was used as the source of the minimal CMV promoter in the synthesis of the 
p7313.m.NT plasmid.
2.3.3.1. NT amplification
The NT gene fragment was amplified from pVACl.NT by PCR using PWO polymerase 
with primer optimisation kit (Roche Diagnostics). Each reaction contained 0.5 /xl 
pVACLNT template DNA, 0.5 fil dNTPs (dATP, dCTP, dGTP, dTTP, each at 100 mM, 
Gibco BRL), 0.125 jiil of primers; 5’-
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GAATTCGCGGCCGCGATGGCGTCCCAAGGCACC AAA-3 ’ and 5
GAATTCC AT ATGTT ACTCG AG ATTGTCGT ACTCCTCTG-3 ’ (MWG-Biotech AG), 
0.25 /xl of PWO enzyme, 16.5 /xl of DNase and RNase free water (Sigma) and 2 /xl of 
PCR optimisation buffer. The reaction was carried out as follows: 60 sec at 95°C, 40 cycles 
(30 sec at 95°C, 30 sec at 45°C, 120 sec at 72°C), 120 sec at 72°C. Optimal pH and MgS04 
conditions were 8.3 and 1.5 mM, respectively. The amplified gene fragment was purified 
using the QIAquick PCR purification protocol (Qiagen) and checked for correct gene 
sequence.
2.3.3.2. p7313.plc.NT plasmid synthesis
The NT gene fragment was ligated with the p7313.plc vector. Firstly, both p7313.plc 
(vector) and NT (insert) were cut with Notl and Ndel (New England Biolabs) for 1 hour at 
37°C. The reaction containing the vector consisted of 2 /xl of DNA, 2 /xl each of Notl and 
Ndel, 4 /xl of 10 x REact 3 buffer (Gibco BRL) and 30 /xl water. The reaction containing 
the insert consisted of 30 /xl of DNA, 2 /xl each of Notl and Ndel, 4 /xl of 10 x REact 3 
buffer and 2 /xl water. The vector and insert were run on a 0.8 % agarose gel (Sigma) 
containing 0.5 /xg/ml Ethidium Bromide (Sigma) in TBE buffer for 20 min at 100 volts, 
excised and purified using the gel purification cleanup protocol (Qiagen). The vector was 
cut again with Notl and Ndel for 1 hour at 37 °C. The reaction contained 5 /xl of 10 x 
REact 3 buffer, 2 /xl each of Notl and Ndel and 41 /xl of DNA (from gel purification 
cleanup). The vector was purified using the QIAquick PCR purification protocol and 
treated with SAP (Roche diagnostics). This reaction contained 1 /xl of SAP, 5 /xl of 10 x 
REact 3 buffer and 45 /xl of vector (from PCR purification cleanup). The reaction was 
carried out as follows: 1 hour at 37°C followed by 20 min at 65°C. The ligation was 
performed for 10 min at RT using 1 /xl of vector, 3 /xl of insert, 4 /xl of 2 x ligase buffer and 
0.8 /xl of ligase (both from Ligafast rapid ligation kit, Promega).
The ligation product (p7313.plc.NT) was transformed into JM109 competent cells 
(Promega) as follows: 2.5 /xl of ligation product was added to 25 /xl of cells and kept on
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Vector name Vector
size
(base
pairs)
Coding
antigen
CD8 T cell 
Epitope analysed
CD4 T cell 
Epitope analysed
Genbank
accession
reference
pVACLNT 6138 Nucleoprotein 
of influenza 
A/NT/60/68
Db restricted 
NT366.374 sequence 
ASNENMDAM
I-Ab restricted 
NT413.435 sequence 
S VQRNLPFDKPTIM AAF 
TGNTEG
J02137
pVACl .OV As 6502 Chicken
ovalbumin
secreted
Kb restricted 
OVA257-264 
sequence 
SIINFEKL
I-Ad restricted 
OV A323-339 sequence 
IS Q AVHA AHAEINE AGR
V00383
pVACl .OV Ac 6124 Chicken
ovalbumin
non-secreted
Kb restricted 
OVA257.264 
sequence 
SIINFEKL
I-Ad restricted 
OVA323-339 sequence 
IS Q AVHA AHAEINE AGR
V00383
Table 2.1. pVACl vectors used and CD8/CD4 epitopes analysed in this study.
63
Chapter 2: Material and methods
BsiGI
.Spel
.SnaBI 
.Dsal 
(Ncol 
.'Sty I
pVACl
4627 bps
Xmnl
SV40 poly(A)
EcoO109
NspI
Neo.MI
Dram
.Ecll36 
/.SacI 
f  .Hindm 
.PstI 
/.BspM I 
~ ^.Bbsl 
.Nhel
Intron /.Rsrll
_ l/.XhoI
TJ
1
.. EcoO109 ++ 
Styl-H- 
\  HindQI 
Bbsl++
\  BspMI 
Dram 
PHMI++ 
EcoO109 ++
V:\ Hindm 
\ \  PacI 
: AscI 
• Notl 
Hpal 
Muni
Clal 
BsaBI 
BamHI
Figure 2.1. Plasmid map of pVACl.
/
64
Chapter 2: Material and methods
p7313 vector Enhancer sequence Mnimal CMV promoter Exonl Intron A
backbone
m.NT 
 ►
me. NT 
 ►
plc.NT
ii.NT 
 ►
 ►
NT gene 
sequence
Figure 2.2. Schematic of different p7313.NT promoter configurations used.
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ice for 15 min. The cells were heat shocked for 45 sec at 42°C and then placed on ice for 1 
min. 100 /zl of SOC medium (containing 20 mg/ml Bacto Tryptone, 5 mg/ml Bacto Yeast 
Extract (both from Gibco BRL), 10 /zM NaCl, 10 /zM KC1, 20 /zM MgCl2, 20 /zM MgS04 
and 20 /zM Glucose (all from Sigma)) was added and the cells incubated at 37°C for 30 
min. The cells were plated on 2 x YT plates (8 mg/ml Bacto Tryptone, 5 mg/ml Bacto 
Yeast Extract and 5 mg/ml NaCl) containing 25 /zg/ml kanamycin (Sigma) and incubated at 
37°C. Forty eight hours later, colonies were picked and transferred to universals containing 
5 ml of 2 x YT broth with 25 /zg/ml of kanamycin and incubated overnight at 37°C. The 
plasmid was prepared using Endofree Maxiprep kits (Qiagen). Correct sequence insertion 
was checked by Bam HI (New England Biolabs) restriction digest as follows: 1 /zl of 
plasmid was incubated together with 0.5 /zl of Bam HI, 1 /zl of 10 x REact 3 buffer and 7.5 
/zl of water for 3 hours at 37°C and then run on a 0.8 % agarose gel containing 0.5 /zg/ml 
Ethidium Bromide in TBE buffer for 20 min at 100 volts.
2.3.3.3. Construction ofp7313.NT plasmids with different promoters
Plasmids p7313.m.NT, p7313.me.NT and p7313.ii.NT were constructed by cutting vectors 
p7313.plc, p7313.me, p7313.ie (p7313.ii vector -  Intron A), p7313.ii, pspCl and plasmid 
p7313.plc.NT with different combinations of Notl, Ndel and Sse8387 (New England 
Biolabs) and ligating combinations of isolated DNA fragments (Figure 2.3).
Restriction enzyme digestion was done in two stages. Firstly, Notl and Ndel digestion was 
performed for 3 hours at 37°C. For reactions where both Notl and Ndel were used, the 
vectors were incubated for 1 hour with Notl and then Ndel was added for a further two 
hours. Concentration of plasmid or vector used was -0.5 /zg//z 1 except for p7313.ii and 
pspCl which were -1 and 2 /zg//z 1, respectively. Next, vectors that required digestion with 
Sse8387 were purified using the QIAquick PCR purification protocol. Sse8387 digestion 
was performed for 2 hours at 37°C using 10 x REact 6 buffer (Gibco BRL). Details of the 
Notl/Ndel and Sse8387 reactions are shown in Figure 2.3. Reaction products were run on a 
0.8 % agarose gel containing 0.5 /zg/ml Ethidium Bromide in TBE buffer for 20 min at 100
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p7313.plc.NT p7313.me p7313.ie p7313.ii pspCl
Restriction 
enzymes used
Notl/
Ndel
Nod/
Ndel
Ndel/
Sse8387
Notl/
Sse8387
Nod/
Sse8387
Notl / reaction 
(Ml)
1.5 1.5 1.5 1.5
Ndel / reaction 
(Ml)
1.5 1.5 1.5
Water
(Ml)
31 31 32.5 33.5 34.0
10 x Rx3 buffer/ 
reaction (/x 1)
4 4 4 4 4
DNA / reaction 
(Ml)
2 2 2 1 0.5
Sse8387 / 
reaction 
(Ml)
1.5 1.5 1.5
BSA / reaction 
(Ml)
5 5 5
10 x Rx6 buffer/ 
reaction (/xl)
5 5 5
DNA / reaction 
(MU
38.5 38.5 38.5
DNA fragment 
isolated (bp)
A: 1512 B:3017 C: 2774 D: 1455 E: 124
DNA fragment 
description
NT insert Vector
backbone
+
me
promoter
Vector
backbone
ii promoter m promoter
Figure 2.3. DNA fragments (pink fill) isolated for ligations following Notl, Ndel (yellow 
fill) and Sse8387 (blue fill) enzyme digestion.
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volts, excised and purified using the gel purification cleanup protocol.
p7313.m.NT was constructed by ligating 1 /xl of fragment A, 2 /xl of fragment C and 1 /xl 
of fragment E, p7313.me.NT by ligating 2 /xl each of fragments A and B and p7313.ii.NT 
by ligating 1 /xl of fragment A with 1.5 /xl each of fragments C and D (Figure 2.3, pink 
fill). Each ligation contained 4 /xl of 2 x ligase buffer and 0.8 /xl of ligase and was 
performed for 2 hours at RT. Transformations and plasmid preparation were done as 
described before. Each plasmid was checked for correct sequence insertion by Bam HI and 
Clal (New England Biolabs) restriction digest as follows: 1 /xl of plasmid was incubated 
together with 0.3 /xl of Bam HI, 0.3 /xl of Clal, 1 /xl of 10 x REact 3 buffer and 7.4 /xl of 
water for 1 hour at 37°C and then run on a 0.8 % agarose gel containing 0.5 /xg/ml 
Ethidium Bromide in TBE buffer for 20 min at 100 volts.
2.4. Peptides and Proteins
Peptides used in in vitro and in vivo assays were purchased from Genemed Synthesis, Inc., 
CA, U.S.A. or Washington Singer Labs. The following sequences were obtained: OVA323- 
3 3 9 , sequence IS Q AVHA AHAEINE AGR, OVA257-264, sequence SIINFEKL, OVA265-280, 
sequence TEWTSSNVMEERKIKV, nucleoprotein of influenza A/NT/60/68366-374 
sequence ASNENMDAM and nucleoprotein of influenza A/NT/6 O/6 8 4 1 3-435, sequence 
SVQRNLPFDKPTIMAAFTGNTEG. Ovalbumin protein was obtained from Sigma and the 
HPV 6  El and HTV polymerase proteins were kindly supplied by Dr Karen Barber and Dr 
Fiona Cook, GSK, U.K. respectively.
23. DNA cartridge preparation for particle-mediated DNA delivery
2.5.1. Standard method
DNA cartridge preparation was based on a method described previously (Eisenbraun et a l , 
1993; Pertmer et al., 1995). Two /xm diameter gold particles (PowderJect Pharmaceuticals, 
Madison, Wisconsin, U.S.A.) were sonicated in the presence of 0.05 M spermidine (Sigma)
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twice for 10 sec. Plasmid DNA (-1000 ng/ml) was added to achieve the standard DLR of 
2000 ng/mg of gold. The DNA was precipitated on to the gold particles by the addition of 1 
M CaCb (American Pharmaceutical Partners Inc., L.A., CA, U.S.A.). The DNA/gold 
complex was incubated for 10 min at RT, washed 3 times in absolute ethanol (previously 
dried on molecular sieve 3A, BDH) and resuspended in absolute ethanol containing 0.05 
mg/ml polyvinylpyrrolidone (Sigma). Tefzel tubing (PowderJect) which had previously 
been dried with N2 was placed inside a tube turner (PowderJect) and the DNA coated gold 
slurry was applied to the inner surface of the tubing by centrifugal force. The tubing was 
cut into 12.5 mm lengths and stored with dessicant at 4°C. Cartridge DLR was assessed by 
elution of 2 cartridges/batch in 50 fil DNase and RNase free water for 30 min at 37°C and 
5% CO2 followed by spectrophotometric quantitation using a Genequant II (Pharmacia 
Biotech). Preparations that contained 500 ng ± 100 ng DNA/cartridge were considered 
suitable for use.
2.5.2. DNA cartridges containing two plasmids
In experiments comparing delivery of two plasmids to the same or different immunisation 
sites, the term “linked” DNA preparation refers to the presence of relevant plasmids on the 
same gold particles, in the same cartridge and delivered to the same immunisation site. The 
term “unlinked” DNA preparation refers to the presence of the relevant plasmids on 
different gold particles, in different cartridges and delivered to different immunisation sites. 
The linked DNA preparation was made by mixing pVACl.NT and pVACl.OVA in a ratio 
1:9 for the DNA number of copies and co-precipitating on gold particles using a DLR of 
2000 ng/mg of gold. Total amount of DNA/cartridge was 500 ± 100 ng. Two cartridges (i.e. 
a total of 1000 ± 200 ng) were delivered per immunisation (Figure 2.4). The unlinked DNA 
preparations were made by mixing pVACl.NT with pVACl and pVACl.OVA with 
pVACl in ratios of 1:9 and 9:1, respectively and co-precipitating those combinations on 
separate gold particles using a DLR of4000 ng/mg of gold. Total amount of DNA/cartridge 
was 1000 ± 200 ng and 1 cartridge from each preparation was delivered to different
69
Chapter 2: Material and methods
Linked DNA preparation
i
DNA cartridge preparation
I
Immunisation at sites A and B
Unlinked DNA preparation
4
DNA cartridge preparation
I
Immunisation at site A
I
DNA cartridge preparation
I
Immunisation at site B
^  pVACl.NT ^  pVACl.OVA ^ pVACl
Figure 2.4. Schematic representation of linked and unlinked DNA cartridge preparations 
and immunisations.
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immunisation sites (Figure 2.4). In this way, a total of 100 ng of pVACl.NT and 900 ng of 
pVACl.OVA were delivered in immunisations using cartridges made from either linked or 
unlinked DNA preparations. Linked DNA controls were made containing pVACl.OVA or 
pVACl.NT mixed with pVACl in ratios of 9:1 and 1:9, respectively.
2.5.3. DNA cartridges in dose response experiments
DNA cartridges for dose response experiments were made using linked DNA preparations. 
pVACl.NT was titrated in log dilutions from 500-0.005 ng in either pVACl.OVA or 
pVACl. The dual plasmid combinations were co-precipitated on gold particles using a 
DLR of 2000 ng/mg of gold. Total amount of DNA/cartridge was 500 ± 100 ng. Three 50/d 
samples of DNA coated gold particles from each slurry batch were kept for quantitative 
PCR (QPCR) analysis.
2.5.3.1. QPCR analysis
QPCR analysis was performed on DNA eluted from gold particles. To remove the DNA, 
the gold particles were centrifuged at 14,000 rpm for 15 ± 5 sec using an Eppendorf 5415C 
centrifuge. The ethanol was removed and replaced by 45 /d of DNase and RNase free water 
prior to incubation of each sample at 37°C and 5% CO2 for 30 min. Elutions were repeated 
(using 50 fil of RNase and DNase free water on the second occasion) and the two eluates 
pooled for analysis.
Eluted DNA was analysed for pVACl.NT and pVACl.OVA in separate QPCR assays. 
Probes and primers sequences (Perkin Elmer) shown in Table 2.2 were re-constituted to 
stock concentrations of 5 pM/jUl and 22.5 pM/jiil, respectively. The probes were 
flourigenically labelled with reporter, dT-FAM (excitation; 494 nm, emission; 517 nm) and 
quencher, TAMRA (excitation; 560 nm, emission; 583 nm). Optimised primer and probe 
concentrations for the pVACl.NT assay were 90 nM forward primer (FP), 90 nM reverse 
primer (RP) and 250 nM probe. Optimised primer and probe concentrations used in the 
pVACl.OVA assay were 270 nM FP, 900 nM RP and 200 nM probe, respectively. In the
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pVACl.NT assay, each reaction contained 2 /xl DNA eluate (1:10 or 1:100 dilution), 0.1 
/xl each of primers, 1.56 /xl probe, 12.5 /xl master mix (Perkin Elmer) and 8.74 /xl of 
DNase and RNase free water. In the pVACl.OVA assay, each reaction contained 2 /xl 
DNA eluate (1:10,000 dilution), 0.3 /xl FP, 1.0 /xl RP, 1.25 /xl probe, 12.5 /xl master mix 
(Perkin Elmer) and 7.95 /xl of DNase and RNase free water. Reactions were done as 
follows: 120 sec at 50°C, 600 sec at 95°C, 40 cycles (15 sec at 95°C, 60 sec at 60°C). 
Standard curves were generated from stock DNA used to prepare cartridges and ranged 
from 200,000-49 copies//xl. Dilutions of DNA eluates and standards were performed using 
DNase and RNase free water. Analysis was performed on an ABI 7700 sequence detector 
(PE Applied Biosystems).
2.6. In vitro transfection by particle-mediated DNA delivery
Transfection of RAW, J774, DAP-3/ICAM, EL4, MC57 and BMDC by PMDD was 
performed using either the suspension method or the plate method (Figure 2.5).
In the suspension method, a 20 /xl volume of cell suspension was transferred to the bottom 
of a 50 ml universal tube (Falcon). The cells were transfected by PMDD using the XR1 
gene gun (PowderJect). Helium gas pressures ranging from 200-900 psi were used to 
discharge the DNA-coated gold from the cartridges into the cells. A range of distances (27- 
63 mm) of the gene gun from the cells was used. After transfection, the cells were washed 
with 1 ml of culture medium and transferred to 12 or 24 well plates for 24 h and at 37°C 
and 5% CO2. In the experiments to investigate the effect of incubation time on transfection 
efficiency by PMDD using the suspension method, 9 individual samples were pooled 
directly after PMDD and plated out in 9 individual petri dishes (Sterilin) for incubation up 
to 24 or 106 h.
For the plate method, 20 /xl of cell suspension was evenly spread in the centre of a 6 well 
plate and transfected while holding the nozzle of the gene gun directly over the cells. A 
pressure range of 100-500 psi was used for the transfections. Once transfected, the cells
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Forward primer
(5’-3’)
Reverse primer 
(5’-3’)
Probe
(5’-3’)
pVACl.NT -TGAGAGGGTCA
GTTGCTCACA-
-TGGACGGCA
TCGGTCACC-
-TTGTCTGCCC
GCCTGTGTGT-
pVACl.OVA -GAGGAGGCTTGG
AACCTATCAAC-
-AAGGACCCATCT
TTCAGTCTGTTTA-
-CTGCAGATCAAGC
CAGAGAGCTCATC-
Table 22. Probes and primers sequences used in the QPCR analysis of DNA eluates.
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were washed with 1 ml of medium and transferred to 12 or 24 well plates for 24 h at 37°C 
and 5% CO2. For both the suspension and plate PMDD methods, cell viability as estimated 
by Trypan blue (Sigma) exclusion was performed on cells after transfection.
2.7. Assessing transfection efficiency
Cells transfected by PMDD were assessed for transfection efficiency using the luciferase 
and j3-galactosidase detection assays.
2.7.1. Luciferase assay
Cells were lysed by addition of 1 ml of cell culture lysis reagent (Promega) and stored at - 
80°C for 1 h. After thawing, 50 fil of cell lysate from each sample was assayed together 
with 50 fil of luciferase assay reagent (Promega) using either a Dynatech ML3000 
microtiter plate luminometer or a Wallac Victor 1420 multi-label counter. An injection 
volume of 50 fil, sample delay time of 2 sec and data integration time of 20 sec was used. 
For the Dynatech luminometer, results were expressed as mean of duplicate or triplicate 
samples (relative light units (rlu)/ml). For the Wallac multi-label counter, results were 
expressed as mean of triplicate wells (counts per second (cps)/ml). Total protein 
concentration was calculated by Coomasie Plus protein assay reagent kit (Pierce). Ten /xl 
of cell lysate was assayed together with 140 /xl of water and 150 /xl of Coomasie blue 
reagent in 96 well flat bottomed plates (Costar). The absorbance was measured at 595 nm 
on a Molecular Devices Spectra Max 340. Results were expressed as mean of triplicate 
readings (fig/m1). Luciferase activity was expressed as rlu or cps/fig of total protein (Figure 
2.5) and reported as mean ± standard error mean of triplicate assays. All assays were 
performed using the Dynatech luminometer unless otherwise stated.
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2.7.2. fi-galactosidase assay
Transfected cells were tested for f3-galactosidase activity 24 h after PMDD. The cells were 
washed once with 2 ml PBS, fixed with 1 ml of 10 % formaldehyde and incubated at RT 
for 10 min. The cells were washed 3 times in PBS (2 ml/well) before the addition of 1 
ml/well staining solution (5 mM potassium ferricyanide, 5 mM potassium ferrocyanide, 2 
mM magnesium chloride (all from Sigma) and 1 mg/ml X-galactosidase substrate 
(Promega)). The cells were incubated for 24 h at 37°C and 5% CO2 and the total number of 
blue cells/well counted (mean of 10 random counts/well under x 20 magnification). Results 
were calculated as % of positive cells/viable cells plated out for each sample (Figure 2.5) 
and reported as mean ± standard error mean of triplicate assays.
2.8. In vitro functional assays
In vitro functional assays were developed which used APC capable of presenting antigen to 
MHC matched effector cells.
2.8.1. Antigen presenting cells
In the MHC I functional assay, EL4, MC57 (normal and activated cultures) and BMDC 
from C57BL/6 mice were used as APC. To make activated MC57s, normal cultures were 
pre-treated with 20 ng/ml IFN-y for 24 h prior to the in vitro assay. For the MHC II 
functional assay, DAP-3/ICAM cells and BMDC from BALB/c and DO. 11.10 mice were 
used as APC. To make BMDC, cells were extracted from femurs, washed once in complete 
IMDM medium and cultured in complete IMDM containing 8 ng/ml of murine GM-CSF 
(Pharmingen) at 37°C and 5% CO2 in sterile 90 mm Sterilin petri dishes. On day 3, the 
medium was replaced to remove the non-adherent cells. Six or 7 days later, the medium 
containing non-adherent cells (putatively BMDC) was transferred to new petri dishes and 
incubated for 1 h at 37 °C and 5% CO2. Contaminant macrophages adhered to the petri dish 
surface leaving the BMDC in the medium. The putative BMDC were subsequently
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Figure 2.5. Schematic of both the plate and suspension PMDD transfection methods 
followed by luciferase and /3-galactosidase reporter gene detection.
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removed, washed once in complete IMDM medium, counted and adjusted to the 
concentration required for PMDD transfections.
2.8.2. Responder cells
Responder cells for MHC I and MHC II functional assays were naive (freshly prepared) 
and activated RAG1/F5 and DO. 11.10 splenocytes, respectively. To make nai've 
splenocytes, spleens from RAG1/F5 or DO.11.10 were teased between sterile ground glass 
microscope slides (super premium microscope slides, 1.0-1.2 mm thick/twin frost, BDH) 
into a 6 well plate well containing 5 ml sterile PBS. This suspension was transferred to a 50 
ml universal tube (Falcon) and centrifuged at 1500 rpm for 5 min. After removal of the 
PBS, red blood cells were lysed by addition of 1 ml of filtered lysis buffer (155 mM 
NH4CI, 10 mM KHCO3 and EDTA, all from Sigma) to the splenocyte pellet for 1-2 min. 
Forty ml of PBS was then added and the tube centrifuged again. For the RAG1/F5 
splenocytes, this final splenocyte pellet was resuspended in 12 ml of complete RPMI 1640 
medium, debris allowed to settle for ~1 min and the upper 10 ml of cells transferred to a 
new universal tube. For the D0.11.10 splenocytes, the pellet was resuspended in 10 ml PBS 
and filtered through a mouse CD4 subset column (R&D systems). The filtrate, enriched for 
CD4+ T cells, was centrifuged for 5 min at 1500 rpm and the cell pellet resuspended in 10 
ml of complete RPMI 1640 medium. The RAG1/F5 and D0.11.10 splenocytes were then 
washed, counted and adjusted to the concentrations used in the in vitro assay (see sections 
2.8.3 and 2.8.4, respectively) or adjusted to 1 x 107 cells/ml in freezing down medium (FCS 
containing 10% DMSO, Sigma) and stored at -20°C.
For activated splenocytes, 1 x 106 nai've splenocytes/well were stimulated with complete 
RPMI 1640 medium containing 500 nM peptide (RAG1/F5 splenocytes, A/NT/6O/68366-374, 
sequence ASNENMDAM; DOT 1.10 splenocytes, OVA323-339, sequence 
ISQAVHAAHAEINEAGR) and 20 ng/ml murine EL-2. Cells were incubated at 37°C and 
5% CO2 in 24 well plates. On day 3, cells were split 1:3 in complete RPMI 1640 medium 
containing 20 ng/ml EL-2 only. The cells were harvested on day 7, washed, counted and
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adjusted to the concentrations used in the in vitro assay (see sections 2.8.3 or 2.8.4), or 
adjusted to 1 x 107 cells ml in freezing down medium and stored at -20°C.
2.8.3. In vitro CD8+ T cell assay
On the day of assay, APC were transfected with plasmid encoding NT by PMDD (4 x 106 
cells in a 20 \i\ volume using the plate method at 250 or 275 psi) and transferred in 
triplicate to pre-coated 96 well multiscreen-IP sterile ELISPOT plates (Millipore) at a cell 
density of 1 x 105 cells/well. RAG1/F5 splenocytes (freshly harvested or thawed from 
frozen stock) were added at a concentration of 1 x 105 cells/well to the APC. When 
RAG1.F5 splenocytes from frozen stock were used, the cells were thawed out at RT, 
washed 3 times in 10 ml of complete RPMI 1640, counted and adjusted to 1 x 105 
cells/well. As positive controls, APC were pulsed with 100-200 nM of NT peptide 
(A/NT/6O/68366-374, sequence ASNENMDAM) by incubation with peptide for 1 hour at 
37 °C and 5% CO2, washed 3 times in PBS and plated. Negative controls were APC not 
pulsed with peptide and/or APC transfected with pVACl by PMDD. The assay was 
performed in complete RPMI 1640 medium alone or complete RPMI 1640 medium + IL-2 
(200 ng/ml). When MC57 cells were used as APC, complete RPMI 1640 was replaced by 
MC57 growth medium (see section 2.2). The final volume/well was 200 /xl. After 
incubation at 37°C and 5% CO2 overnight, cells were assayed for peptide specific CD8+ T 
cell activation by IFN-y ELISPOT (section 2.9).
2.8.4. In vitro CD4+ T cell assay
On the day of assay, APC were transfected with pVACl.OVAs by PMDD (4 x 106 cells in 
a 20 jitl volume using the plate method at 250 or 275 psi) and transferred in triplicate to 
pre-coated 96 well multiscreen-IP sterile ELISPOT plates (for IL-2 ELISPOT assay) and/or 
to 96 well Costar flat bottomed plates (for IL-2 ELISA and T cell proliferation assays) at a 
cell density of 2 x 105 cells/well. DO.11.10 splenocytes (freshly harvested or thawed from 
frozen stock) were added at a concentration of 2 x 105 cells/well to the APC. DAP-3/ICAM 
cells pulsed with OVA peptide (OVA323-339, sequence ISQAVHAAHAEINEAGR) or
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protein (1000-10 nM) were positive controls. Negative controls were APC not pulsed with 
peptide and/or APC transfected with pVACl by PMDD. Final volume/well was 200 fil. 
After incubation at 37 °C and 5% CO2 overnight, cells were assayed for peptide specific 
CD4+ T cell activation by IL-2 ELISPOT (section 2.9) and/or IL-2 ELISA (section 2.10) 
and thymidine incorporation assays (section 2.11).
2.9. Cytokine detection-ELISPOT
96 well multiscreen-IP sterile ELISPOT plates were pre-coated with purified rat IgG2a anti 
mouse IL-2 (clone JES6-1A12) or rat IgGi anti mouse IFN-y (clone XMG1.2) at a 
concentration of 15 /xg/ml (50 ^1/well) by incubation at 4°C overnight. The plates were 
blocked with complete RPMI 1640 medium for 1 h at 37 °C and 5% CO2 before sample 
addition. After incubation of samples (for both in vitro and in vivo experiments) at 37°C 
and 5% CO2 overnight, plates were washed with PBS, distilled water (100 /x 1/well for 5 min 
at RT) and a further 3 washes with PBS. Detection antibodies were biotin conjugated rat 
IgG2b anti mouse IL-2 (clone JES6-5H4) or rat IgGi anti mouse IFN-y (clone R4-6A2). 
They were added for 2 h at RT at a concentration of 1 pig/ml (50 1/well) while shaking. 
Streptavidin alkaline phosphatase conjugate (Caltag) at a 1:1,000 dilution was added and 
incubated for 2 h at RT (50 /xl/well) while shaking. All antibodies were purchased from 
Pharmingen unless otherwise stated. Three washes with PBS were performed between each 
step. Fifty /xl/well of alkaline phosphatase conjugated substrate (BIO-RAD) was used to 
develop the assay and the assay stopped by the addition of water once spots appeared 
(usually between 10 and 30 min after substrate addition). After drying at RT overnight, 
cytokine producing cells were enumerated by an image analysis system developed by GSK. 
For in vitro experiments, number and/or area of cytokine spots (normalised to spots/million 
cells) were calculated and results reported as mean ± standard deviation of triplicate wells. 
For in vivo experiments, number of cytokine spots (normalised to spots/million cells) were 
calculated and results reported as mean ± standard error mean of triplicate samples.
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2.10. Cytokine detection-ELISA
Purified rat IgG2a anti mouse IL-2 (clone JES6-1A12) was coated on Nunc maxisorb 96 
well plates at a concentration of 2 /ng/ml in PBS (50 /xl/well) and incubated at RT 
overnight. Non specific binding was blocked by addition of 50 /xl/well of PBS with 1 % 
BSA (Sigma) and incubation for 1 h at RT. Fifty /xl of culture medium supernatant (1:5 
dilution) collected after the incubation of APC and T cells (see section 2.8.4) and 
recombinant murine IL-2 (Pharmingen) were added and incubated for 2 h at RT while 
shaking. Detection antibody was biotin conjugated rat IgG2b anti mouse IL-2 (clone JES6- 
5H4) and was added at a concentration of 1 /xg/ml (50 /xl/well) while shaking. After 2 h at 
RT, streptavidin-HRP conjugate (Caltag) at a 1:2,000 dilution was added and left for 30 
min in the dark at RT (50 /xl). Three washes with PBS containing 1% BSA were performed 
between each step. Fifty /xl/well of tetramethyl benzidine substrate (Sigma) was used for 
colour development, the reaction stopped with 1 N H2SO4, and plates read at 450 nm on a 
Molecular Devices Spectra Max 340. Results were reported as mean ± standard deviation 
of triplicate wells.
2.11. T cell proliferation
Fifty /xl of complete RPMI 1640 medium was added back to the 96 well plates to replace 
that taken for EL-2 ELISA analysis (see section 2.10). The cells were pulsed with 20 /xl of 
- low activity 3H thymidine (33 KBq/well) (Amersham Life Sciences). After incubation 
overnight at 37 °C and 5% CO2, the cells were harvested and thymidine incorporation 
measured using a liquid scintillation counter (Wallac 1205 Betaplate). Results were 
reported as mean ± standard deviation of triplicate wells.
2.12. Western blot analysis
MC57 cells were transfected with plasmid encoding NT by PMDD (4 x 106 cells in a 20 /xl 
volume using the plate method at 275 psi), adjusted to 1 x 106 cells/ml in MC57 growth 
medium and incubated overnight at 37°C and 5% CO2 in 24 well plates (1 ml cells/well).
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For each sample, cells were removed from wells, transferred to Eppendorf tubes, washed 
once in 500 /tl of PBS and resuspended in 100 /xl of PBS for analysis. Samples were run on 
a NuPAGE No vex gel (Invitrogen). Sixteen /xl of sample were incubated with 5 /xl of 4 x 
buffer and 1.5 /xl of 10 x buffer (both from NuPAGE lysis kit, Invitrogen) for 10 min at 
80°C and 20 /xl of sample loaded on the gel. For positive control, 1 /xl of PR-GST fusion 
protein (1 mg/ml) was incubated with 9 /xl of water, 5 /xl of 4 x buffer and 1.5 /xl of 10 x 
buffer and 5 /xl loaded on the gel. For internal protein marker, 5 /xl of SeeBlue protein (4- 
250 kDa ladder, Invitrogen) was added to 2 or 3 wells. The gel was mn for 35 min at 200 
volts in mnning buffer and on completion, transferred to an Immobilon P membrane 
(Millipore) in transfer buffer for 1 h at 30 volts. Running buffer and transfer buffer were 
made by diluting 10 x NuPAGE MES running buffer and 10 x NuPage transfer buffer (both 
from Invitrogen) 1:10 in deionised water, respectively. Next, 10 ml of block buffer (PBS 
with 0.1% Tween and 100 mg/ml condensed milk, both from BDH) was added to the blot 
for 1 h at RT. The blot was incubated for 2 h with primary antibody (rabbit serum anti NT- 
GST fusion, 1:500 dilution) and 1 h with secondary antibody (swine anti rabbit 
immunoglobulin-HRP (Dako), 1:20,000 dilution). Both incubations were performed in 10 
ml of block buffer at RT. Four washes in PBS containing 0.1% Tween were done between 
each step. Then, 6 ml of ECL detection substrate (BioWest or Amersham) was added to the 
blot for 5 min at RT while gently shaking. Finally, the blot was placed between plastic 
sheets and exposed on a EpiChemi II darkroom (Ultra-Violet Products) and/or a Fugi X- 
Ray developer using Hyperfilm™ ECL™ film (Amersham).
2.13. Immunisations
Immunisations were kindly performed by Dr L Thomsen, Dr F Cook, Dr G Bembridge or 
Dr K Barber, GSK, U.K. Recipient mice (3 per group), 4 to 10 weeks of age, were shaved 
on their abdomen and given 2 cartridges, one cartridge on either side of the ventral mid­
line. PMDD was performed using the Powderject XR1 device. Helium pressure of 500 psi 
was used to discharge the DNA (typically 500 ng/cartridge) from the cartridges to the mice. 
For immunisations involving unlinked DNA preparations, (refer to section 2.5.2 and Figure
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2.4), one cartridge containing one plasmid was delivered to one side of their abdomen and 
the second cartridge containing the second plasmid was delivered to the other side.
2.13.1. Cytokine producing cells
On the day of analysis, spleens were removed and single cell suspension of splenocytes 
prepared. The method used was that described for nai've RAG1/F5 splenocytes (section 
2.8.2). Cytokine producing cells were analysed by ELISPOT as described in section 2.9. 
For each assay, 2 or 4 x 105 splenocytes (100 /d/well) were assayed in triplicate. The 
following combinations were added to give a final volume of 200 /xl/well: complete RPMI 
1640 medium + 50 ng/ml IL-2 or complete RPMI 1640 medium + 50 ng/ml IL-2 + peptide. 
NT peptide, ASNENMDAM, or OVA peptide, SIINFEKL were added at 100 nM. NT 
peptide, SVQRNLPFDKPTIMAAFTGNTEG, OVA peptide, TEWTSSNVMEERKIKV or 
HPV 6 El protein were added at 20 fiM and HIV polymerase protein was added at a 
concentration of 10 /xg/ml. The concentrations of NT peptides, OVA peptides and HPV 6 
El and HIV protein used were previously determined by Dr K Barber, Dr L Thomsen and 
Dr F Cook, respectively. Results (mean ± standard error mean) for each group of mice were 
calculated as the means of individual means of triplicate results for each individual mouse.
2.13.2. Intracellular cytokine staining
- Aliquots of sample prepared for ELISPOT analysis (see section 2.13.1) were taken for ICS 
analysis. Pooled splenocytes (2 x 106) were incubated for 6 h at 37°C and 5% CO2 in flow 
cytometry tubes (Beckman Coulter) containing 1 ml of complete RPMI 1640 medium with 
100 nM NT peptide, sequence ASNENMDAM and 50 ng/ml IL-2. After 2 h, Brefeldin A 
(Sigma) was added to a final concentration of 10 /xg/ml. After incubation for the remaining 
4 h, they were centrifuged for 5 min at 1500 rpm, washed with 3 ml of FACS buffer (PBS 
containing 1% FCS) and surface stained with rat IgG2a anti mouse CD62L-FITC 
(Pharmingen, clone MEL-14, 0.125 fig/sample) and rat IgG2a anti mouse CD8-Cy-Chrome 
(Pharmingen, clone 53-6.7, 0.5 fig/sample). Staining was done in FACS buffer (100 
/xl/sample) for 20 min at 4°C. Cells were washed twice and kept overnight at 4°C in
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fixative solution (Intra prep, kit, Immunotech, 100 /fi/sample). Next, they were washed 
twice and stained for rat IgGi anti mouse IFN-y-PE (Pharmingen, clone XMG1.2, 0.1 
/xg/sample) for 15 min at RT in permeabilisation solution (Intra prep, kit, 100 /xl/s ample). 
Finally, they were washed twice in FACS buffer and resuspended in an 800 /xl volume for 
analysis. Flow cytometry analysis was performed on a Beckman Coulter EPICS XL using 
system II acquisition software.
2.14. Statistical analysis
For in vitro analyses, Dunnett’s test or Student’s T-test was performed in experiments that 
were repeated at least three times. For in vivo analyses, Student’s T-test was performed in 
all experiments where applicable.
The Dunnett’s test is a multiple comparison procedure for comparing each mean against a 
standard control group mean. The Student’s T-test is used to test hypotheses between 
population means. For the in vivo experiments, 3 mice/group were routinely used. Because 
of this limited sample size, the degrees of freedom associated with these groups are small 
thus making it difficult to detect significance between group means.
The in vivo and in vitro immunising dose and promoter dose responses were compared 
using correlation analysis. Mean values was used for correlation and linear trend-line 
regression coefficient (R2) was fitted to the data.
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3.1. Introduction
The ability of the adaptive immune response to develop immunological memory forms the 
basis for the successful application of vaccination in human health-care. In the past, many 
vaccine strategies have been developed to eradicate infectious diseases with varying 
degrees of success. Recently, taking advantage of developments in recombinant DNA 
technology and molecular biology, research in the field of vaccination has focused on the 
development of DNA vaccines in various forms. Before such vaccines can be successfully 
utilised, prophylactically or therapeutically in man, many important issues need to be 
addressed. These issues centre not only upon the biological potency of DNA vaccines 
themselves and their ability to evoke a complete and balanced immune response, but also 
on the efficacy of the technology used to deliver the DNA.
This is especially pertinent to PMDD where compressed helium gas is used to accelerate 
microscopic gold beads coated with DNA into the target tissue. Optimal delivery is 
dependent on a number of variables, some of which may be manipulated or improved to 
enhance the efficiency of delivery. These variables may be broadly categorised as ballistic 
(i.e. associated with the PMDD process) or non-ballistic (i.e. independent of the PMDD 
process). Given that responses to DNA vaccines in man are at present unsatisfactory, 
optimising these parameters will help play an important role in determining the success of 
this type of vaccine strategy.
Since the emergence of PMDD as a vaccination tool with implications in the clinic, the 
application of this technique for the transfection of mammalian cells has also gained 
interest. It was first pioneered as a means of introducing genetic material into plant cells 
(Klein et al., 1987) and now the technique assumes an important role as a transfection tool 
in this field. Due to improvements in device technology and more importantly, it’s direct 
applicability to the in vivo transfection process, PMDD to mammalian cells ex vivo and in 
vitro is becoming the subject of an increased amount of research. In terms of efficiency, it 
compares favourably with lipofection and calcium phosphate transfection (Thompson et al, 
1993; Yang et a l , 1990; Heiser, 1994; Guo et a l, 1996). It is not as efficient as viral
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transfection techniques but it is easier and quicker to use and does not suffer from the same 
complications associated with gene delivery. Unlike most other transfection methods, 
PMDD is a mechanical way of introducing genes across the plasma membrane and 
therefore is not affected to the same extent as other methods by the characteristics of the 
targeted cell.
However, there are still inconsistencies associated with the technique which prevent its 
more widespread use. Significantly, PMDD to mammalian cells in vitro has employed 
different delivery devices and reports have incompletely defined the extent of experimental 
parameter optimisation (Fitzpatrick-McElligott, 1992; Zelenin et al., 1989). Furthermore, 
transfected cell lines show different expression rates for the introduced gene (Gainer et a l, 
2000) highlighting the requirement for the assessment of each individual cell line for each 
gene introduced. In this chapter, the effect of various ballistic and non-ballistic variables on 
PMDD transfection efficacy has been assessed. Different methods of PMDD to mammalian 
cells of varying lineage in vitro were investigated and compared using the 3-galactosidase 
and firefly luciferase reporter genes.
32. Objective
• To develop and optimise a PMDD method for transfection of mammalian cells in 
vitro using the PowderJect XR1 delivery device.
• To investigate PMDD transfection efficiency in a range of cell lines.
• To identify suitable cell lines on the basis of transfection efficiency for subsequent 
use in in vitrolin vivo correlation studies.
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33. Results
3.3.1. In vitro transfection by PMDD using the suspension method
Optimisation of in vitro transfection by PMDD using the suspension method (described in 
Figure 3.1) was performed using mouse macrophage cell lines, RAW and J774 and the 
transformed fibroblast cell line DAP-3/ICAM. Process variables investigated were cell 
suspension volume and concentration of cells transfected, device positioning, PMDD 
pressure and incubation time after PMDD. The effect of cell suspension volume and 
concentration of cells transfected on PMDD efficiency is shown in Figure 3.2, panel A. The 
data indicates that for both J774 and RAW cell lines, a higher cell concentration (1 x 107 
cells) was optimal for transfection efficacy while altering the cell suspension volume had 
less influence on the level of transfection. Neither parameter affected cell viability. RAWs 
transfected much more efficiently than J774 cells and were less susceptible to cell death 
following the transfection process (-7.0 % for RAWs compared with ~ 13.3 % for J774s).
The effect of device positioning on transfection efficacy is represented in Figure 3.2, panel 
B and shows that optimal transfection was achieved when the PMDD device was 
positioned closest to the cell suspension (i.e. 27 mm from the RAW suspension and 27-36 
mm from the J774 cell suspension). Cell death was at its greatest at the 27 mm distance 
(-28.0 % for RAW and -31.3 % for J774). As expected, there was an overall decrease in 
transfection efficiency and cell death as the device was moved away from the cells.
For PMDD pressure, transfection efficacy increased with increasing PMDD pressure to an 
optimal delivery pressure of 800 psi in one assay and 900 psi in the other two (Figure 3.3, 
panel A). The accompanying cell death data (Figure 3.3, panel B) was generally low (<10 
%) except at 900 psi where the mean of three assays was -13 %. The final variable 
investigated was that of incubation time after PMDD. Two separate time-course 
experiments were performed using DAP-3/ICAM cells only (0-24 h) and DAP-3/ICAM 
and RAW cells (8-106 h). In the 24 h time-course experiment, luciferase expression
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Figure 3.1. Schematic representation of suspension and plate PMDD transfection methods.
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Figure 3.2. The effect of cell suspension volume and cell concentration (Panel A) and 
device positioning (Panel B) on PMDD efficiency using the suspension method. PMDD of 
pGL3-CMV-luciferase was carried out at 500 psi using RAW and J774 cells. In A, the 
delivery device was positioned 63 mm from the cell suspension. In B, a cell suspension 
volume of 20 /tl and cell concentration of 4 x 106 cells was used. For both A and B, 
luciferase activity was measured 3.5 h after PMDD with results expressed as rlu//xg protein. 
Data are from one experiment and represent mean of duplicate analyses. Bars represent data 
for luciferase activity. Lines and symbols represent cell viability data.
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Figure 3.3. The effect of PMDD pressure on transfection efficiency (A) and cell viability 
following PMDD (B) using the suspension method. PMDD of pGL3-CMV-luciferase was 
carried out using DAP-3/ICAM cells (4 x 106 cells in 20 /zl) with the delivery device 
positioned 27 mm from the cells. Luciferase activity was measured 24 h after PMDD with 
results expressed as rlu//xg protein. Data are from three separate experiments and represent 
mean of triplicate analyses of one transfection suspension. Broken line joins the means of 
all experiments. Panels C and D: effect of incubation time on PMDD transfection efficiency 
using the suspension method. PMDD of pGL3-CMV-luciferase was carried out using DAP- 
3/ICAM and RAW cells (C) or DAP-3/ICAM cells only (D) (4 x 106 cells in 20 /xl) at 500 
psi with the delivery device positioned 27 mm from the cells. Luciferase activity was 
expressed as rlu//zg protein. For both C and D, data are from one experiment and represent 
mean of triplicate analyses of one transfection suspension.
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increased continually to a maximum at 21.5 h (Figure 3.3, panel D) and then decreased. 
This is in accordance with the longer time course experiment (Figure 3.3, panel C) which 
shows an increase in luciferase expression up to 24 h followed by a gradual decrease to a 
background level of expression after -72-80 h. Collectively, the data infers an optimal 
incubation time of between 20 and 24 h for DAP-3/ICAM cells. In contrast, RAWs cells 
appear to reach a peak level of expression much earlier (at least by 8 h) which decreases to 
a background level of expression after 48 h.
3.3.2. Comparison of suspension and plate methods
Preliminary experiments with the suspension method suggested that transfection was best 
with a high cell concentration (i.e. > 4 x 106 cells) in a small volume (i.e. 20 /xl) with the 
device positioned close to the cells (i.e. < 27 mm). Under these conditions, optimal 
transfection efficacy was achieved at pressures of > 800 psi (Figure 3.3, panel A). For the 
plate method (described in Figure 3.1), optimal luciferase expression was achieved using 
PMDD pressures of 250-350 psi (Figure 3.4). Both data sets appear to show similar levels 
of inter-assay variability, especially around the optimal PMDD pressures (i.e. 700-900 psi 
for the suspension method and 200-350 psi for the plate method). Highest average reading 
for luciferase expression was -1365 and -1400 rlu//xg protein for the suspension method 
(900 psi) and plate method (250 psi), respectively.
To make a more accurate comparison of both transfection methods, DAP-3/ICAM cells 
were transfected with (3-galactosidase and luciferase plasmids by both methods using the 
same conditions and reporter gene expression (Figure 3.5, panels A and B) and cell death 
following transfection (Figure 3.5, panels C and D) were assessed. Optimal (3-galactosidase 
and luciferase expression was obtained at PMDD pressures of 700 and 900 psi for the 
suspension method and at 200 and 300 psi for the plate method, respectively. In both 
assays, the maximum level of reporter gene expression using the plate method exceeded 
that of the suspension method. Cell viability using the suspension method was high in both 
the (3-galactosidase and luciferase assays (Figure 3.5, panels C and D) over the PMDD
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Figure 3.4. The effect of PMDD pressure on transfection efficiency using the plate method. 
PMDD of pGL3-CMV-luciferase was carried out using DAP-3/ICAM cells (4 x 106 cells in 
20 /d) with the delivery device positioned against the base of the tissue culture well directly 
over the cells. Luciferase activity was measured 24 h after PMDD with results expressed as 
rlu//xg protein. Data are from three separate experiments and represent mean of triplicate 
analyses of one transfection suspension. Broken line joins the means of all experiments.
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Figure 3.5. Comparison of PMDD suspension and plate methods. PMDD of pCIneo-CMV- 
p-galactosidase and pGL3-CMV-luciferase was performed using DAP-3/ICAM cells (4 x 
106 cells in 20 /xl) with the delivery device positioned 27 mm from the cell suspension for 
the suspension method or against the base of the tissue culture well directly over the cells 
for the plate method. The effect of PMDD pressure on P-galactosidase and luciferase 
transfection efficiency is shown in panels A and B, respectively. The effect of PMDD 
pressure on cell viability following PMDD of P-galactosidase and luciferase plasmids is 
shown in panels C and D, respectively. Activity was measured 24 h after PMDD with p- 
galactosidase results expressed as % of positive cells total viable cells plated out and 
luciferase results expressed as rlu//xg protein. Data are from one experiment and represent 
mean of triplicate analyses of one transfection suspension.
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pressure range investigated. However, when the plate method was employed for 
transfection, increasing the PMDD pressure above 400 psi in both assays resulted in near 
total cell death.
3.3.3. Evaluation of transfection ability of a range of cell lines
Cell lines EL4, MC57 and BMDC purified from BALB/c mice were assessed for 
transfection efficiency using the plate method and the P-galactosidase reporter plasmid 
(Figure 3.6). Results demonstrate that both EL4 and MC57 cells are transfectable while the 
BMDC prove refractory to transfection. The EL4 cells transfected at frequencies of -1.4 
and -0.1 and MC57 cells at -3.2 and -8.3 % in assay one (using cartridge preparation A) 
and two (using cartridge preparation B), respectively. Representative P-galactosidase 
transfections of EL4 and MC57 cells from assay two is shown in Figure 3.6, panels B-E. 
The data shows that there is considerable inter and intra-assay variation within these assays, 
a feature previously reported (Yang et al., 1990). DAP-3/ICAM and FS-DC cells were 
assessed for transfection efficiency in separate studies transfecting at -0.8 % (Figure 3.5, 
panel A) and 0 % (data not shown), respectively.
3.3.4. Further optimisation of transfection of the MC57 cell line
Transfection of the MC57 cell line was investigated further and optimal transfection 
conditions were more completely defined. Initially, incubation time after PMDD was 
optimised, followed by cell resting time after PMDD (i.e. incubation time between 
transfection and resuspension of cells in medium after transfection), then PMDD pressure 
and finally concentration of cells transfected. Each condition was investigated using 
luciferase and/or p-galactosidase reporter plasmids. Luciferase detection for these assays 
was performed using a Wallac Victor 1420 Multi-label counter and the cell death data 
represented is that associated with the P-galactosidase transfection assays. For the effect of 
incubation time after PMDD on transfection efficacy, reporter gene expression was 
assessed from 12-28 h post PMDD (at 4 hourly intervals). In general, a relatively constant
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Figure 3.6. Transfection of EL4 (n=5), MC57 (n=5) and BMDC (n=4) with pCIneo-CMV- 
(3-galactosidase using the plate method (panel A). PMDD was performed at 250 psi using 4 
x 106 cells in 20 jul with the delivery device positioned against the base of the tissue culture 
well directly over the cells. P-galactosidase activity was measured 24 h after PMDD with 
results expressed as % of positive cells/total viable cells plated out. Panels B-E are 
representative photographs after P-galactosidase staining of pVACl.OVAs transfected EL4 
cells, pCIneo-CMV-p-galactosidase transfected EL4 cells, pVACl.OVAs transfected 
MC57 cells and pCIneo-CMV-P-galactosidase MC57 cells, respectively. Photographs were 
taken using a Nikon CF PL with Kodak NC film (magnification: X 250).
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EL4 MC57 BMDC
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level of reporter gene expression was obtained over the time-course investigated with 
average readings for luciferase (-21,440 cps//xg protein) and P-galactosidase expression 
(-4.0 %) peaking at the 20 h time-point (Figure 3.7, panels A and B, respectively). For cell 
resting time after PMDD (0-15 min) results for luciferase expression showed an average 
maximum level of expression (14,210 cps//xg protein) using a resting time of 6 min (Figure
3.8, panel A). In contrast, the p-galactosidase transfections recorded the highest average 
reading (-1.8 %) at a resting time of 9 min (Figure 3.8, panel B). The cell death data 
indicated that cell viability is not affected by cell resting time with average values 
remaining constant over the cell resting time range investigated (Figure 3.8, panel C).
The contribution of PMDD pressure on transfection efficacy was also investigated. Cells 
were transfected using a PMDD pressure range of 100-450 psi. Optimal luciferase 
expression was obtained at 300 psi, with all assays exhibiting a similar trend over the 
PMDD pressure range investigated (Figure 3.9, panel A). For P-galactosidase expression 
optimal expression was observed at 350 psi in two assays and 200 psi in the third (Figure
3.9, panel B). The highest average values for luciferase and P-galactosidase expression 
were -17,710 cps//xg protein and -1.7 % at 300 and 200 psi, respectively. Viability of cells 
decreased with increasing PMDD pressure (Figure 3.9, panel C) with a difference of 25.1 
% in the average cell death between the highest and lowest PMDD pressures used (-79.7 % 
at 450 psi and -54.6 % at 100 psi).
The final variable optimised was cell concentration. Three concentrations of cells (2, 4 and 
8 x 106 cells in a 20 /xl volume) were transfected using the luciferase reporter plasmid. 
Although optimal luciferase expression was achieved at a cell concentration of 4 x 106 
cells/20 /x 1 in two of the three assays performed, the highest average value for luciferase 
expression (-28,040 cps//xg protein) was obtained at 2 x 106 cells/20 /xl (Figure 3.10). 
Optimal conditions for PMDD to MC57 cells were identified as follows: incubation time 
after PMDD of 20 h, cell resting time of 6-9 min, PMDD pressure of 200-300 psi and cell 
concentration of 2-4 x 106 cells/20 /xl.
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Figure 3.7. The effect of incubation time after PMDD on luciferase and P-galactosidase 
transfection efficiency in MC57 cells is shown in panels A and B, respectively. PMDD of 
pGL3-CMV-luciferase and pCIneo-CMV-P-galactosidase was performed at 250 psi using 
the plate method (8 x 106 cells in 20 /xl) with the delivery device positioned against the base 
of the tissue culture well directly over the cells. Cell resting time of 9 min was used. 
Activity was measured 24 hrs after PMDD with P-galactosidase results expressed as % of 
positive cell s/total viable cells plated out and luciferase results expressed as cps //xg protein. 
For each experiment, data represent mean of triplicate analyses of three transfection 
suspensions. Broken line joins the means of all experiments on each graph.
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Figure 3.8. The effect of cell resting time on luciferase and (3-galactosidase transfection 
efficiency in MC57 cells is shown in panels A and B, respectively. The effect of cell resting 
time on MC57 cell viability following PMDD of (3-galactosidase is shown in panel C. 
PMDD of pGL3-CMV-luciferase and pCIneo-CMV-(3-galactosidase was performed at 250 
psi using the plate method (8 x 106 cells in 20 jLil) with the delivery device positioned 
against the base of the tissue culture well directly over the cells. Activity was measured 20 
h after PMDD with (3-galactosidase results expressed as % of positive cells/total viable 
cells plated out and luciferase results expressed as cps//xg protein. For each experiment, 
data represent mean of triplicate analyses of three transfection suspensions. Broken fine 
joins the means of all experiments on each graph.
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Figure 3.9. The effect of PMDD pressure on luciferase and P-galactosidase transfection 
efficiency in MC57 cells is shown in panels A and B, respectively. The effect of PMDD 
pressure on MC57 cell viability following PMDD of p-galactosidase is shown in panel C. 
PMDD of pGL3-CMV-luciferase and pCIneo-CMV-P-galactosidase was performed using 
the plate method (8 x 106 cells in 20 fi\) with the delivery device positioned against the base 
of the tissue culture well directly over the cells. A cell resting time of 6 min was used. 
Activity was measured 20 h after PMDD with p-galactosidase results expressed as % of 
positive cells/total viable cells plated out and luciferase results expressed as cps//xg protein. 
For each experiment, data represent mean of triplicate analyses of three transfection 
suspensions. Broken line joins the means of all experiments on each graph.
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Figure 3.10. The effect of cell concentration on luciferase transfection efficiency. PMDD 
of pGL3-CMV-luciferase was performed at 300 psi using the plate method (2-8 x 106 cells 
in 20 fx 1). Cell resting time of 6 min was used. Activity was measured 20 hrs after PMDD 
with results expressed as cps/jUg protein. For each experiment, data represent mean of 
triplicate analyses of three transfection suspensions. Broken line joins the means of all 
experiments on each graph.
100
Chapter 3: Optimisation of PMDD in vitro
3.4. Discussion
As an emerging technology, PMDD is constantly undergoing modifications to enhance its 
potential as a delivery system and increase its applications as a transfection tool. Many 
variants of the delivery device such as those with gun powder, electric charge and helium 
gas actuation mechanisms have been successfully used in the transfection of mammalian 
cells. However, this makes it difficult to compare findings between laboratories in terms of 
optimisation procedures and transfection efficacy of cell lines. Indeed published results 
demonstrate significant differences in transfection efficiency with different transfection 
methods (Andreason et al., 1989; Ray et al., 1992). Furthermore, it is evident that certain 
cell lines such as malignant melanoma B-16 and human breast adenocarcinoma MCF7
(NovakOvic et al., 1999) are receptive to PMDD while others such as human monocyte 
derived dendritic cells transfect very poorly or not at all (Smith et a l, 2001). Though there 
is a certain degree of uniformity with respect to transfection conditions used, it is 
acknowledged that for any one type of delivery device, optimal transfection conditions 
must be empirically defined for each cell line (Heiser, 1994). In accordance with such 
findings, transfection of mammalian cells in vitro by PMDD using the PowderJect XR1 
device in this study appeared to be influenced by both ballistic and non ballistic parameters 
of the transfection techniques. By using reporter gene assays, it was possible to assess these 
variables in terms of quality and quantity of transfection.
3.4.1. Influence of ballistic variables
For the suspension method of PMDD, ballistic variables investigated were volume and 
concentration of cells, PMDD pressure and device positioning. All with the exception of 
volume of cells proved important. Increasing the concentration of cells and PMDD pressure 
led to increased transfection efficacy as did positioning the delivery device close to the cell 
suspension. For the plate method, the effect of concentration of cells, PMDD pressure and 
cell resting time on transfection efficiency was assessed using MC57s. Results from these 
studies are not dissimilar to those seen with the suspension method in that increasing
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PMDD pressure and cell concentration to a certain point leads to increased transfection 
efficiency. Beyond this point, transfection efficiency diminishes.
For both methods, there may be reasons why the individual parameters studied affect 
transfection quality. For example, having a concentrated suspension of cells may create a 
more viscous target for the DNA coated gold particles, which, when delivered are more 
successfully retained in the target area leading to increased transfection. Likewise, the 
distance of the delivery device from the cell suspension determines the target area of the 
DNA coated gold particles. Thus, the greater the target area and consequent lower density 
of gold particles is consistent with a lack of improvement in transfection efficiency. 
Additionally, since the gold particles used are small (2 fxM in size), their flight may easily 
be disrupted by the presence of gasses and particles overlaying the cells. The latter idea is 
supported by the findings of Klein et al. (1987), who observed that increasing the distance 
between device and target caused an increase in the deceleration force which led to reduced 
transfection efficiency. However, it is noteworthy that in that particular study, a gun 
powder charge actuation device was used to accelerate plasmid coated tungsten particles 
from a cylindrical nylon disc on to target cells. Therefore, although it would be incorrect to 
assume that the presence of gasses and particles between the device and target cells plays 
an important role in determining transfection efficiency using the XR1 device, it warrants 
further investigation.
The variable of greatest importance appears to be PMDD pressure. Increasing pressure has 
a positive influence on transfection efficiency which may be due to the increasing 
penetration force of the delivered gold particles. However, results using both methods 
highlight the importance of achieving a delicate balance between force required for cell 
penetration by the gold particles and protection offered to the cells. With the plate method, 
it is evident that exceeding a delivery pressure of 250-300 psi disrupts this balance resulting 
in decreased cell viability and transfection efficiency. In contrast, it appears as though this 
balance has not yet been reached when DNA is delivered at 900 psi using the suspension 
method with little significant difference in cell death between this and lower pressures used. 
Due to the technical constraint of the pressure regulator, it was not possible to investigate
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delivery pressures above 900 psi with the XR1 device. This is unfortunate as many 
researchers have obtained optimal delivery using PMDD pressures above 900 psi. 
Fitzpatrick-McElligiot (1992) showed optimal transfection efficiency in Chinese hamster 
ovary cells and mouse T lymphocyte cell lines (i.e. EL4 and BF-1) at a pressure of 1300 
psi. Similarly, Timares et al. (1998) demonstrated optimal transfection efficiency of mouse 
DC (i.e. XS106) and fibroblast (i.e. NS46) cell lines at 950 and 1000 psi, respectively.
In addition to assessing the contribution of individual variables on transfection efficiency, it 
is also important to consider the relationship that exists between the individual ballistic 
parameters and the overall effect that this interactivity has on transfection efficiency. For 
example, the relationship between particle size, target distance and chamber vacuum on 
particle velocity using a gun powder actuated device was shown by Klein et al. (1987). 
Interestingly, Heiser (1994) demonstrated an interaction between these parameters using a 
similar device (i.e. using a helium gas and not gun powder actuation mechanism) but 
suggested that the interactive relationship applied only to a single particle size (i.e. 1.6 /xm). 
Intuitively, one would expect that interactivity of various ballistic parameters may affect 
transfection efficiency regardless of the type of delivery device used. A possible negative 
example of this interactive relationship in these studies is the unusually low transfection 
efficiency obtained when luciferase plasmid was delivered to DAP-3/ICAMs at 500 psi 
using the suspension method (Figure 3.3, panel A). In each of the three assays performed, 
the transfection efficiency obtained at this pressure was not in keeping with the general 
trend of the data (i.e. increasing transfection efficiency with increasing PMDD pressure). 
The relationship between PMDD pressure, particle size and target distance on particle 
velocity at this PMDD pressure may be a negative one and may result in poor transfection 
efficiency.
3.4.2. Influence of non ballistic variables
For both transfection methods, non ballistic variables investigated were cell type 
transfected and incubation time after PMDD. The reporter gene expression profiles over 
time of RAWs, DAP-3/ICAMs and MC57s obtained in this study may be representative of
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the different biological functions that they perform in vivo. Macrophages play a key role in 
innate immunity performing such functions as phagocytosis and cytokine secretion such 
that early promoter activity and gene induction may be advantageous. Data obtained for the 
macrophage cell line in this study (i.e. RAWs) is in agreement with previous findings in 
which it was demonstrated that murine macrophages transfected by PMDD expressed high 
levels of transgene after only 4-8 h (Burkholder et a l, 1993). Fibroblasts, on the other hand 
are typical bystander cells which can act as depots for the slow release of antigen in an 
immune response and therefore sustained gene expression may be considered beneficial. 
Another important consideration in the determination of optimal incubation time is choice 
of reporter gene. Tanner et al. (1997) showed that the difference between the kinetics of the 
GFP and luciferase gene expression following PMDD may affect the determination of 
optimal incubation time. In that study, luciferase protein showed optimal expression at -12 
h after transfection but degraded rapidly after this point while GFP protein remained intact 
for longer expressing optimally at -24 h. However, for the MC57s investigated in this 
study, the luciferase and p-galactosidase reporter genes used for transfection generally 
showed similar expression profiles over the time-course studied.
Possibly the most influential variable in determining PMDD efficiency is also the one that 
is least controllable; the cell line transfected. Yang et al. (1990) reported variable 
chloramphenicol acetlytransferase activity in eight different human cell lines of varying 
origin using a high-voltage electric discharge device. Furthermore, occasion to occasion
variability within the same cell line was demonstrated by NovakOvic et al. (1999) who 
recorded transfection rates of 2-27 % (average of 10.5 %) and 1-11 % (average of 3.9 %) 
for MCF7 and L929 cell lines, respectively, using a helium gas driven device. However the 
inter-assay variation observed with the MC57s in these studies was not as large with 
transfection efficiencies ranging from 1.7—8.3 %. In general, tumour cell lines (i.e. like 
MC57s) appear receptive to PMDD with reported transfection rates of up to 35 % (Zhang et 
al, 2002) while dendritic cells (i.e. like BMDCs) transfect very poorly or not all (Smith et 
al, 2001; Zhong et al., 1999). These studies as well as the data presented in this chapter 
support the opinion that, even after process optimisation, it is the intrinsic transfectability of
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the cell line itself which may have the greatest influence on determining PMDD 
transfection rates.
3.5. Conclusions
When the plate and suspension methods of PMDD to mammalian cells were evaluated, the 
maximum level of reporter gene expression using the plate method exceeded that of the 
suspension method. Of the cell lines investigated, MC57s transfected the best. EL4 and 
DAP-3/ICAM displayed only adequate levels of transfection while BMDC proved 
refractory to transfection by this method. These results demonstrate two important features 
of this transfection technique.
• The first is that with the possible exception of delivery pressure, optimising 
experimental variables and transfection methods has relatively little effect on 
improving the transfection efficacy of a cell line. However, the contribution of 
certain potentially important variables such as gold particle size and DNA loading 
has not been evaluated. Also, possible improvements in delivery device design may 
make these parameters more influential and facilitate improved transfection.
• Secondly and more significantly, large differences in transfection efficiencies 
between cell lines achieved here and elsewhere infer that it is the intrinsic 
transfection ability of the cell line itself that ultimately dictates transfection efficacy.
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4.1. Introduction
During the development of DNA vaccines they are tested in prophylactic or therapeutic 
efficacy models in animals and success in these models is the critical requirement for 
progression into man. Thus, there is almost a total reliance on in vivo studies with in vitro 
or ex-vivo methods not yet routine surrogates for in vivo vaccine potency. One reason for 
this may be because it is not clear if the biological markers exploited in vitro, such as 
cytokine production, T cell activation or target cell activity, are true functional surrogates 
of in vivo vaccine efficacy. Secondly, it is not fully understood if various different aspects 
that underpin the use of gene gun technology in vivo such as the importance of DNA dose, 
method of antigen presentation, the relationship between antigen presented on the APC 
surface and the magnitude and sensitivity of the resulting T cell response and co­
immunisation strategies can be adequately studied in vitro.
Along with B lymphocytes, T lymphocytes are the mediators of the adaptive response in 
vivo. The two key elements that characterise their response are specificity and memory. 
Although having a variety of responsibilities, T cells are generally divided into sub-groups 
based on their effector function (i.e. Th (CD4+ T cells) or Tc (CD8+ T cells)). CD4+ T 
cells interact with B lymphocytes helping them to divide and differentiate into either 
plasma cells or memory B cells. They also interact with macrophages and monocytes 
allowing these cells to destroy intracellular pathogens. CD8+ T cells recognise and 
eliminate host cells infected by virus or intracellular pathogens. Exploring the correlation 
between CD4+ and CD8+ T cell responses in vivo and in vitro would provide useful 
information on whether these biological markers, studied in vitro are predictive of the in 
vivo immune response. Performing parallel studies in vitro and in vivo would also allow 
gene gun immunisation to be dissected into its individual component parts. This would 
provide a mechanism to assess the relative contribution of each of these component parts to 
the overall technology.
In this chapter, functional bioassays in which PMDD transfected APCs were used to 
stimulate antigen specific CD4+ and CD8+ T cell proliferation were developed. The 
optimal in vitro PMDD conditions established in chapter 3 were used for transfections. The
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APCs used were those cell lines previously found to be transfectable by PMDD. 
Additionally, because of their immunological importance and unique ability to activate 
cellular and humoral responses in vivo, BMDCs were also assessed as potential APCs. It is 
anticipated that such cells, if effectively transfected would present antigen in both the MHC 
I and II pathways, and could therefore be employed as APCs in both in vitro CD8+ and 
CD4+ T cell assays. Responder cells were MHC matched splenocytes or purified T cells 
from transgenic mice. Using transgenic mice as sources of responder cells provided a 
population of specific T cells at a much higher frequency than normal mice, an important 
consideration when dealing with APC with low transfection efficiency. Responder cells 
used in the development of these assays were either freshly isolated (i.e. naive) or cultured 
for a period in the presence of specific peptide and IL-2 (i.e. activated).
4.2. Objective
• Development and validation of CD8+ and CD4+ in vitro activation assays using 
PMDD transfected APCs.
43. Results
The term ‘transfection’ refers to PMDD transfection using the plate method with a cell 
concentration of 4 x 106 cells/20 fx 1 and PMDD pressure of 250 psi as optimised in chapter 
3. For individual experiments, data is represented as mean ± standard deviation of triplicate 
analyses of an individual transfection. Any deviations from this PMDD transfection method 
or data representation are noted.
4.3.1. In vitro CD8+ T cell assay
4.3.1.1. Cell surface marker expression of responder cells
In the in vitro CD8+ T cell assay, EL4 and MC57s transfected with pVACl.NT were 
investigated as APCs for naive or activated RAG1.F5 splenocytes. Presenter and responder
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Figure 4.1. Phenotypic analysis of RAG1.F5 splenocytes as assessed by flow cytometry. 
Naive RAG1.F5 splenocytes were prepared from the spleens of RAG1.F5 mice on day of 
harvest. Cultured (activated) RAG1.F5 splenocytes were prepared by culturing naive 
splenocytes in RPMI medium containing 500 nM NT peptide (ASNENMDAM) and 20 
ng/ml EL-2 for 7 days. Panels A-D are representative fluorescence histograms of CD8, 
CD62L, CD44 and NK1.1 cell surface expression on naive (blue) and 7 day in vitro 
cultured splenocytes (red), respectively. Cells in panels B-D were gated on CD8+ 
splenocytes.
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cells were combined in a 1:1 ratio of 1 x 105 cells each with T cell activation measured by 
IFN-y ELISPOT. The difference in cell surface marker expression between naive and 
activated RAG1.F5 splenocytes is shown in Figure 4.1. When the naive splenocytes are 
cultured for 7 days in vitro in the presence of NT antigen and IL-2 (i.e. activated 
splenocytes), their CD8 marker becomes expressed on a greater number of cells but the 
actual intensity of expression decreases when compared with the nai've freshly isolated 
RAGl.F5s (panel A). When the naive splenocytes were gated on their CD8+ population, 
they exhibited a high level of CD62L expression (e.g. -96 %) and a low level of CD44 
expression (i.e. -7.6 %). In contrast, activated RAG1.F5 splenocytes when gated on their 
CD8+ cells expressed very low levels of CD62L (i.e. -1.6 %) and very high levels of CD44 
(i.e. -92%). Additionally, activated splenocytes were a much purer source of CD8+ T cells 
with these cells expressing the NK cell marker, NK1.1 at -2 % compared to the 
intermediate expression levels observed for nai've splenocytes (i.e. -23 %).
4.3.1.2. MC57 in vitro CD8 T cell assay
The smallest number of spots detectable in the in vitro CD8+ T cell assay and the minimum 
number of APCs that achieved this was determined using A/NT/60/68366-374 peptide pulsed 
MC57 cells as APCs to activated RAG1.F5 splenocytes (Figure 4.2, panels A and B). Cells 
were pulsed with a range of peptide concentrations (500-1 nM) and added at log dilutions 
of 1 x 104 to 1 x 101 with 1 x 105 activated splenocytes. Results from panel A revealed that 
the IFN-y ELISPOT assay was capable of detecting >10 cytokine spots (i.e. -12, -17, -19 
and -39 IFN-y spots were obtained when cells were pulsed with peptide concentrations of 
1, 20, 100 and 500 nM, respectively and added at 1 x 102 cells/well). The minimum number 
of cells that gave an actual readout in the assay was 1 x 102 cells. This was achieved at all 
peptide concentrations tested in panel A but only at peptide concentrations of 500 and 100 
nM in panel B. This suggests that the cells may need to be pulsed with a peptide 
concentration of >100 nM before T cell activation occurs consistently, especially at the 
lower cell numbers. Above the lower limits of the assay (i.e. 1 x 102 APC/well and 
detection of >10 spots), the relationship between number of peptide pulsed MC57 cells/well 
(pulsed with 500 nM peptide) and resulting cytokine spots detected was investigated
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(Figure 4.2, panel C). Results show a good correlation between the log of MC57 cells/well 
and resulting cytokine spots detected with an average R2 value of 0.99 obtained (mean of 4 
assays) over the cell number/well range investigated (1 x 102-1 x 104 cells).
Next, the minimum number of PMDD transfected MC57s required to stimulate activated 
RAG1.F5 splenocytes was established (Figure 4.3). Transfected MC57s were combined in 
log dilutions from 1 x 105-1 x 101 with 1 x 105 activated splenocytes and specific activation 
measured by number (panels A and C) and area (panels B and D) of IFN-y spot forming 
cells on three occasions. Results show that, irrespective of whether the splenocytes came 
from the same (row A) or different (row B) preparations, the minimum number which 
yielded a response was 1 x 104 cells. When this number of PMDD transfected cells was 
used as APC, < 10 resulting cytokine spots were detected (~4 and -7 spots /well in panels 
A and C respectively). Therefore, it is likely that >1 x 104 transfected MC57s/well (i.e. 1 x 
105) are required to get a good level of RAG1.F5 splenocyte stimulation in this assay 
system. One hundred thousand MC57s/well yielded -90 cytokine spots regardless of 
whether the same or different splenocyte preparations were used as responders. Using the 
P-galactosidase reporter gene, it has previously been established that MC57 PMDD has a 
transfection efficiency of -2.5 % (see Figure 3.6). Together, this gives a transfected 
APC:cytokine spot ratio of 2500:90 (i.e. 2.5 % of 1 x 105 = 2500). When the peptide pulsed 
MC57s were used as APC, a corresponding pulsed APC:cytokine spot ratio of 2500:110 
was obtained (Figure 4.2, panel C).
4.3.1.3. Choice of antigen presenting cells
EL4 and MC57s were compared for their ability to stimulate nai've RAG1.F5 splenocytes 
(Figure 4.4). Results for EL4 cells as APC showed no difference between cells transfected 
with pVACl.NT and irrelevant plasmid (mean values of -30 and -40 IFN-y spots/well, 
respectively) indicating no NT specific T cell activation. When MC57s were used as APC, 
cells transfected with pVACl.NT yielded a mean value of -35 IFN-y spots /well compared 
to -17 IFN-y spots/well for cells transfected with the irrelevant plasmid. However, this
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Figure 4.2. Panels A and B: Minimum number of cytokine spots detected in the IFN-y 
ELISPOT assay. MC57 cells were pulsed with NT peptide (500-1 nM) and added at log 
dilutions of 1 x 104 to 1 x 101 with 1 x 105 activated RAG1.F5 splenocytes. Panel C: 
Relationship between MC57 cells/well and cytokine spots detected. Cells were pulsed with 
500 nM NT peptide and added at log dilutions of 1 x 104 to 1 x 102 with 1 x 105 activated 
RAG1.F5 splenocytes. For A and B, data is from one experiment and is mean ± standard 
deviation of triplicate analyses of an individual transfection. For C, each symbol 
corresponds to an individual experiment with bars showing the mean of all experiments for 
each group.
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Figure 4.3. Stimulation of activated RAG1.F5 splenocytes by MC57 cells. MC57s were 
transfected with pVACl.NT and added at log dilutions of 1 x 105 to 1 x 101 cells with 1 x 
105 activated RAG1.F5 splenocytes and 200 ng/ml IL-2. The assay was performed using 
the same (Row A) or different (Row B) batches of splenocytes and IFN-y was measured by 
number (panels A and C) and area (panels B and D) of cytokine positive spots in ELISPOT 
assays. Each bar represents mean ± SEM of three individual assays after subtraction of 
corresponding negative controls groups (i.e. pVACl.OVAs control groups).
113
Chapter 4: Development of an in vitro CD8+ T ceil assay
100
APC: EL4
80 -
<u5
O
CL
GO
J- 4°-z
LL
20 -
100
APC: MC57
8 0 -
<155
-  6 0 -  u o Q.<n+
4 0 -
Z
Li-
20 -
MC57s transfected MC57s transfected RAG1.F5 splenocytes Transfected 
with with irrelevant only MC57 only
pVACl.NT plasmid
Figure 4.4. Stimulation of nai've RAG1.F5 splenocytes by EL4 and MC57 cells are shown 
in upper and lower panels, respectively. Cells were transfected with pVACl.NT or 
irrelevant plasmid (either pVACl or pGL3-CMV-luciferase) and incubated overnight with 
1 x 105 nai've RAG1.F5 splenocytes and 200 ng/ml IL-2 before IFN-y ELISPOT analysis. 
Groups containing splenocytes and transfected APC only were included as additional 
negative controls. Each symbol corresponds to an individual experiment with bars showing 
the mean of all experiments for each group. Student’s T-test on EL4 and MC57 group 
means: pVACl .NT and irrelevant plasmid group are similar.
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Figure 4.5. Panel A: Stimulation of activated and nai've RAG1.F5 splenocytes by MC57 
cells as measured by IFN-y ELISPOT. MC57 cells were transfected with pVACl.NT or 
pVACl and incubated overnight with 1 x 105 activated or naive RAG1.F5 splenocytes and 
200 ng/ml IL-2. Groups containing splenocytes and transfected APC only were included as 
additional negative controls. Data is from one experiment and is mean ± standard deviation 
of triplicate analyses of an individual transfection. Panel B: Activation of activated 
RAG1.F5 splenocytes by MC57 cells measured by IFN-y ELISPOT. MC57s were 
transfected with pVACl.NT or pVACl and incubated overnight with 1 x 105 activated 
RAG1.F5 splenocytes and 200 ng/ml IL-2. Positive control was 5 x 1 0  MC57 cells pulsed 
with 500 nM NT peptide. Groups containing RAGI.F5 splenocytes and transfected MC57s 
only were included as additional negative controls. Each symbol corresponds to an 
individual experiment with bars showing the mean of all experiments for each group. 
Student’s T-test on panel B: the pVACl.NT and pVACl groups are significantly different
(p<0.001).
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result did not achieve significance due to high value obtained for the irrelevant plasmid 
group in one of the three assays performed (-40 IFN-y spots/well). When this assay was 
removed from the analysis, there was then a noticeable difference between the positive and 
negative PMDD transfected groups. For both cell types, the control groups of RAG1.F5 
splenocytes only, or transfected APCs only, gave similar background levels of T cell 
activation as the group transfected with irrelevant plasmid (in two of the three assays).
4.3.1.4. Activation state of responder cells
Using transfected MC57 as APC, nai've and activated RAG1.F5 splenocytes were directly 
compared as responders in the CD8+ in vitro assay (Figure 4.5, panel A). Results revealed 
that the activated splenocytes responded much more efficiently than the nai've splenocytes 
(-340 compared with -5 IFN-y spots/well). Secondly, when activated RAG1.F5 
splenocytes were used as responders, there was a 15 fold difference in NT specific T cell 
activation between the MC57 groups transfected with pVACl.NT and pVACl.OVAs 
(control group) (i.e. -340 and -22 IFN-y spots/well, respectively). Activated splenocytes as 
responders to pVACl.NT transfected MC57s were further investigated in Figure 4.5, panel 
B. These transfections were performed using a PMDD pressure of 275 psi, resting time of 6 
min and incubation time after PMDD of 20 hrs. Individual experiments represents mean of 
triplicate analyses of the mean of three transfections. Results indicated specific T cell 
activation with pVACl.NT and pVACl transfected APCs gave -1625 and -10 IFN-y 
spots/well, respectively. A surprising observation from the data shown in Figure 4.4 was 
the unusually high level of IFN-y secretion associated with activated splenocytes only in 
panel A (-110 IFN-y spots/well). This result was from an individual assay and was not in 
accordance with the similar group shown in panel B which yielded a mean value of only -2 
IFN-y spots/well (three assays performed).
4.3.2. In vitro CD4+ T cell assay
DAP-3/ICAM cells transfected with pVACl.OVAs were used as APCs to DO. 11.10 
splenocytes or CD4+ T cells isolated from these splenocytes. Presenter and responder cells
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were combined in a 1:1 ratio (2 x 105 cells each). Production of EL-2 (indicating specific T 
cell proliferation) as measured by ELISA and ELISPOT, and T cell proliferation were used 
to measure activation.
The minimum number of OVA323-329 peptide pulsed DAP-3/ICAM cells required to 
stimulate nai've CD4+ DO.l 1.10 T cells was investigated (Figure 4.6). Results showed that 
if the IL-2 ELISA and T cell proliferation assays were used to measure activation, at least 1 
x 103 DAP-3/ICAMs/well were required for T cell stimulation. If the IL-2 ELISPOT assay 
was used, only 1 x 102 DAP-3/ICAMs/well were required. Using the p-galactosidase 
reporter gene, it was shown that DAP-3/ICAMs had a PMDD transfection efficiency of 
~0.8 % (see Figure 3.5). Together, this predicts that 2 x 105 transfected DAP-3/ICAMs 
would generate a detectable response in all three readout assays, especially the IL-2 
ELISPOT (i.e. 0.8 % of 2 x 105 is 1.6 x 103 cells). This prediction is based on the 
assumption that each transfected DAP-3/ICAM cell can effectively produce, process and 
present the synthesised antigen.
DAP-3/ICAM cells transfected with pVACl.OVAs were assessed for their ability to 
stimulate nai've DO. 11.10 CD4+ T cells or activated DO.l 1.10 splenocytes. When the nai've 
DO.l 1.10 CD4+ T cells were used as responders (Figure 4.7), no specific T cell activation 
was evident in any of the readout assays with both transfected and non-transfected DAP- 
3/ICAM groups showing approximately equal levels of T cell activity. It is also clear from 
the T cell proliferation and IL-2 ELISPOT data that DAP-3/ICAM cells pulsed with OVA 
peptide yielded a noticeably stronger IL-2 response than did cells pulsed with whole protein 
(i.e. 3.2 and 1.4 fold increases in T cell activity in the proliferation and ELISPOT assays, 
respectively). DAP-3/ICAM cells pulsed with whole protein did not produce a detectable 
response in the IL2-ELISA. A similar result was obtained when activated DO.l 1.10 
splenocytes were employed as responders in an IL-2 ELISPOT assay (Figure 4.8). No 
detectable CD4+ T cell specific activation was observed with the pVACl.OVAs and 
pVACl transfected DAP-3/ICAM groups generating a similar response.
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4.3.3. T cell stimulation by PMDD transfected dendritic cells
The ability of BMDCs to stimulate T cell activity is shown in Figure 4.9. BMDCs derived 
from DO.l 1.10 and BALB/c mice were transfected with pVACl.OVAs and incubated with 
purified nai've DO.l 1.10 CD4+ T cells. Consistent with the findings from the reporter gene 
studies (section 3.3.3), the overall results revealed that no specific T cell activation was 
obtained compared with non transfected BMDCs. Actually, EL-2 secretion in the non­
transfected population was greater than that of BMDCs transfected with pVAC 1.OVA (all 
had a seeding density of 4 x 104 cells/well) regardless of the type of BMDCs transfected. 
This result may indicate possible deleterious effects of the PMDD transfection procedure 
on this type of BMDCs.
4.4. Discussion
In order to establish in vitro functional assays, different PMDD transfected cell lines were 
investigated as APCs to DO.l 1.10 and RAG1.F5 responder cells in a number of in vitro 
experimental systems. In each case, successful activation was dependent on a number of 
factors. These included efficiency of PMDD transfection of the APCs, sensitivity of the 
assay system used, maturation state of the APCs and responder cells and whether the 
synthesised peptide was presented through the correct pathway.
4.4.1. Efficacy of PMDD transfection of antigen presenting cells
The stimulatory potential of each APC appeared to be proportional to the amount of 
synthesised gene product within the cells themselves. Transfection efficiency of all of the 
cell lines was <1 % except for MC57s which transfected at an efficiency of -2.5 %. These 
transfection levels were reflected in MC57s ability to stimulate naive RAG1.F5 splenocytes 
compared with EL4s. Likewise, EL4s and DAP-3/ICAMs transfected with similar 
efficiency by PMDD and both cell lines demonstrated no capacity to stimulate responder 
cells. This finding may suggest that for non professional APCs at least, the most influential
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Figure 4.6. Minimum number of APC which gave a detectable response in the in vitro 
CD4+ T cell assay as measured by T cell proliferation (A), ELISA (B) and ELISPOT (C). 
DAP-3/ICAM cells (pulsed with 100/LtM OVA323-329 peptide) at log dilutions of 1 x 104 to 1 
x 101 were incubated overnight with 2 x 105 naive DO.l 1.10 CD4+ T cells and IL-2. For 
each assay, data is from one experiment and is mean (± standard deviation) of triplicate 
analyses of an individual transfection.
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Figure 4.7. Activation of naive DO.l 1.10 CD4+ T cells by DAP-3/ICAM cells. IL-2 
secretion was measured by ELISA (A), T cell proliferation (B) and ELISPOT (C). 
Transfected or non-transfected DAP-3/ICAMs (2 x 105 cells) were incubated overnight 
with 2 x 105 naive DO.l 1.10 CD4+ T cells prior to analysis. Positive controls were 1 x 105 
DAP-3/ICAM cells pulsed with 1/xM OVA323-329 peptide or OVA protein. In panels A and 
B, each symbol corresponds to an individual experiment with bars showing the mean of all 
experiments for each group. In panel C, each symbol is one experiment and is mean (± 
standard deviation) of triplicate analyses of an individual transfection.
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Figure 4.8. Stimulation of activated DO.l 1.10 splenocytes by DAP-3/ICAM cells 
measured by IL-2 ELISPOT. DAP-3/ICAMs (2 x 105 cells) were transfected with 
pVACl.OVAs or pVACl and incubated overnight with 2 x 105 activated DO.l 1.10 
splenocytes. Positive control was 1 x 104 DAP-3/ICAM cells pulsed with 1/liM OVA323-329 
peptide. A group containing DO.l 1.10 splenocytes only was included as an additional 
negative control. Each symbol corresponds to an individual experiment with bars 
representing the mean of all experiments for each group.
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Figure 4.9. Activation of nai've DO.l 1.10 CD4+ T cells by BMDC measured by IL-2 
ELISPOT. Panels A and B are DO.l 1.10 and BALB/c BMDC transfected with 
pVACl.OVAs, respectively. Positive controls were 4 x 104 BMDC pulsed with OVA 
protein (0.1 and 0.01 \iM) or OVA323-329 peptide (0.1 and 0.0InM). Transfected BMDC, 
non-transfected BMDC and positive controls were incubated overnight with 2 x 105 
DO.l 1.10 CD4+ T cells. For each type of BMDC transfected, data is from one experiment 
and is mean (± standard deviation) of triplicate analyses of an individual transfection.
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factor in influencing T cell stimulatory capacity is the transfection efficiency of the APC 
and that once a certain threshold level of transfection is reached (as in the case of MC57s), 
then the APC has the capacity to stimulate T cell activity. DCs are the most potent APC for 
inducing a T cell immune response in vivo and are capable of MHC class I and class II 
antigen presentation (Banchereau and Steinman, 1998). For these cells, particle mediated 
transfection efficacy in vitro appears to be dependent on the type of DC precursor used. 
With human DCs, cells derived from CD34+ hematopoietic progenitors which divide in 
culture (e.g. BMDCs) have been shown not be transfected by PMDD (Lundqvist et at, 
2002). For non dividing cells, such as monocyte derived DCs, some investigators have 
shown successful transfection by PMDD (Tuting et al., 1998) while others have not (Smith 
et al, 2001; Zhong et a l, 1999). In contrast, murine DCs, whether dividing or non­
dividing, prove totally refractory to PMDD with the only reported exception been the 
transfection of a DC line which exhibited the phenotypic and functional characteristics of 
mature Langerhans cells (Timares et a l, 1998). In that particular study, the percentage of 
GFP-positive cells was in the range of 0.1-0.6 % with a mean transfection efficiency of 
0.25 %. Results from the reporter gene and functional studies described in this chapter 
concur with the overall view that murine DC are non-transfectable and this most likely 
explains the failure of pVAC 1.OVA transfected BMDCs to stimulate DO. 11.10 CD4+ T 
cells.
4.4.2. Sensitivity of immuno-assays
The sensitivities of the readout assays for the in vitro functional assays were examined in 
order to determine whether these limited the ability to detect T cell activation. For the class 
I in vitro assay, the sensitivity of the IFN-y ELISPOT readout assay was established using 
peptide pulsed and PMDD transfected MC57s as presenters to activated RAG1.F5 
splenocytes. For the peptide pulsed MC57s, the smallest number of spots detectable and the 
number of APC that gave these spots was calculated to be ~1 x 101 and 1 x 102, 
respectively. When PMDD transfected MC57s were used, the smallest number of spots 
detectable was <1 x 101 and the number of APC that gave these spots was 1 x 104. 
Therefore, as expected, positive responses were obtained when 1 x 105 PMDD transfected
123
Chapter 4: Development of an in vitro CD8+ T cell assay
MC57s were used as APCs to naive and activated RAG1.F5 splenocytes. Above the limits 
of the assay as established by peptide pulsed MC57s, there was a relationship between the 
numbers of APC/well and resulting cytokine spots formed. This relationship was semi- 
logarithmic and not linear (Figure 4.2, panel C) with the APC:cytokine spot ratio very high 
(e.g. when 1 x 103 peptide pulsed cells/well were used, the APC: cytokine spot ratio was 
1000:70). Theoretically, the expectation is that one APC with intact MHC I/NT peptide 
complexes present on its surface should be sufficient to stimulate T cell activity (i.e. a 
theoretical APC:cytokine spot ratio of 1:1), yet this clearly did not happen. One possibility 
for this may be the lack of responsiveness of the activated RAG1.F5 splenocytes. The in 
vitro culturing process (i.e. in the presence of IL-2 and NT peptide) was important for 
increasing the responsiveness of the splenocytes relative to naive, freshly isolated 
splenocytes but may have left the cells vulnerable to AICD when re-exposed to peptide 
laden APC in the in vitro assay. Furthermore, there were no CD4+ helper cells present in 
the in vitro system which may have served to support the activity of and maintain the 
activated RAG1.F5 responders for the duration of the assay. This notion is supported by the 
data obtained when PMDD transfected MC57s were used as APC. When 1 x 105 MC57 
cells/well were used in the assay and adjusted for a PMDD transfection rate of ~2.5 %, an 
APC:cytokine spot ratio of 2500:90 was obtained. When the same number of peptide 
pulsed cells were used as APC, a ratio of 2500:110 was obtained. The similarity between 
these ratios may suggest that it is the behaviour of the responders (although in vast excess 
compared with the number of APC present in the assay) that are responsible for the high 
APC:resulting cytokine spot ratio. The similarity between the ratios also suggests that the 
MC57 cells when transfected by PMDD are proficient at protein synthesis and peptide 
processing and presentation. An alternative explanation for the high APC:resulting cytokine 
spot ratio may lie with the MC57 cells themselves. It is possible that these cells are 
heterogeneous in their ability to present antigen and this would have the effect of increasing 
this ratio.
For the class II assay, the sensitivity of the three readout assays was established using 
peptide pulsed DAP-3/ICAMs as presenters to nai've D0.11.10 CD4+ T cells. ELISA and T 
cell proliferation assays required >1 x 103 peptide pulsed APCs in order to obtain a positive
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response. For IL-2 ELISPOT, this was achieved with ten fold less APCs. Therefore, 
assuming that protein synthesis and peptide processing and presentation within the APCs 
are efficient and taking into account the DAP-3/ICAM PMDD transfection rate, then each 
assay, and especially ELISPOT, should be sensitive enough to detect specific T cell 
activation after PMDD. However, no specific activation was obtained with either naive or 
activated responders suggesting that inefficient and/or incorrect processing and presentation 
may be the limiting parameters of these assays (see section 4.4.4).
4.4.3. Activation state of antigen presenting and responder cells
For BMDCs, the degree of maturation may be important in determining its in vivo and in 
vitro T cell stimulatory potential (Barratt-Boyes et al., 2000; Labeur et al., 1999). There is 
evidence that indicates that mature DCs transfect in vitro with a greater efficiency than 
immature DCs (Miller et a l, 2003). Although the DCs used in the study were not matured 
prior to transfection, this may not have been critical, as the physical process of PMDD 
results in DC maturation and leads to increased expression of cell surface MHC and co­
stimulatory molecules as well as increased cytokine secretion (Smith et al., 2001). 
However, results showed more IL-2 secretion associated with the non-transfected 
populations than the transfected populations. This suggests that possibly the positive effects 
of PMDD in increasing DC maturation in vitro were outweighed by the deleterious effect of 
the technique on cell viability. The state of activation of non-professional APCs does not 
appear to be as critical to their immuno-stimulatory capacity. When MC57s pre-treated 
with IFN-y were used as APC in the in vitro CD8+ T cell assay, a much larger NT response 
was obtained compared with untreated MC57s as APC (see Figure 6.9). However, specific 
T cell activation (i.e. relative difference between positive and negative groups) was 
approximately equivalent suggesting that the effect of IFN-y pre-treatment was 
predominantly non specific.
Increasing the responsiveness of responder cells proved important. Culturing naive 
RAG1.F5 splenocytes in the presence of IL-2 and specific peptide resulted in a more active 
phenotype typified by increased CD8 and CD44 and decreased NK1.1 and CD62L
125
Chapter 4: Development of an in vitro CD8+ T cell assay
expression profiles. The difference in responsiveness between naive and activated 
RAG1.F5 splenocytes (calculated to be ~85 fold) is more than likely due to the fact that 
activated splenocytes behave like a memory T cell population (having come in contact with 
specific peptide during the culturing process). As such, they require fewer MHC/peptide 
complexes on the APC surface and are less dependent on the presence of the co-stimulation 
signal on the APC surface for activation to occur.
Separately, when naive purified CD8+ T cells were used as responders instead of nai've 
RAG1.F5 splenocytes, peptide pulsed MC57s could only weakly stimulate antigen specific 
IFN-y (data not shown). This may be because the MC57s lack co-stimulatory molecules 
(CD80 and CD86) found on professional APCs. In contrast, endogenous APC present 
within the splenocyte population which once activated may be able to mature, upregulate 
costimulatory molecules and decrease the threshold required for CD8+ T cell activation 
(Ruedl et al., 1999). With this in mind, it would be interesting to combine naive and 
activated RAG1.F5 splenocytes as a responder population in an in vitro assay and compare 
this mixed population with naive and activated splenocytes used separately as responders to 
PMDD MC57 cells. Having a certain proportion of naive splenocytes present in such a 
population may compensate for loss of endogenous APCs due to the culturing process 
while having activated splenocytes present retains the responsiveness of the activated only 
splenocyte population.
4.4.4. Providing correct T cell receptor specificity
All of the in vitro systems investigated share the requirement of providing correct TcR 
specificity if responder cell activation is to occur. Direct transfer of plasmid to APCs (as in 
the case of the CD8+ and CD4+ in vitro assays) mainly results in endogenous synthesis of 
the resulting antigen and subsequent processing and presentation through the class I 
pathway. This was clearly demonstrated in the CD8+ T cell in vitro assay where direct 
transfection of MC57s with pVACl.NT resulted in the presentation of NT peptide/MHC I 
complex in a manner which led to the stimulation of RAG1.F5 splenocytes. The need for a 
particular TcR specificity may explain why BMDC and particularly, DAP-3/ICAMs failed 
to stimulate DO.11.10 effector cells. After direct PMDD of DAP-3/ICAMs with
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pVACl.OVAs, ovalbumin is primarily produced and presented in the context of MHC 
class I hence not providing the correct specificity for the CD4 TcR. The ovalbumin plasmid 
used in these experiments contained a secretory signal thus allowing it, in theory to access 
the class II loading compartment. In vivo, endogenous APCs resident in the immune 
microenvironment may capture and process secreted peptide through their exogenous 
pathway. However, in this in vitro system, there may be no other efficient presenters (only 
DAP-3/ICAMs and DO. 11.10 CD4+ T cells) thus attenuating CD4 activation via this route.
This explanation does not hold true for BMDCs for two reasons. Firstly, unlike DAP- 
3/ICAMs, other bystander BMDCs as professional APCs are capable of capturing secreted 
peptide and processing it through their exogenous pathway. Secondly, directly transfected 
DCs can cross present endogenously synthesised peptide thus opening up the class II 
pathway (Malnati et al., 1992; Sloan et al., 2002; Weissman et al., 2000). Therefore, the 
most likely reason for the failure of BMDC to stimulate DO. 11.10 T cell activity is that 
these cells are totally refractive to transfection by PMDD.
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4.5. Conclusions
In this chapter, in vitro functional assays in which PMDD transfected APCs were used to 
stimulate antigen specific CD4+ and CD8+ T cell proliferation were investigated. The main 
observations from this work were that
• A major factor in determining successful T cell activation was PMDD transfection 
efficiency. Transfecting APCs at a level below the sensitivity of the readout assay 
resulted in the failure to detect an antigen specific response.
• Manipulation of the activation state of the responder cells greatly improved assay 
sensitivity.
• The requirement for correct TcR specificity was essential in generating a working 
assay.
Development and validation of an in vitro functional assay for CD4+ T cell activation was 
not achieved, at least partly because of poor PMDD transfection efficiencies. However, a 
robust in vitro functional assay for assessment of CD8+ T cell activation by transfected 
APCs has been developed and validated using PMDD transfected MC57 cells and T cells 
from RAG1.F5 transgenic mice. This in vitro functional assay is used to investigate in 
following chapters, the correlation between in vitro and in vivo immune responses.
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5.1. Introduction
Varying the amount of NT antigen available for presentation and studying its effect on 
resulting immune response provides a way to assess features of gene gun technology such 
as the importance of DNA dose and the relationship between presented antigen and 
resulting immune response. In this chapter, both these aspects are studied in vitro using the 
CD8+ T cell assay described in chapter 4 (i.e. pVACl.NT PMDD transfected MC57s were 
used as APC to activated RAG1.F5 splenocytes) and in vivo using IFN-y ELISPOT and 
intracellular IFN-y staining analysis. By comparing both sets of data, the ability of the in 
vitro CD8+ T cell assay to predict in vivo responses is assessed.
In order to do this, the amount of NT antigen made available for presentation was varied in 
two different ways. Firstly, the amount of NT encoding plasmid delivered by PMDD was 
varied (i.e. immunisation dose responses). The effects of such dose responses were 
examined in parallel in vitro and in vivo experiments. From a quantitative perspective, the 
relationship between amount of DNA administered by PMDD and elicitation of the CD8+ 
response has been much studied. Nanogram quantities of nucleoprotein and haemagglutinin 
encoding DNA delivered intradermally are sufficient to raise cellular responses in vivo 
(Fynan et a l, 1993; Pertmer et a l, 1995; Degano et a l, 1998). For this type of dose 
response, DNA cartridges containing variable amounts of pVACl.NT were mixed with an 
“empty plasmid” (i.e. pVACl). This ensured that the total amount of DNA delivered by 
PMDD was constant at 500 ng/cartridge.
Secondly, the amount of intracellular NT protein produced was manipulated at the 
transcriptional level. Plasmids with different promoters were created for this purpose (i.e. 
the p7313 vectors) based on the CMV immediate-early (IE) promoter. This constitutive 
promoter has, in various combinations, been shown to drive high gene expression in 
transfected cultured cells (Xu et al., 2001; Foecking and Hofstetter, 1986; Boshart et al, 
1985) and in multiple tissues in transgenic mice (Schmidt et a l, 1990). Among a number of 
viral promoters tested, the CMV-EE promoter consistently resulted in the greatest amount of
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gene expression in human prostate cancer cell lines transfected by PMDD (Zhang et al 
2002).
Of the various additional components introduced to form the different promoters, the 
CMV-IE enhancer and intron A DNA sequences are the most important. In all constmcts, 
the CMV-IE enhancer was positioned immediately upstream of the transcriptional start site. 
It is a highly complex regulatory region containing sequences which bind to host encoded 
transcriptional effector proteins allowing them to activate or repress gene transcription. 
They function by increasing the probability of stable promoter/transcription factor 
complexes which result in a greater number of cells expressing a transcriptionally active 
form of the promoter (Walters et al., 1995) and lead to an increased amount of active RNA 
polymerases present at these transcriptional start sites (Weber and Schaffher, 1985). Intron 
A, the largest intron of the CMV-IE 1 gene has been demonstrated to enhance CMV driven 
gene expression in vitro (Niwa et al., 1990; Chapman et al., 1991; Xu et al, 2001). 
Improved expression is attributed to an increased level of RNA polyadenylation and/or 
nuclear transport related with RNA splicing (Huang and Gorman, 1990). The effect of these 
plasmids on intracellular NT production and resulting CD8+ T cell responses were 
examined in vitro and in vivo.
5.2. Objective
The importance of DNA dose and the relationship between presented antigen and resulting 
immune response in gene gun vaccination was investigated by assessing in vitro and in vivo
• the effect of immunising DNA dose on resulting CD8+ immune responses.
• the effect of a NT promoter dependent dose response on resulting CD8+ immune 
responses.
The in vitro and in vivo data were directly compared and the ability of the in vitro CD8+ T 
cell assay to predict in vivo responses was assessed.
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Cartridge composition
Group name Theoretical loading 
pVACl.NT
Theoretical loading 
pVACl
ng DNA / cartridge ng DNA / cartridge
a 500 0
b 50 450
c 5 495
d 0.5 499.5
e 0.05 499.95
f 0.005 4999.995
g 0 500
Table 5.1. Nomenclature used to denote amount of influenza nucleoprotein encoding 
plasmid DNA and control plasmid DNA in cartridge preparations for all in vitro and in vivo 
experiments presented in chapter 5.
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(Ct) is shown in A and the resulting values are plotted against a pVACl.NT standard curve 
for copy number determination (B)
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A B c D E
G roup nam e T heoretical loading pV A C l.N T  
in vitro  study
pV A C l.N T  
prim ary  im m unisation
pV A C l.N T  
boost im m unisation
Theoretical loading
ng D N A / cartridge ng DNA /  c a rtrid g e ng DNA/ ca rtridge ng DNA/ cartridge copies / gold bead
a 500 500 500 500 24,368
b 50 71 .5 41 66 2,436
c 5 6.2 8 6 243
d 0.5 0.5 1 0.5 24
e 0 .05 - 0.15 0.05 T
f 0.005 - 0.05 0.005 -
g 0 0 0 -
Table 5.2. Results from QPCR analysis performed on pVACl.NT containing gold slurries. 
The theoretical loading quantity of pVACl.NT for each group is shown in panel A. Gold 
slurry used for the first in vitro experiment (refer to Figure 5.2) is shown in panel B. Gold 
slurries used for manufacture of cartridges for in vivo experiments are shown in panels C- 
D. The theoretical number of DNA copies/gold particle for each pVACl.NT group is 
represented in panel E. DNA copies/gold particle calculations are based on the precipitation 
of a single plasmid only.
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53. Results
For all in vitro and in vivo dose response experiments, the nomenclature used to denote 
amount of NT encoding DNA delivered by PMDD is shown in Table 5.1. To facilitate 
comparison of data, the in vitro results are expressed as number and area of IFN-y 
producing cells/million responder cells and the in vivo results are expressed as number of 
IFN-y producing cells/million responder cells.
5.3.1. Effect of immunising DNA dose on CD8+ T cell responses in vitro
and in vivo
5.3.1.1. QPCR analysis
Plasmid pVACl.NT (in log dilutions from 500-0 ng) was mixed with different amounts of 
pVACl plasmid (Table 5.1). The total amount of DNA/cartridge was 500 ng. Prior to the in 
vitro and in vivo dose response studies, QPCR analysis was carried out on gold slurries 
from a certain number of DNA cartridge batches to confirm the correct ratio of pVACl.NT 
against pVACl. The analyses involved calculating the number of amplification cycles 
required for measurement of specific plasmid copy number in each sample (known as cycle 
threshold or Ct) and comparing these values against a standard curve of known copy 
numbers (Figure 5.1). For the in vitro study, results presented in Table 5.2, column B 
represent the QPCR analysis of the cartridges used in the first dose response study. For the 
first in vivo study, cartridges prepared for the boost (column D) compared more favourably 
with the theoretical DNA loading (column A) than did cartridges prepared for the primary 
immunisation (column C). Overall, QPCR analyses verified that the pVACl.NT plasmids 
precipitated in the expected proportion with approximately a log difference between 
successive groups in cartridge batches. This difference is maintained even at the lowest 
concentration of plasmid (i.e. 0.005 ng). The theoretical number of pVACl.NT DNA 
copies/gold bead is shown in column E. The columns shows that on average, cartridges 
containing 0.5 ng DNA result in 24 copies of NT plasmid been precipitated on individual 
gold beads, while 0.05 ng gives 2 copies of plasmid/gold bead. These calculations are based
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on a DNA loading rate of 2 fig/mg gold, that 1 mg gold contains 1.22 x 107 gold particles 
and that 1 copy of pVACl .NT plasmid contains 4.05 x 106 pg DNA/pmole.
5.3.1.2. CD8+ restricted T cell responses to pVACl.NT in vitro
The pVACl.NT/pVACl dose responses were investigated in vitro using the CD8+ T cell 
assay (i.e. MC57s transfected with pVACl.NT were used as APCs to activated RAG1.F5 
splenocytes). The in vitro functional assay conditions and IFN-y detection are described in 
sections 2.8.3 and 2.9, respectively. The two batches of cartridges used in parallel in vivo 
experiments were assessed in vitro. Each batch contained a dose response of pVACl.NT 
against pVACl (500-0 ng). Detection was reported by number and area of IFN-y producing 
cells/million cells. Results of the first batch are shown in Figure 5.2, row A and relate to in 
vivo experiments represented in Figures 5.4A and 5.5A. Significance was obtained in the 
500 ng group only when the data was reported by number and area of IFN-y producing 
cells/million cells.
Similar analyses were performed for the second batch of cartridges (in vivo data 
represented in Figures 5.4B and 5.5B) and are shown in Figure 5.2, row B. Results reveal 
that only the 500 ng group was significantly above control when data was reported by area 
of IFN-y producing cells/million cells while the 500 and 50 ng groups achieved significance 
when data was reported by number of IFN-y producing cells/million cells.
To investigate the relationship between number and area of data reporting further, both 
methods were compared for the pVACl.NT/pVACl dose response studies (Figure 5.3, 
panels A and B). R2 values of 0.993 and 0.984 were obtained for the first and second batch 
of cartridges, respectively. When this type of correlation was extended to include all in 
vitro assays performed (n=8), a R2 value of 0.988 was obtained (Figure 5.3, panel C). These 
results suggests that both methods are similar and that either one may be used to report the 
in vitro functional data.
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Figure 5.2. Activation of NT specific activated RAG1.F5 splenocytes by MC57 cells as 
measured by IFN-y ELISPOT. MC57s were transfected with pVACl.NT/pVACl 
containing cartridges and incubated overnight in a 1:1 ratio with 1 x 10 cultured RAG1.F5 
splenocytes and 200 ng/ml EL-2. Initial and repeat experiments are shown in row A and B, 
respectively. Detection was reported by number (left hand column) and area (right hand 
column) of IFN-y producing cells/million cells. Each symbol (except bars) corresponds to 
an individual experiment. Bars are the mean of all experiments for each group. For each 
individual experiment, data is mean of triplicate analyses of pooled triplicate transfections. 
Stars on top of groups represent Dunnefs test comparison of group means with 
corresponding control groups (group g) (* p < 0.05, *** p <0.001).
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Figure 5.3. Comparison of data reporting methods for the pVACl.NT/pVACl dose 
response studies. Panels A and B represent correlation plots of dose response studies shown 
in Figure 5.2, row A and row B, respectively. Panel C: Correlation plot of all in vitro 
pVACl.NT/pVACl dose response studies performed (n=8). Mean values of number (x- 
axis) and area fy- axis) of IFN-y producing cells/million cells from each group (denoted by 
horizontal bars in Figures 5.2) were used for correlation and linear trend-line regression 
coefficient (R2) was fitted to data.
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5.3.1.3 CD8+ restricted T cell responses to pVACl.NT in vivo
The p VAC 1.NT/p VAC 1 plasmid containing batches were also assessed in two in vivo dose 
response studies. CD8+ specific T cell responses were measured by IFN-y ELISPOT and 
intracellular IFN-y staining (see section 2.13). For the ELISPOT data, results presented are 
the number of IFN-y spots in the media + EL-2 + peptide group minus the media + EL-2 
group.
In the IFN-y ELISPOT analysis of the first experiment (Figure 5.4A), significant results 
were obtained in the 500 ng pVACl.NT group only at day 14 post primary (PP). After 
boost, the sensitivity and magnitude of the pVACl.NT response increased. Significance 
was obtained in groups down to 5 and 0.05 ng pVACl.NT at days 7 and 14, respectively. 
Responses above control were observed in the 500, 50 and 0.5 ng groups at day 7 post 
boost (PB) but these groups were not statistically significant due to the high background 
levels of IFN-y associated with these groups. In the repeat experiment (Figure 5.4B), 
significant results were obtained at each time-point. Groups immunised with 500, 50 and 5 
ng pVACl.NT were significantly above control at day 7 PP while the 500 and 50 ng groups 
achieved significance at day 14 PP. Maximum sensitivity and magnitude of the pVACl.NT 
response was observed at day 7 PB where significance was obtained in groups down to 0.5 
ng. This response decreased at day 14 PB where groups down to 5 ng were significantly 
above control. The magnitude of the response also decreased at this time-point. For 
example, the frequency of cytokine producing cells in the 50 ng group at day 14 PB was 
-450 spots/million cells compared with -200, -400 and -1100 at days 7 and 14 PP and day 
7 PB, respectively. The lowest amount of pVACl.NT capable of eliciting a response above 
control as detected in both experiments was 0.05 and 0.5 ng in the first and second 
experiments, respectively.
The intracellular IFN-y staining analysis of the first dose response study is shown in Figure 
5.5A. Groups immunised with 500 and 50 ng were significantly different from the control 
group at day 14 PP. After boost, the pVACl.NT response increased with significance 
reached in groups down to 0.5 ng at day 7 and 14. The magnitude of the response was
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greatest at day 7 PB (e.g. in the 50 ng group, the frequency of CD8high CD62Liow IFN-y 
producing cells was 1.9 % at this time-point compared with 0.25 and 0.78 % at day 14 PP 
and day 14 PB, respectively). In the second experiment (Figure 5.5B), significant results 
were obtained in groups down to 5 ng pVACl.NT at all time-points. The sensitivity of the 
pVACl.NT response increased after boost with significance reached in the 0.5 ng group at 
day 7 PB. The maximum response was obtained at day 14 PB (e.g. the frequency of CD8high 
CD62Liow IFN-y producing cells in the 50 ng group was 0.6 % at this time-point compared 
with 0.29, 0.57 and 0.31 % at day 7 and 14 PP and day 7 PB, respectively). Representative 
flow cytometry analysis of the 500 ng pVACLNT and pVACl groups at day 14 PB is 
shown in Figure 5.6. In conclusion, the lowest amount of pVACl.NT capable of eliciting a 
response above control as detected in both experiments was 0.5 ng.
5.3.1.4. Comparing the in vitro model with CD8+ T cell responses in vivo
To investigate the relationship between the in vitro functional assay and CD8+ responses in 
vivo, the in vitro pVACl.NT/pVACl dose response data was plotted against the in vivo 
IFN-y ELISPOT and intracellular IFN-y staining dose response data. Analysis was 
performed on two batches of cartridges which were examined both in the in vivo and in 
vitro assays. For the in vitro pVACl.NT/pVACl dose responses, data generated using 
number of IFN-y producing cells/million cells as the reporting method was used for 
correlation.
The regression coefficients obtained from both sets of plots for the second batch of 
cartridges are shown in Figure 5.7. When the in vitro data (represented in Figure 5.2, row 
B) was plotted against the in vivo IFN-y ELISPOT data (represented in Figure 5.4B), results 
revealed a good correlation between both sets of data points (Figure 5.7, left hand column). 
The best correlation was achieved at day 7 PP (i.e. a R2 value of 0.997). This value 
decreased to 0.822 and 0.648 at day 14 PP and 7 PB, respectively before increasing to 
0.830 at day 14 PB. This trend was not observed when the in vitro data was plotted against 
the in vivo intracellular IFN-y staining (represented in Figure 5.5B). The optimal correlation
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Figure 5.4. NT specific IFN-y producing CD8+ T cells detected by ELISPOT. Mice were 
primed and boosted (on day 28) with a pVACl.NT/pVACl dose response and spleens 
collected at day 14 PP and days 7 and 14 PB in the initial experiment (A) and at days 7 and 
14 PP and PB in the repeat (B). Prior to ELISPOT analysis, splenocytes were cultured 
overnight in the presence of media + 50 ng/ml IL-2 or media + 50 ng/ml IL-2 + lOOnM NT 
peptide. Results are mean of individual means ± SEM of 3 mice/group. Stars on top of 
groups represent Student’s T-test comparison with pVACl only group (group g) (* p < 
0.05, ** p < 0.01, *** p < 0.001).
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Figure 5.5. NT specific CD8+ T ceil responses measured by IFN-y intracellular staining. 
Mice were primed and boosted (on day 28) with a pVACl.NT/pVACl dose response and 
CD8 T cell responses detected as NT specific IFN-y producing cells in splenocytes 
collected at day 14 PP and days 7 and 14 PB in the initial experiment (A) and days 7 and 14 
PP and PB in the repeat experiment (B). Splenocytes were incubated with 100 nM NT for 6 
hrs and 10 fig/ml Brefeldin A (last 4 hrs) before staining and flow cytometry analysis. 
Results are mean of individual means ± SEM of 3 mice/group. Stars on top of groups 
represent Student’s T-test comparison with pVACl only group (group g) (* p < 0.05, ** p
< 0 . 0 1 ,  * * * p <  0 . 0 0 1 ) .
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Figure 5.6. Representative data from flow cytometry analysis of NT specific IFN-y 
producing CD8+ T cells. Data is from the day 14 PB pVACl.NT/pVACl dose response 
(shown in Figure 5.5A) and compares the intracellular IFN-y production in spleen cells of 
mouse immunised with 500 ng pVACl.NT (left hand column) with mouse immunised with 
control group (right hand column). 5 x 105 splenocytes were collected for each analysis and 
CD62Liow and IFN-y + cells (final row) were gated on the CD8high population (middle row).
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Figure 5.7. Comparison of the in vitro and in vivo pVACl.NT/pVACl dose response 
studies for the second batch of cartridges. The in vitro IFN-y ELISPOT data (Figure 5.2B) 
was plotted against the in vivo IFN-y ELISPOT (Figure 5.4B) and intracellular IFN-y 
staining data (Figures 5.5B) and the resulting correlation plots are shown on the left hand 
and right hand columns, respectively. The dose responses were compared for the day 7 PP, 
day 14 PP, day 7 PB and day 14 PB in vivo time-points. Mean values was used for 
correlation and linear trend-line regression coefficient (R2) was fitted to data.
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R2 values from the in vitro IFN-y ELISPOT / in vivo IFN-y ELISPOT
correlation plots
Time-point Cartridge batch 1 Cartridge batch 2
Day 7 PP - 0.997
Day 14 PP 0.885 0.822
Day 7 PB 0.144 0.648
Day 14 PB 0.180 0.830
Table 5.3. Comparison of the in vitro and in vivo pVACl.NT/pVACl dose response 
studies for the first and second batch of cartridges. R2 values were obtained by plotting in 
vitro IFN-y ELISPOT data against the in vivo IFN-y ELISPOT data.
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from this analysis was 0.876 obtained at day 7 PB (Figure 5.7, right hand column). The 
regression coefficients from the in vitro IFN-y ELISPOT/m vivo IFN-y ELISPOT 
correlation plots for the first and second batch of cartridges are represented in Table 5.3. 
For both sets of data, the best correlations were achieved when the in vitro data was plotted 
against the data from the early in vivo time-points (i.e. R2 values of 0.855 and 0.997 for day 
7 PP using cartridge batch 1 and day 14 PP using cartridge batch 2, respectively).
5.3.2. Effect of a promoter dose response on CD8+ NT response in vitro
and in vivo
5.3.2.1. Cloning ofp7313.NT plasmids
Four p7313.NT plasmids with different promoter configurations were constructed as 
described in chapter 2 (Figure 5.8). Firstly, p7313.plc.NT was synthesised by the ligation of 
the NT insert with the p7313.plc vector. Following this, plasmids p7313.ii.NT, 
p7313.me.NT and p7313.m.NT were constructed. After transformation and overnight 
incubation on agar plates, selected colonies were scaled up and the purified plasmid 
analysed for correct vector sequence by Bam HI and Clal restriction enzyme digest. All 
vectors showed correct DNA fragment profile (Figure 5.9).
5.3.2.2. Characterisation ofp7313.NT plasmids
Each of the p7313 plasmids were transfected into MC57 cells by PMDD on three separate 
occasions and antigen production monitored by Western blot analysis of cell lysates and by 
the in vitro CD8+ T cell assay. A representative Western blot analysis is shown in Figure 
5.10A. The plasmid containing the weakest promoter (p7313.m.NT) was undetectable 
suggesting that this promoter configuration (minimal CMV promoter only) is extremely 
inefficient at driving RNA transcription relative to the other promoters. The ii.NT plasmid 
appears to be the strongest p7313 plasmid generating more NT antigen than the 
corresponding pVACl.NT plasmid. The in vitro response measured by IFN-y ELISPOT
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broadly correlated to expression level (Figure 5.10B). However, only the ii.NT plasmid was 
significantly greater than the control plasmid (i.e. pCMV-GFP).
5.3.2.3. NT promoter dose response in vitro
Cartridges containing the 50 ng p7313 plasmids were compared against 
pVACl.NT/pVACl dose responses in vitro. The results for the first set of cartridges are 
represented in Figure 5.11. Results show that the ii and plc.NT groups were clearly the 
strongest with these groups been significantly different from the empty p7313 plasmid 
control. Overall, the in vitro data presented in Figures 5.10 and 5.11 suggest that the ii and 
plc.NT are the best p7313 plasmids while the me.NT and especially m.NT are weaker.
5.3.2.4. The NT promoter dose response in vivo
The strength of the p7313 plasmids was also examined in vivo. In the first in vivo 
experiment, cartridges containing 50 ng of the different p7313 plasmids were compared 
against a pVACl.NT/pVACl dose response. CD8+ specific T cell responses were 
monitored using IFN-y ELISPOT and IFN-y intracellular staining at day 14 PP and days 7 
and 14 PB. For the repeat experiment, cartridges containing 5 ng p7313 plasmids were 
compared against a pVACl.NT/pVACl dose response with responses monitored at day 14 
PP and day 7 PB. For the IFN-y ELISPOT analysis, results presented are the number of 
IFN-y spots in the media + EL-2 + peptide group minus the media + EL-2 group. Results 
from the first in vivo study revealed that the ii, pic and me.NT plasmids were significantly 
greater than the empty p7313 plasmid at all time-points (Figure 5.12A). Following boost, 
the magnitude of the IFN-y response increased to a maximum level at day 7 with the me.NT 
plasmid yielding the strongest response (-1250 spots/million cells). In the second 
experiment, a similar trend emerged. The ii, pic and me.NT plasmids were significantly 
greater than the empty p7313 plasmid at the day 7 PB time-point (Figure 5.12B). However, 
unlike the first analysis, the ii.NT proved to be the best p7313 plasmid yielding the greatest 
response at days 14 PP and 7 PB. At day 7 PP, the ii and plc.NT groups were comparable to
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3’
p7313.ii.NT vector backbone — ^  i NT sequence
p7313.rn.NT vector backbone NT sequence
p7313.me.NT vector backbone NT sequence
p7313.plc.NT vector backbone NT sequence
; -' ' i7'J CMV enhancer sequence
□  empty
minimal CMV promoter
CMV exon 1 
CMV intron A
Figure 5.8. Schematic of the different p7313.NT promoter configurations used.
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3054 bp
2000 bp 
1650 bp
850 bp 
500 bp 
200 bp
DNA fragment size after Cla I and Bam HI digest
plc.NT 216 1038 1614 3067
me.NT 216 770 1050 2493
ii.NT 216 1050 1982 2493
m.NT 216 651 1050 2493
Figure 5.9. Bam HI and Clal restriction enzyme digest of the p7313 plasmids. All 
plasmids show correct DNA fragment profile as outlined in the table.
I
me.NT m.NT
plc.NT ii.NT
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500 ng pVAC 1 .NT
PlcNT m.NT
li.NT
58.6 kD
500 ng 
p7313 DNA
2000
1600 -
1200  -
800
400 -
p7313.ii.NT p7313.plc.NT p7313.me.NT p7313.m.NT pCMV-GFP
Figure 5.10. Characterisation of p7313.NT plasmids by Western blot analysis (panel A) 
and using the in vitro CD8+ T cell assay (panel B). For Western blot analysis, MC57 cells 
were transfected with 500 ng of p7313.NT plasmids, incubated overnight, lysed and 
assayed as described in section 2.12. For the in vitro CD8+ T cell assay, transfected cells 
were incubated overnight in a 1:1 ratio with 1 x 105 activated RAG1.F5 splenocytes and 
200 ng/ml IL-2 and measured by EFN-y ELISPOT. Negative control was MC57s transfected 
with pCMV-GFP plasmid. Each symbol (except bars) represents an individual experiment. 
Bars are the mean of all experiments for each group. Stars on top of p7313.ii.NT group 
represent Dunnet’s test comparison of group mean with negative control group mean (** p 
< 0.01).
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Figure 5.11. Comparison of pVACl.NT and p7313.NT plasmid potency using the in vitro 
CD8+ T cell assay. MC57 cells were transfected with a pVACl.NT/pVACl dose response 
and 50 ng of p7313.NT plasmids. Data is for the first batch of cartridges. Cells were 
incubated overnight in a 1:1 ratio with 1 x 105 activated RAG1.F5 splenocytes and 200 
ng/ml IL-2 and then measured by IFN-y ELISPOT. Each symbol (except bars) represents 
an individual experiment. Bars are the mean of all experiments for each group. Stars on top 
of the ii.NT and plc.NT groups represent Dunnet’s test comparison of group means with the 
p7313 control group mean (* p< 0.05, ** p < 0.01). ND: not done.
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the corresponding 5 ng pVACl.NT group (i.e. group C), but after boost, only the ii.NT 
yielded a response similar to the pVACl.NT group. For the first set of cartridges, the 
results obtained for intracellular EFN-y staining are shown in Figure 5.13A. No responses 
were observed in any group at day 14 PP. After boost, significant responses were obtained 
in the ii, pic and me.NT groups at day 7 and in the ii and plc.NT groups at day 14. The data 
was similar to that observed in the IFN-y ELISPOT analysis in that the me.NT plasmid was 
the strongest p7313 plasmid at day 7 and day 14 PB (e.g. the frequency of CD8high 
CD62Liow IFN-y producing cells was -0.75 % at day 7 PB). The results obtained for 
intracellular LFN-y staining in the repeat experiment are shown in Figure 5.13B. At day 14 
PP, of the p7313 plasmids, only the group immunised with the ii.NT plasmid yielded a 
response above control (0.46 % of CD8high splenocytes were CD62Liow IFN-y producing 
cells). After boost, the magnitude and sensitivity of the response increased with the 5 ng 
p7313.ii, pic, me.NT and pVACl.NT plasmid groups giving similar responses. 
Representative flow cytometry analysis of the four p7313.NT plasmids at day 7 PB in the 
first study is shown in Figure 5.14.
5.3.2.5. Comparing the in vitro model with CD8+ T cell responses in vivo
For the first batch of cartridges, the results from the in vitro EFN-y ELISPOT assays 
(represented in Figure 5.11) were plotted against the corresponding in vivo IFN-y ELISPOT 
(represented in Figure 5.12A) and IFN-y intracellular staining (represented in Figure 5.13A) 
results and are presented in Figure 5.15. When the data from the in vitro study was 
compared with the in vivo IFN-y ELISPOT data, the best correlation was obtained at day 14 
PP (R2 value of 0.883). After boost, the correlation coefficients decreased to 0.162 and 0.02 
at days 7 and 14, respectively. The in vivo intracellular staining data did not correlate with 
the in vitro ELISPOT data at any time-point. Correlation coefficients of 0.364, 0.415 and 
0.211 were achieved at day 14 PP, 7 PB and 14 PB, respectively.
The regression coefficients from the in vitro EFN-y ELISPOT/m vivo IFN-y ELISPOT 
correlation plots for the first and second batch of cartridges are represented in Table 5.4.
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The best correlations were achieved when the in vitro data was plotted against the data 
from the post primary in vivo time-points (i.e. at day 14 PP, R2 values of 0.883 and 0.835 
were obtained for cartridge batches 1 and 2, respectively).
5.4. Discussion
5.4.1. Effect of immunising dose on immune response
5.4.1.1. Difference in sensitivity between the in vitro and in vivo assays
An important observation from these analyses was the difference in sensitivity (i.e. 
detection of the lowest statistically relevant group) between the in vitro and in vivo dose 
responses. Significance was generally obtained in the 500 ng DNA group only in the in 
vitro dose response studies, although the second batch of cartridges did register a dose 
response end-point of 50 ng when area of cytokine producing cells was used as reporting 
method. Although the regression coefficients obtained from the correlation plots of number 
versus area of cytokine producing cells suggested that both reporting methods were similar, 
this relationship is not absolute.
In contrast, the in vivo dose response curves expectedly showed a far greater level of assay 
sensitivity, especially after boost. For these experiments, the lowest amount of pVACl.NT 
capable of eliciting a significant response was generally observed to be 0.5 ng. The one 
exception to this was the first dose response with IFN-y ELISPOT as detection method. 
Here, significance was obtained in groups down to 0.05 ng DNA (Day 14 PB data shown in 
Figure 5.4A). The different results obtained may be due to the differences in the ELISPOT 
and intracellular staining technologies as detection methods. Theoretically, both measure 
the influenza366-374 specific IFN-y producing CD8+ T cells. ELISPOT measures the total 
amount of cytokine secreted from functionally active cells. The image processing software 
calculates number and area of cytokine spots but does not discriminate between spots that 
are the product of one versus more than one functionally active T cell. On the other hand,
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Figure 5.12. NT specific CD8+ T cell responses as measured by IFN-y ELISPOT. For the 
first experiment (panel A), mice were primed and boosted (on day 28) with a 
p VAC 1.NT/p VAC 1 dose titration and 50 ng of p7313.NT plasmids and spleen cells were 
collected at day 14 PP and day 7 and 14 PB. For the repeat (panel B), mice were primed 
and boosted (on day 28) with a pVACl.NT/pVACl dose response and 5 ng of p7313.NT 
plasmids and responses monitored at day 14 PP and day 7 PB. Results are mean of 
individual means ± SEM of 3 mice/group. Stars on top of groups represent Student s T-test 
comparison with p7313 control group (* p < 0.05, ** p < 0.01, *** p < 0.001).
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Figure 5.13. CD8+ T cell responses assessed by IFN-y intracellular staining. For the first 
experiment (panel A), mice were primed and boosted (on day 28) with a 
pVACl.NT/pVACl dose response and 50 ng of p7313.NT plasmids and spleen cells were 
collected at day 14 PP and days 7 and 14 PB. For the repeat (panel B), mice were primed 
and boosted (on day 28) with a pVACl.NT/pVACl dose response and 5 ng of p7313.NT 
plasmids and spleen cells collected at day 14 PP and day 7 PB. Splenocytes were incubated 
in the presence of 100 nM NT for 6 hrs and 10 /ig/ml Brefeldin A (last 4 hrs) before 
staining and flow cytometry analysis. Results are mean of individual means ± SEM of 3 
mice/group. Stars on top of groups represent Student’s T-test comparison with p7313 
control group (* p < 0.05, ** p < 0.01***, p < 0.001).
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IFN-y + splenocytes (0.3%) IFN-y + splenocytes (0.9%)
IFN-y + splenocytes (0.1%)IFN-y + splenocytes (0.2%)
FITC-C D62L
Figure 5.14. Representative data from flow cytometry analysis of NT specific IFN-y 
producing CD8+ T cells. Data is taken from day 7 PB of the first experiment (described in 
Figure 5.13A) and compares intracellular IFN-y production in spleen cells of mouse 
immunised with 50 ng of plasmids p7313.ii.NT (A), p7313.plc.NT (B), p7313.me.NT (C) 
and p7313.m.NT (D). 5 x 105 splenocytes were collected for each analysis and were gated 
on the CD8high population.
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Figure Comparison of p7313 plasmids in vitro and in vivo for the first batch of 
cartridges. The in vitro IFN-y ELISPOT data (Figure 5.11) was plotted against the in vivo 
IFN-y ELISPOT (Figure 5.12A) and intracellular IFN-y staining data (Figures 5.13A) and 
the resulting correlation plots are’ shown in the left hand and right hand columns, 
respectively. The dose responses were compared for the day 14 PP, day 7 PB and day 14 
PB in vivo time-points. Mean values was used for correlation and linear trend-line 
regression coefficient (R2) was fitted to data.
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R2 values from the in vitro IFN-y ELISPOT / in vivo IFN-y ELISPOT
correlation plots
Time-point Cartridge batch 1 Cartridge batch 2
Day 14 PP 0.883 0.835
Day 7 PB 0.162 0.689
Day 14 PB 0.020 -
Table 5.4. Comparison of p7313 plasmids in vitro and in vivo for the first and second batch 
of cartridges. R2 values were obtained by plotting in vitro IFN-y ELISPOT data against the 
in vivo IFN-y ELISPOT data.
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intracellular staining measures the cytokine sequestered in the cytoplasm of individual cells 
and not secreted cytokine. Additionally, this technique may be compromised by sensitivity 
/technical issues associated with fluorescent staining of cytoplasmically localised protein. 
Both may offer possible explanations for the difference in results obtained for the IFN-y 
ELISPOT and intracellular staining data at this time-point.
The sensitivity data obtained for the in vivo dose responses are in general agreement with 
that of Pertmer et al. (1995) who reported CTL responses following delivery of 16 ng DNA 
encoding A/PR/8/34 nucleoprotein using a similar immunisation schedule. In contradiction 
to results obtained here, increasing the dose above 16 ng/immunisation in that particular 
study did not lead to an increase in CTL lytic capacity suggesting that there was a threshold 
dose of DNA required for effector CTL. Once that was reached, increasing the amount of 
DNA administered had little effect on CTL efficacy. However, no CTL functional analysis 
was performed in this study so the link between CD8+ responses detected by ELISPOT and 
intracellular staining and CTL effector function was not established.
The sensitivity data observed in the dose responses compares well with the theoretical 
plasmid loading rate data presented in Table 5.2, column E. Loading 0.5 ng DNA/cartridge 
theoretically results in the precipitation of 24 copies of pVACl.NT plasmid/individual gold 
bead while loading 0.05 ng DNA/cartridge equates to the precipitation of ~2 copies 
plasmid/bead. These results are in agreement with other investigators who have reported 
that as little as 1-20 peptide-MHC complexes can trigger activation of CTL in other 
systems (Sykulev et al., 1996; Montoya and Del Val, 1999; Christinck et al., 1991). 
Actually, Genequant analysis of DNA eluted from cartridges indicates that the loading rate 
is not the theoretical 2 /tg/mg gold but half of this. Therefore, in the case of the 0.05 ng 
group, this correlates to 1 plasmid copy/individual gold bead. This calculation suggests that 
it may be possible to elicit a response in vivo when gold beads carrying just a single copy of 
plasmid get delivered to appropriate APCs. However, trying to relate immune responses 
with number of plasmid copies/bead is difficult. It assumes that pVACl.NT precipitates 
onto each gold bead in a homogenous manner and this may not be correct. It is not known 
how many gold particles penetrate the same APC and how many APC are transfected
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during gene gun immunisation. The QPCR analysis which was performed on DNA gold 
slurries prior to cartridge manufacture confirmed that the plasmids precipitated onto gold 
beads in the expected proportion but it offered no information on the heterogeneity of DNA 
distribution/gold bead. In agreement with Creusot et al. (2003b), it is impossible to know 
whether or not the immune response raised using the DNA dose of 0.05 ng was due to the 
delivery to an individual APC of a single gold bead or multiple beads coated with 1 
plasmid. Alternatively, an immune response may have been elicited at this dose because a 
bead or many beads coated with a disproportionately high number of plasmid copies (e.g. 
-10 copies) may have been delivered to a single APC or multiple APCs.
5.4.1.2. Differences between primary and memory CD8+ T cell responses
During viral infection, the primary immune response is directed towards immunodominant 
viral epitopes resulting in selection of dominant T cell clones. In general, subsequent re­
stimulation of the memory response is characterised by a quantitatively and qualitatively 
superior response accompanied by further epitope dependent T cell selection. In the in vivo 
pVACLNT dose responses, analysing the CD8+ specific responses to the immunodominant 
influenza366-374 epitope reveals some interesting features about the development of the 
CD8+ T cell response. Examination of the ELISPOT and intracellular cytokine staining 
data shows an expected increase in the magnitude and sensitivity of the CD8+ T cell 
response after boosting. However, there is no indication of a linear relationship between 
dose administered and resulting response. After boosting, the increase is greatest in groups 
containing lesser quantities of pVACLNT (i.e. 0.05-50 ng DNA) compared with groups 
immunised with the top dose of pVACl.NT and the overall difference in frequency of the 
influenza366-374 specific CD8+ T cell subset between the top dose and lower doses becomes 
minimal. The data presented here compares well with others who have demonstrated that 
excessive levels of epitope expression (-6 x 104 epitopes/cell) only marginally increases the 
size of the memory response compared with that achieved at high epitope expression levels 
(-3 x 104 epitopes/cell) and results in a qualitatively inferior memory CTL population 
(Wherry et al., 2002; Bullock et a l , 2000). Another possible explanation for the 
disproportionately higher increase in IFN-y producing CD8+ T cells in groups immunised
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with lower doses of pVACl.NT compared with the top dose following boost is that 
excessive epitope levels may result in a skewing of the immune response from 
predominantly IFN-y producing Tel cells to EL 10 producing Tc2 cells (Croft et al., 1994; 
Tanchot et al., 1998). While there is no direct evidence to indicate that two individual 
administrations of the top dose of pVACl.NT (1000 ng) in the space of 28 days leads to the 
generation of excessive levels of nucleoprotein366-374 epitope, this explanation does support 
the results obtained here. Consistent with this interpretation is the concept that T cell clones 
which dominate the primary response and undergo massive expansion are detectable in the 
memory response at lower frequencies (Callan et al., 2000; Davenport et al, 2002). 
Presumably, preferential elimination of dominant T cell clones during the primary response 
allows other epitope specific clonotypes to become more prevalent in the memory response 
thus preventing the immune response from becoming too focused. Therefore, mice 
immunised with increasing quantities of nucleoprotein encoding plasmid are more 
susceptible to immunodominant epitope T cell down regulation in the recall response. It 
would be interesting to monitor the response elicited against a second subdominant epitope 
to investigate if the T cell response to that epitope has altered with repeat exposure to 
antigen.
5.4.2. Effect of NT promoter dose response on immune response
The amount of NT antigen made available for presentation was varied by using NT 
encoding plasmids with different promoters. Construct design centred upon the ubiquitous 
human CMV-IE promoter which allows for constitutive expression in a wide range of cells 
in vitro and in vivo. Many investigators have found this promoter more effective than a 
range of other viral and cellular promoters (Burkholder et al., 1993; Lee et al., 1997; 
Garapin et al., 2001; Zhang et al., 2002). Inclusion of various molecular units such as CMV 
enhancer, intron A and exon 1 to this promoter resulted in a group of plasmids each capable 
of generating differing quantities of NT. There is much evidence which suggests that each 
of these promoter components contribute positively towards protein production. The CMV 
enhancer is a powerful and versatile unit which effectively augments CMV promoter driven 
transcription. From a viral perspective, it is required for the synthesis of EE gene expression
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and hence the initiation of the infectious cycle (Angulo et al., 1998). Its ubiquitous activity 
was nicely demonstrated by Schmidt et al. (1990) who investigated the activity of the CMV 
promoter-enhancer combination in transgenic mice, recording transient gene expression in 
twenty four of twenty eight tissues tested. However, it is noteworthy that there is also 
evidence that this promoter-enhancer gives limited and variable transient gene expression 
in studies involving a number of transgenic mouse lines (Mikkelsen et al., 1992). Another 
positive element for CMV-DE initiated transcription is CMV-IE 1 intron A. It has been 
successfully used to increase gene expression in a number of transient systems and 
permanent cell lines in vitro and in transgenic mice in vivo (Huang et a l, 1990; Palmiter et 
al., 1991). Postulated mechanisms of action include stabilisation of mRNA by splicing 
and/or polyadenylation (Niwa et a l, 1990) or by acting as an enhancer (Buchman and Berg, 
1988). Its position within the transcription unit is an important consideration with 
placement at the 5’ untranslated region (relative to CMV promoter) essential for efficient 
expression (Lee et a l, 1997). The final element incorporated into the p7313 promoter 
design was the CMV-IE exon-1 sequence. Although not widely recognised as important for 
gene expression improvement, there is evidence which demonstrates that inclusion of 
sequences from the initial portion of exon-1 in the presence of intron A results in a three 
fold increase in gene expression (Simari et al., 1998).
Comparing the magnitude of the NT specific CD8+ T cell responses using different 
constructs in parallel in vitro and in vivo experiments provided an opportunity to examine 
the relationship between amount of antigen produced and resulting response following gene 
gun immunisation. The general observation from the in vitro studies was that the ii and 
plc.NT plasmids were the strongest p7313 plasmids and that the me and m.NT plasmids 
were much weaker. The second important observation was the generally broad correlation 
between the amount of antigen produced by these different plasmids and the resulting in 
vitro response. This suggests that the RAG1.F5 responders are responsive to the level of 
antigen that is processed and presented by the APCs.
A different pattern emerged in vivo. In the first promoter study, the me .NT plasmid gave 
the best response. In the second study, ii.NT was the most potent p7313 plasmid as
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assessed by ELISPOT while ii, pic and me.NT gave similar results when intracellular 
staining was used. Although this inconsistency may be partly related to the detection 
method used (see section 5.4.1.1), there is still a difference between the in vitro and in vivo 
data. This may suggest that transient gene expression in vitro does not necessarily reflect 
the behaviour of promoters under in vivo conditions (Scharfmann et al., 1991; Loirat et al, 
1999; Locher et al., 2002). More specifically, there is a discrepancy between the amount of 
antigen produced by the different p7313 plasmids (as observed in Figure 5.10A) and the 
response elicited to these plasmids. There is almost a threshold type relationship between 
the amount of antigen available for presentation and the resulting response, especially after 
boost. Once this threshold is reached, a good immune response is elicited irrespective of the 
amount of antigen in the system. This reasoning is further supported by the observation that 
a similar magnitude of NT response was obtained in the first and second in vivo 
experiments despite a 10 fold difference in p 7313 plasmid used for immunisations (i.e. 50 
and 5 ng p7313 plasmids used in experiments 1 and 2, respectively). Finally, from the in 
vivo data, there is inconclusive evidence to suggest that the inclusion of the enhancer 
subunit (present in ii.NT only) resulted in improved promoter potency. However, these 
results implicate sequences from the initial portion of CMV exon-1 promoter as important 
in providing enhanced gene expression.
5.4.3. Can the in vitro model predict in vivo immune responses?
Assessing the immunising dose and promoter dose responses in vitro and in vivo provided 
an opportunity to investigate if the in vitro CD8+ assay could be predictive of the in vivo 
immune response. When the in vitro and in vivo immune responses were compared against 
each other for the immunising dose and promoter dose data, the best correlations were 
achieved when the post primary in vivo time-points were used for correlation (see Tables 
5.3 and 5.4). A possible explanation for this is that early on in the in vivo immune response 
(especially day 7 PP), the influenza366-374 specific CD8+ T cells may still be clonally 
expanding in response to the first antigenic stimulus with the memory phenotype not 
established. Assuming that T cell recruitment is not limiting and that a naive cytokine 
milieu exists within the immune micro-environment at this time-point (i.e. no cytokine or T
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cell help available from already established T cell populations), the main factor in shaping 
the immune response is the amount of available antigen present. The response at this stage 
is not affected by events such as affinity maturation of the T cell repertoire or 
competition/co-operation effects at the TcR level. Likewise, the in vitro bioassay is a one 
dimensional system which is not complicated by the presence of different types of 
presenting and responding cell populations. It is responsive to the level of antigen presented 
which is effectively, in this system at least, determined by the amount of plasmid 
administered and the amount of antigen produced within the APC. Despite the fact that in 
vitro, the MC57 cells are non professional APC, the in vitro bioassay is useful as a guide to 
determining the early stage primary response in vivo but is not suitable for predicting the 
immune response to a mature memory CD8+ T cell population.
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55. Conclusions
In this chapter, parallel in vitro and in vivo experiments were performed in which the 
influence of immunising DNA dose on resulting immune response was assessed. The main 
observations were
• That there was a difference in sensitivity between the in vitro and in vivo 
experiments, with the in vivo dose response studies showing a far greater level of 
assay sensitivity.
• There was a broad correlation between antigen produced and resulting response in 
vitro but not in vivo.
• The immune response observed in vivo suggested that there was a lack of 
correlation between the amount of antigen available for presentation within the 
APCs and the resulting response after boost.
As a corollary to the dose response studies, the predictive capacity of the in vitro assay was 
assessed. The positive correlations between the in vitro data and the early in vivo time- 
points suggested that the in vitro assay was useful in determining the early stage primary 
response in vivo.
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6.1. Introduction
In the previous chapter, the p VAC 1.NT/p VAC 1 dose response was compared in vitro and 
in vivo. The correlations obtained suggested that the in vitro assay was useful as a guide in 
determining the early stage primary response in vivo but not good for predicting the 
immune response to a mature memory CD8+ T cell population. A possible explanation for 
this outcome was that similar to the in vitro assay, an early stage in vivo response is 
dominated by its dependence on antigenic load. After this time-point in vivo, the immune 
response moves towards more of a memory phenotype which is influenced more by the 
behaviour of the memory T cell population than by the amount of antigen available for 
presentation.
In the previous chapter, an immune response was elicited against the influenza 
nucleoprotein only. In this chapter, the in vitro and in vivo models are extended to look at 
the interaction between two antigens. This was achieved by replacing the non antigen 
coding plasmid (i.e. pVACl) with an antigen coding plasmid (i.e. pVACl.OVAs). In doing 
so, the effect that a second coding plasmid has on the outcome of the NT CD8+ T cell 
response is examined. Such an analysis may help to explain better the mechanism of 
antigenic competition within the APC in vivo when more than one plasmid is delivered by 
PMDD and the effect that this has on overall antigen presentation.t
Secondly, the effect that the nature of the antigen produced by pVACl.OVA has on the NT 
response was assessed. This was achieved by comparing responses to NT encoding plasmid 
in the presence of pVACl.OVAs which secretes the encoded ovalbumin with 
pVACl.OVAc which retains the encoded ovalbumin within the cytoplasm or pVACl. 
Several studies have demonstrated that altering the cellular location of expressed antigen 
has quantitative and qualitative effects on immune responses (Boyle et al., 1997; Rush et 
al, 2002; Torres et a l, 1999). Generally, these studies report that following intra-dermal 
DNA immunisation, membrane bound or secreted forms of antigen favour antibody 
mediated responses while cytoplasmically localised sources of antigen are more effective at
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initiating cellular responses. The influence of cytoplasmically and secreted forms of 
ovalbumin on the in vivo and in vitro NT CD8+ response is investigated in this chapter.
6.2. Objective
The relationship between available antigen and resulting CD8+ NT response during dual 
plasmid immunisation was examined by investigating in vitro and in vivo
• The effect of a pVACl.NT/pVACl.OVAs dose response on resulting CD8+ 
immune responses.
• The effect that different forms of pVAC 1 .OVA has on the CD8+ response.
The ability of the in vitro CD8+ T cell assay to predict in vivo responses was assessed by 
comparing the in vitro and in vivo data sets.
63. Results
For all experiments, the nomenclature used to denote amount of NT encoding DNA 
delivered by PMDD is shown in Table 6.1. The in vitro results are expressed as number and 
area of IFN-y producing cells/million responder cells and the in vivo results are expressed 
as number of IFN-y producing cells/million cells.
6.3.1. CD8+ restricted T cell responses to pVACl.NT in vitro
For the dose response, cartridges were prepared by mixing pVACl.NT (in log dilutions 
from 500-0.5 ng) with variable amounts of pVACl.OVAs. The total amount of 
DNA/cartridge was 500 ng. The pVACl.NT/pVACl.OVAs dose response was assessed in 
vitro using the CD8+ T cell assay (Figure 6.1). Results show that only the 500 ng group 
was significantly above control (i.e. pVACl.OVAs only group). Next, two more batches of
168
Chapter 6: Effect of antigen dose on PMDD efficacy following dual plasmid immunisation
Cartridge composition
Group name Theoretical loading 
pVACl.NT
Theoretical loading 
pVACl.OVAs
ng DNA / cartridge ng DNA / cartridge
a 500 0
b 50 450
c 5 495
d 0.5 499.5
e 0.05 499.95
f 0.005 4999.995
g 0 500
Table 6.1. Nomenclature used to denote amount of influenza nucleoprotein and ovalbumin 
encoding plasmid DNA in cartridge preparations for all in vitro and in vivo experiments 
presented in chapter 6.
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Figure 6.1. Activation of RAG1.F5 splenocytes by MC57 cells as measured by EFN-y 
ELISPOT. MC57s were transfected with pVACl.NT/pVACl.OVAs containing cartridges 
and incubated overnight in a 1:1 ratio with 1 x 105 activated RAG1.F5 splenocytes and 200 
ng/ml IL-2. Each symbol (except bars) corresponds to an individual experiment. Bars are 
the mean of all experiments for each group. For each individual assay, data is mean of 
triplicate analyses of pooled triplicate transfections. Stars on top of group a represents 
Dunnet’s test comparison of group mean with control group mean (group g) (p <0.001).
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Figure 6.2. Activation of NT specific activated RAG1.F5 splenocytes by MC57 cells 
measured by IFN-y ELISPOT. MC57s were transfected with pVACl.NT/pVACl.OVAs 
containing cartridges and incubated overnight in a 1:1 ratio with 1 x 105 activated RAG1.F5 
splenocytes and 200 ng/ml IL-2. First and second experiments are shown in rows A and B, 
respectively. Detection was reported by number (left hand column) and area (right hand 
column) of IFN-y producing cells/million cells. Each symbol (except bars) corresponds to 
an individual experiment. Bars are the mean of all experiments for each group. For each 
individual assay, data is mean of triplicate analyses of pooled triplicate transfections. Stars 
on top of groups represent Dunnet’s test comparison of group means with corresponding 
control groups (group g) (* p < 0.05, *** p <0.001).
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Figure 6.3. Comparison of data reporting methods for the pVACl.NT/pVACl.OVAs dose 
response studies. Panels A and B represent correlation plots of dose response studies shown 
in Figure 6.2, row A and row B, respectively. Panel C: Correlation plot of all in vitro 
pVACl.NT/pVACl.OVAs dose response studies performed (n=8). Mean values of number 
(x-axis) a .a area (y-axis) of IFN-y producing cells/million cells from each group (denoted 
by horizontal bars in Figures 6.2) was used for correlation and linear trend-line regression 
coefficient (R7) was fitted to data.
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pVACl.NT/pVACl.OVAs cartridges used in parallel in vivo experiments (represented in 
Figure 6.4 and 6.5) were assessed in vitro. Detection was reported by number and area of 
IFN-y producing cells/million responder cells. Results of the first batch are shown in Figure
6.2, row A. Due to the variability between assays especially at the higher doses of 
pVACLNT, no groups were significantly different from control. Responses above control 
were evident at the top dose of pVACl.NT but this group was not tested for significance 
(n=2 assays at this dose). Similar analyses were performed for the second batch of 
cartridges. In this dose response, significance was obtained in the 50 ng groups when both 
number and area of IFN-y producing cells/million responder cells was used as reporting 
method (Figure 6.2, row B).
To examine the relationship between number and area of data reporting further, both 
methods were compared. Regression coefficients of 0.990 and 0.827 were obtained for the 
first and second batches of cartridges, respectively. When this correlation was performed 
using the data from all in vitro pVACl.NT/pVACl.OVAs dose responses (n=8), a R2 value 
of 0.999 was obtained (Figure 6.3, panel C).
6.3.2. CD8+ restricted T cell responses to pVACl.NT in vivo
Cartridges containing mixtures of p VAC 1.NT/p VAC l.OVAs were assessed in two in vivo 
dose response studies. CD8+ specific T cell responses were measured by IFN-y ELISPOT 
and intracellular IFN-y staining. For the IFN-y ELISPOT data, results presented are the 
number of IFN-y spots in the media + IL-2 + peptide group minus the media + IL-2 group.
For the ELISPOT analysis of the first experiment, significant results were obtained in 
groups down to 5 ng pVACl.NT at all time-points (Figure 6.4A). Generally, the magnitude 
of the IFN-y response was optimal at day 7 PB before decreasing slightly at day 14 PB. The 
500 and 50 ng groups showed the greatest change in IFN-y production over the time-points 
studied (e.g. the 50 ng group gave ~140, ~640 and ~400 cytokine producing cells/million 
cells at day 14 PP and days 7 and 14 PB, respectively). In the repeat experiment (Figure 
6.4B), groups immunised with 500 and 50 ng pVACl.NT were significantly different from
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the control group at day 7 and 14 PP. After boost, groups down to 0.5 ng reached 
significance at day 7 and 14. As in the first experiment, the frequency of cytokine 
producing cells was generally maximal at day 7 PB. The first two groups in the dose 
response series (500 and 50 ng groups) showed the greatest difference in frequency of IFN- 
y producing cells over the four time-points. The 500 ng pVACl.NT group yielded -1330 
IFN-y spots/million cells compared to -500, -560 and -660 at days 7 and 14 PP and day 14 
PB, respectively. The lowest amount of pVACl.NT capable of eliciting an immune 
response as measured by ELISPOT was 5 ng in the initial experiment compared with 0.5 ng 
in the repeat. In contrast to the p VAC 1.NT/p VAC 1 dose responses (Figures 5.4A and 
5.5A), there is clear evidence for a linear type relationship between dose of DNA and 
resulting response.
The results obtained for intracellular IFN-y staining in the first experiment are represented 
in Figure 6.5A. Significant results were obtained at all time-points. The magnitude and 
sensitivity of response was greatest at day 7 PB where groups immunised with 0.5 ng 
pVACl.NT were significantly above control. As with the IFN-y ELISPOT analysis of this 
experiment, the 500 and 50 ng groups showed the greatest change in frequency of CD8high 
CD62Liow IFN-y producing cells over the different time-points (e.g. the 500 ng group gave 
0.16, 1.33 and 0.5 % CD8high CD62Liow IFN-y producing cells at day 14 PP and days 7 and 
14 PB, respectively).
Results of the intracellular IFN-y staining analysis of the second experiment are shown in 
Figure 6.5B. In general, the results correlated well with the ELISPOT data except for two 
notable differences. Firstly, the frequency of CD8high CD62Liow IFN-y producing cells was 
highest at day 14 PB (500 ng group yielded 0.71 % compared with 0.11, 0.44 and 0.43 % at 
days 7 and 14 PP and day 7 PB, respectively). Secondly, all groups down to 0.5 ng 
pVACl.NT were significantly above control at day 7 PP compared with just the 500 and 50 
ng groups in the IFN-y ELISPOT analysis. Overall, the lowest amount of pVACl.NT 
capable of eliciting a response above control as detected by intracellular IFN-y staining in 
both experiments was 0.5 ng.
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Figure 6.4. NT specific IFN-y producing CD8+ T cells detected by ELISPOT. Mice were 
primed and boosted (on day 28) with a pVACl.NT/pVACl.OVAs dose response and 
spleens collected at day 14 PP and days 7 and 14 PB in the first experiment (A) and at days 
7 and 14 PP and PB in the repeat (B). Prior to ELISPOT analysis, splenocytes were 
cultured overnight in the presence of media + 50 ng/ml IL-2 or media + 50 ng/ml EL-2 + 
lOOnM NT peptide. Results are mean of individual means ± SEM of 3 mice/group. Stars on 
top of groups represent Student’s T-test comparison with pVACl.OVAs only group (group 
g) (* p < 0.05, ** p < 0.01, *** p < 0.001).
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Figure 6.5. Intracellular staining analysis of NT specific CD8+ T cells. Mice were primed 
and boosted (on day 28) with a pVACl.NT/pVACl.OVAs dose response and CD8+ T cell 
responses detected as NT specific IFN-y producing cells in splenocytes collected at day 14 
PP and days 7 and 14 PB in the first experiment (A) and days 7 and 14 PP and PB in the 
repeat experiment (B). Splenocytes were incubated with 100 nM NT for 6 hrs and 10 /xg/ml 
Brefeldin A (last 4 hrs) before staining and flow cytometry analysis. Results are mean of 
individual means ± SEM of 3 mice/group. Stars on top of groups represent Student’s T-test 
comparison with pVACl.OVAs only group (group g) (* p < 0.05, ** p < 0.01).
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6.3.3. Comparison of T cell responses in vitro and in vivo
The in vitro pVACl.NT/pVACl.OVAs dose response data (using number of IFN-y 
producing cells/million cells as reporting method) was plotted against the in vivo dose 
response data. For the first batch of cartridges, results showed a good correlation between 
in vitro and in vivo data sets (Figure 6.6). The best correlation coefficient was obtained at 
day 14 PB (R2 value of 0.965). A similar trend was observed when the in vitro IFN-y 
ELISPOT and in vivo intracellular IFN-y staining data sets were plotted against each other. 
Regression coefficients > 0.9 were obtained at each time-point with the best result at day 14 
PB (R2 value of 0.999). The regression coefficients from the in vitro EFN-y ELISPOT/m 
vivo IFN-y ELISPOT correlation plots for the first and second batches of cartridges are 
represented in Table 6.2. For both sets of data, good correlations were generally achieved 
when the in vitro data was plotted against data from both the post primary and post boost in 
vivo time-points.
The predictive ability of the in vitro bioassay was also assessed by plotting the 
pVACl.NT/pVACl (see chapter 5) and p VAC 1.NT/p VAC l.OVAs dose responses against 
each other (for the in vitro and in vivo IFN-y ELISPOT data sets) and comparing the 
resulting regression coefficients. For the in vitro data, results generated using number of 
IFN-y producing cells/million responders as reporting method was used for correlation. 
When the pVACl.NT/pVACl and p VAC 1.NT/p VAC l.OVAs dose responses were 
compared for all in vitro assays performed (n=ll), an R2 value of 0.999 was obtained 
(Figure 6.7). This type of analysis was also performed for the in vivo ELISPOT data at each 
experimental time-point. In contrast to the in vitro data, the correlations between the two in 
vivo dose responses for the first batch of cartridges were lower with R2 values of 0.757, 
0.610 and 0.399 obtained at day 14 PP, day 7 PB and day 14 PB, respectively (Figure 6.8). 
The regression coefficients for the first and second batches of cartridges are compared in 
Table 6.3. For the second batch of cartridges, correlations between dose responses were 
also low with the exception of the day 7 PP time-point which yielded a R2 value of 0.972.
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Figure 6.6. Comparison of the in vitro and in vivo pVACl.NT/pVAC l.OVAs dose 
response studies for the first batch of cartridges. The in vitro IFN-y ELISPOT data (Figure 
6.2, row A) was plotted against the in vivo IFN-y ELISPOT (Figure 6.4A) and intracellular 
IFN-y staining data (Figures 6.5A) and the resulting correlation plots are shown on the left 
hand and right hand columns, respectively. The dose responses were compared for the day 
14 PP, day 7 PB and day 14 PB in vivo time-points. Mean values were used for correlation 
and linear trend-line regression coefficient (R ) was fitted to data.
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R2 values from the in vitro IFN-y ELISPOT / in vivo IFN-y ELISPOT
correlation plots
Time-point Cartridge batch 1 Cartridge batch 2
Day 7 PP - 0.973
Day 14 PP 0.905 0.636
Day 7 PB 0.836 0.953
Day 14 PB 0.965 0.989
Table 6.2. Comparison of the in vitro and in vivo p V AC l.NT/p VAC l.OVAs dose response 
studies for the first and second batch of cartridges. R2 values were obtained by plotting in 
vitro IFN-y ELISPOT data against the in vivo IFN-y ELISPOT data.
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Figure 6.7. Comparison of all in vitro p V AC l.NT/p VAC l.OVAs and pVACl.NT/pVACl 
dose responses performed (n=ll). For each dose response, mean values were used for 
correlation and linear trend-line regression coefficient (R ) was fitted to data.
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Figure 6.8. Comparison of in vivo pVACl.NT/pVACl.OVAs and pVACl.NT/pVACl 
dose responses for the first batch of cartridges. Data from IFN-y ELISPOT (shown in 
Figures 6 !A and 5.4A) was used for correlation. Panels A-C: Correlation plots of day 14 
PP, day 7 PB and day 14 PB data. Mean values were used for correlation and linear trend- 
line regression coefficient (R2) was fitted to data.
181
Chapter 6: Effect of antigen dose on PMDD efficacy following dual plasmid immunisation
R2 values from the in vivo pVACl.NT/ pVACl and pVACl.NT/ pVACl.OVAs
IFN-y ELISPOT correlation plots
Time-point Cartridge batch 1 Cartridge batch 2
Day 7 PP - 0.972
Day 14 PP 0.757 0.525
Day 7 PB 0.610 0.558
Day 14 PB 0.399 0.775
Table 63. Comparison of in vivo p V AC 1.NT/p VAC l.OVAs and pVACl.NT/pVACl dose 
responses for the first and second batches of cartridges. Data from IFN-y ELISPOT was 
used for correlation. Mean values were used for correlation and linear trend-line regression 
coefficient (R2) was fitted to data.
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6.3.4. Effect of expressed Ovalbumin on the NT response
MC57 cells were transfected by PMDD with cartridges containing 50 ng pVACl.NT and 
450 ng of pVACl, pVACl.OVAc or pVACl.OVAs and the resulting NT response 
analysed using the in vitro assay. MC57 cell cultures were treated with 20 ng/ml of IFN-y 
for 24 hrs prior to the assay in an effort to increase assay sensitivity by up-regulation of 
surface expressed MHC I. These cells were then compared with normal MC57 cells for 
their ability to stimulate NT specific IFN-y secretion (Figure 6.9A). Cells with up-regulated 
MHC I expression proved superior in their antigen presenting capacity compared to normal 
MC57s with each PMDD group showing a significant increase in IFN-y secretion (between 
-180-270 %). In contrast, both positive control groups (i.e. peptide pulsed cells) yielded 
similar results. This assay was repeated on two further occasions (IFN-y treated) and the 
results from all three assays are shown in Figure 6.9B. Although, the magnitude of the EFN- 
y response to the different plasmid combinations was increased over that usually observed 
with normal MC57 cells, there was no significant difference between any of the PMDD 
transfected groups. The effect of IFN-y treatment on expression of MHC I Kd surface 
expression is represented in Figure 6.9C.
To directly compare the in vitro model with immune responses in vivo, cartridges 
containing the different plasmid combinations were assessed both in vitro and in vivo. In 
these experiments, the MC57 cells were not pre-treated with IFN-y prior to use in the in 
vitro assay. Results revealed no difference in IFN-y secretion between any of the PMDD 
transfected groups (Figure 6.10). The in vitro results contrasted markedly with those 
obtained in vivo (Figure 6.11A). At each time-point, the pVACl.NT/pVACl group elicited 
the strongest response yielding ~165 and -1080 spots/million cells at day 7 PP and 7 PB, 
respectively. After boost, all groups were significantly different from each other. When this 
analysis was repeated in vivo using a separate batch of cartridges, a similar trend emerged 
(Figure 6.1 IB). Again, the greatest response was obtained in the pVACl.NT/pVACl 
groups at both time-points (-250 and 1125 spots/million cells at day 7 PP and 7 PB, 
respectively) with this group attaining significance over the pVACl.NT/pVACl.OVAc and 
pVACl.NT/p VAC l.OVAs groups at day 7 PB.
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Figure 6.9. Effect of dual plasmid immunisation measured in vitro by IFN-y ELISPOT. 
MC57 cehs were transfected with different plasmid combinations and incubated overnight 
in a 1:1 ratio with 1 x 105 activated RAG1.F5 splenocytes and 200 ng/ml IL-2. Panel A: 
Comparison of IFN-y treated (diagonal bars) and untreated (horizontal bars) MC57s in 
stimulating a NT specific response. Data is from one experiment and is mean (± standard 
deviation) of triplicate analyses of pooled triplicate transfections. Stars represent Student’s 
T-test comparison between corresponding groups (* p < 0.05, ** p < 0.01). Panel B: Effect 
of IFN-y treated MC57 cells in stimulating NT specific IFN-y secretion in the in vitro 
CD8+ T cell assay. Each symbol (except bars) represents an individual experiment. Bars 
are the mean of all experiments for each group. For each individual experiment, data is 
mean of triplicate analyses of pooled triplicate transfections. Panel C: Representative data 
showing the effect of IFN-y treatment (20 ng/ml for 24 hrs) on MHC I Kd expression.
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Figure 6.10. Assessing the effect of dual plasmid immunisation on the NT response in vitro 
using the CD8+ T cell assay. MC57 cells were transfected with different plasmid 
combinations and incubated overnight in a 1:1 ratio with 1 x 105 activated RAG1.F5 
splenocytes and 200 ng/ml IL-2 prior to IFN-y ELISPOT analysis. Each symbol (except 
bars) represents individual experiments. Bars are the mean of all experiments for each 
group. For each individual experiment, data is mean of triplicate analyses of pooled 
triplicate transfections.
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Figure 6.11. Assessing the effect of dual plasmid immunisation on the NT response in vivo 
by IFN-y ELISPOT. Mice were primed and boosted (on day 28) with different plasmid 
combinations and spleen cells were collected at day 7 PP and PB. Purified splenocytes were 
cultured overnight in media + 50 ng/ml EL-2 or media + 50 ng/ml IL-2 + lOOnM NT 
peptide prior to ELISPOT analysis. Results are mean of individual means ± SEM of 3 
mice/group. Initial and repeat experiments are shown in panels A and B, respectively. Stars 
represent Student’s T-test comparison between corresponding groups (* p < 0.05, ** p < 
0.01).
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6.4. Discussion
6.4.1. Effect of co-immunisation on the NT response in vitro
The effect of co-immunisation on the NT response was investigated in vitro in the form of a 
pV AC l.NT/p VAC l.OVAs dose response. Results showed that the presence of 
pVACl.OVAs plasmid appeared to have no effect on the magnitude or the sensitivity of the 
NT response in the various dose response groups. Furthermore, the sensitivity of both dose 
responses was similar at 50 ng DNA (second batch of pVACl .NT/pVAC 1 .OVAs cartridges 
only). The same result was obtained when MC57 cells were transfected with pVACl.NT in 
the presence of pVACl.OVAs, pVACl.OVAc or pVACl. These results suggest that there 
is no significant competition at the level of transcription, processing and MHC loading at 
least in the MC57 fibrosarcoma cell line.
The effect of MC57 IFN-y stimulation on resulting NT response in vitro was also 
investigated. IFN-y is known to enhance MHC expression by stimulating the rate of 
transcription of class I and II genes in a wide range of cells (Rosa et al., 1988; Pace et al, 
1983). In this study, there was a significant increase in the magnitude of the NT response in 
groups containing MC57 cells treated with IFN-y. There was, however, no difference 
between any of the plasmid combinations. Interestingly, although the PMDD treated groups 
reported an overall increase in the NT response in cells pre-treated with IFN-y, the positive 
control groups in these experiments (i.e. peptide pulsed cells) did not. This suggests that the 
impact of IFN-y pre-treatment in this cell line was more to do with the enhancement of 
proteins involved in antigen processing and presentation, namely P2 microglobulin and the 
TAP heterodimer (Mutlu et al., 1991; Schiffer et al., 2002) than the up-regulation of 
surface MHC 1.
6.4.2. The NT and OVA relationship in vivo
The influence that pVACl.OVAs has on the NT CD8+ response is clearly demonstrated in 
the in vivo dose response and co-immunisation studies. The magnitude of the
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pVACl.NT/pVACl.OVAs and pVACl.NT/pVACl dose responses is markedly different 
(see Figure 5.4 and 5.5). The threshold type association between plasmid administered and 
resulting response observed in the pVACl.NT/pVACl dose response after boost is 
replaced by a more linear type of relationship here (at all time-points). A possible 
explanation for this difference may be that in a pVACl.NT/pVACl dose response, an 
immune response is elicited against the influenza nucleoprotein only. There are no limiting 
factors associated with the APC or the T cell repertoire such as access to cytokines, access 
to the DC surface, number of antigen loaded DC and T cell affinity maturation which may 
impede the resulting response. After boost, memory T cells react vigorously to NT antigen 
presented, regardless of the amount. Consequently, there is a threshold type relationship 
between antigen dose and resulting response.
For the pVACl.NT/pV AC l.OVAs dose response, the difference in magnitude of the 
influenza366-374 specific CD8+ T cell subset between the top dose and lower doses is clear. 
The increase in magnitude of the NT secondary response only occurs in the top dose (i.e. 
group containing pVACl.NT only) with all other groups remaining either equal to, or only 
marginally higher, than the equivalent primary response groups. The data indicates that a 
second coding plasmid, pVACl.OVAs, interferes effectively against NT in launching an 
immune response. This interference, or competition, may occur at one or more levels.
6.4.2.1. Intracellular competition between OVA and NT
The down regulation of the NT response may be due to intracellular competition between 
the NT and OVA plasmids within the APC in vivo. This view is supported by the data from 
the co-immunisation studies (Figure 6.11). The primary finding was that mice immunised 
with pVACl.NT/pVACl showed the greatest NT specific CD8+ response after primary 
and boost immunisation. A lesser response was elicited when NT encoding plasmid was 
administered in the presence of the ovalbumin encoding plasmids. Intracellular competition 
is also consistent with investigations by Manoj et al. (2003) who reported significant 
reductions in specific antigen response with the use of a dual plasmid immunisation 
strategy or a bicistronic vector compared to single plasmid immunisation. Delivering
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pVACl.NT in the presence of pVACl.OVAs appeared to have a less suppressive effect on 
the NT CD8+ response compared with co-delivering pVACl.NT and pVACl.OVAc. As 
pVACl.NT and pVACl.OVAc encode predominately cell retained antigen, this result may 
reflect the competition effect between NT and OVAc for entry into the MHC I department. 
Indeed, if the major cell type transfected were skin DC (i.e. the Langherhans cells), 
competition would not only occur at the MHC loading step but also at the protein synthesis 
stage prior to this. In contrast, the pVACl.OVAs plasmid encodes for a predominately 
secreted form of OVA leading to reduced level of antigenic competition compared with 
OVAc. Furthermore, this may result in a superior helper effect mediated by secreted 
ovalbumin derived CD4+ T cells. A non specific mechanism of action may include the 
secretion of cytokines such as IL-2 and IFN-y which may promote the responsiveness of the 
CD8+ NT cells. Additionally, OVA CD4+ T cells may provide help by the activation of the 
APC, a mechanism referred to by Wodarz and Jansen (2001) as CD4-APC-CD8 help. This 
pathway leads to EL-12 secretion by activated DC which helps to promote a Thl phenotype 
and is important for priming and maintenance of the CD8+ response (Celia et al., 1996).
However, this explanation is not entirely consistent with previous data on the nature of the 
OVAs response. In single plasmid immunisations, several studies have demonstrated that 
the cellular location of expressed antigen quantitatively and qualitatively affects the 
immune responses (Boyle et al., 1997; van Drunen Littel-van den Hurk et al., 1998; Lewis 
et al., 1999; Higgins et al., 2000). Indeed for intra-dermal gene gun immunisation, it is 
widely acknowledged that secreted forms of antigen result in the formation of a humoral 
response with a prominent Th2 type antibody profile (Scheiblhofer et al., 2001; Kaur et al., 
2002). Therefore, the expectation would be that NT/OVAs co-immunisation would create 
an immune micro-environment with a Th2 type profile (relative to NT/OVAc co­
immunisation) resulting in a reduced CD8+ NT response. The fact that this did not happen 
together with the in vitro data suggests that an alternative mechanism may be wholly or 
partially responsible for the suppressive effects of OVA on the CD8+ NT response.
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6.4.2.2. Clonal competition
Antigenic competition between the NT and the OVA response may also occur at the T cell 
level. The competition may be specific (e.g. T cell-T cell inhibition) or non-specific (e.g. 
access to cytokines) in nature. Following immunisation with pVACl.NT and 
pVACl.OVAs, the NT and OVA responses are predominately focused on their respective 
immunodominant epitopes which are of a different specificity (in terms of antigenic 
determinant and MHC restriction). There is a lot of evidence suggesting that T cells of 
different specificity do not compete with each other for DC access and T cell activation 
(Probst et al., 2002; Smith et al., 2000; Creusot et al., 2003a; Creusot et al., 2003b). 
Therefore, it is unlikely that specific T cell competition occurs.
Alternatively, it is possible that competition for non specific factors around the DC-T cell 
cluster takes place. These include access to cytokines such as DL-2 (Wodarz and Jansen, 
2001), IL-7 and IL-15 (Ge et al., 2004) and IL-12 (Eberl et al., 1996) which are necessary 
for activation and proliferation. This may provide an explanation for the lower NT 
responses obtained in the p V AC 1.NT/p VAC l.OVAs dose responses, especially 
considering the possibility that the NT and OVAs antigens are presented on different DCs. 
There is also the likelihood that, following pVACl.NT and pVACl .OVA co-immunisation, 
the number of DC available for stimulation in the secondary response is insufficient to 
sustain activation of both memory subsets (Lanzavecchia et al., 2002). In support of this 
hypothesis as a possible mechanism to explain the suppressive effect of OVA on NT, it is 
noteworthy that the lowest amount of pVACl.NT capable of eliciting a significant response 
in both types of dose responses was similar (0.5 ng). It was the magnitude and not the 
sensitivity of the NT response which was reduced in the p V AC l.NT/pV AC l.OVAs dose 
responses suggesting a level of competition for factors important for either T cell activation 
and/or proliferation. The functional relationship between these T cell repertoires and the 
implications for the resulting immune response is investigated further in chapter 7.
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6.4.3. Can the in vitro model predict in vivo immune responses?
For the pVACl.NT/pVACl dose response, the best correlations were achieved when the in 
vitro model was compared with the early in vivo time-points (see section 5.4.3). Here, the 
ability of the in vitro CD8-I- T cell assay to predict in vivo responses was assessed under 
conditions of dual plasmid immunisation. For the p V AC 1.NT/p VAC l.OVAs dose 
response, positive correlations were generally achieved when the in vitro data was 
compared against the in vivo data at all time-points, post primary and post boost. This 
difference in trend is a consequence of the differing nature of the two dose responses in 
vivo (see section 6.4.2). The pVACl.NT/pVACl dose response exhibits a threshold type 
relationship between dose and resulting response after boost and this is reflected in the 
lesser correlations achieved between the in vitro assay and the post boost in vivo time- 
points. In contrast, there is a linear relationship between dose and response for the in vivo 
p V AC l.NT/p VAC l.OVAs dose response at all time-points. This may be due to the 
competitive interaction between the NT and OVA responses, especially after boost. The 
result of this was that good correlations were obtained when the in vitro data was compared 
against the in vivo data at all time-points.
This result superficially suggests that the in vitro model is useful in predicting the in vivo 
response to NT under conditions of dual plasmid immunisation. However, interpreting the 
data in this way is misleading. Another approach is to plot the pVACl.NT/pVACl and 
pV AC l.NT/p VAC l.OVAs dose responses against each other (in vitro and in vivo) and 
compare the regression coefficients of these plots (Figures 6.7, 6.8 and Table 6.3). The in 
vitro result from this type of analysis (R2 = 0.999) suggested that the response elicited by 
RAG1.F5 splenocytes to pVACl.NT was similar regardless of whether MC57s were 
transfected with cartridges containing the pVACl.NT/pVACl or 
pV AC l.NT/p VAC l.OVAs plasmids. This was supported by the comparability of the 
sensitivity data obtained for both sets of dose responses (i.e. 50 ng pVACl.NT) and was 
further confirmed by the finding that the in vitro assay revealed no difference in NT 
specific responses when MC57 cells were transfected with pVACl.NT in the presence of 
pVACl.OVAs, pVACl.OVAc or pVACl. When the dose responses were compared in
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vivo, a different trend emerged. With the exception of the day 7PP in vivo time-point 
(R2=0.972 for the second experiment), the correlations were poor. Separately, when the 
different plasmid combinations were assessed, the response to NT in the 
pVACl.NT/pVACl group was much greater than the response to NT in the 
pV AC l.NT/p VAC l.OVAs and pVACl.NT/pVACl.OVAc groups. Together, these results 
clearly indicate that the in vivo response is influenced by the co-immunising plasmid.
When the in vitro and in vivo data were compared in these two ways, it is evident that the in 
vitro model is useful in predicting the early stage primary response to pVACl.NT in vivo 
(for both dose responses) for reasons explained in section 5.4.3. However, in vivo immune 
responses to NT were strongly affected by the presence or absence of a second antigen, 
while in contrast in vitro responses did not share this effect.
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6.5. Conclusions
During this and the preceding chapter, the relationship between available antigen and 
resulting CD8+ NT response during single and dual plasmid immunisation was examined 
in vitro and in vivo. The primary findings were that
• The in vitro assay revealed no difference in NT specific responses when MC57 cells 
were transfected with cartridges containing the pVACl.NT/pVACl or 
p V AC l.NT/p VAC l.OVAs dose response or when MC57 cells were transfected 
with pVACl.NT in the presence of pVACl.OVAs, pVACl.OVAc or pVACl.
• The in vivo immune response to NT was strongly affected by the presence or 
absence of a second coding antigen with the presence of OVAs resulting in the 
inhibition of the NT response. Furthermore, the data suggests that the cellular 
location of the antigen produced by pVACl.OVA may affect the NT response in 
vivo.
The effect of NT and OVA co-immunisation in shaping the CD4+ and CD8+ T cell 
response and the co-operation/competition between these immune subsets is discussed in 
the following chapter.
Additionally, the predictive capacity of the in vitro model was assessed by comparing the in 
vitro and in vivo data. Results suggest that the in vitro bioassay is useful as a guide to 
determining the early stage primary response in vivo (for single and dual immunisations) 
but does not accurately represent the immune response to a mature memory CD8+ T cell 
population.
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7.1. Introduction
The analyses described in the previous chapter highlighted the contribution of 
pVACl.OVA in shaping the immune response to pVACl.NT. This was particularly evident 
after boost, where the presence of pVACl.OVA resulted in a much reduced NT response 
compared with immunisation with pVACl.NT only. The cause of the reduction in NT 
response and the mechanisms which may have led to this are investigated further in this 
chapter.
Under conditions of dual plasmid immunisation, the immune responses to the different 
antigens may interact negatively with each other (i.e. antigenic competition) leading to a 
focusing of the immune response towards a particular epitope on a particular antigen. 
Alternatively, both immune responses may interact positively (i.e. antigen co-operation) 
resulting in a broad and comprehensive response to both antigens. It is most likely 
however, that following dual plasmid immunisation, both phenomena occur in unison, with 
the resulting immune response a reflection of the balance achieved between both immune 
mechanisms.
Antigenic competition, in which responses to one antigenic determinant dominates the 
immune responses to other determinants is central to the concept of immunodominance 
(Rammensee et al., 1993). Several factors are known to contribute to immunodominance 
such as the processing and presenting capacity of the APC (Sercarz et al., 1993), affinity of 
synthesised peptide for APC MHC I (Campos-Lima et a l, 1997) and competition between 
T cell populations for response to antigen (Smith et al., 2000; Butz and Bevan, 1998a; 
Sandberg et al., 1998). Intraclonal and interclonal T cell competition is described in more 
detail in Section 1.3.5.2. Although the preponderance of reports are associated with CD8+ 
T cell competition (Lawson et al., 2001; Grossmann et al., 2001; Palmowski et al, 2002), 
there is also evidence of competition between CD4+ T cells (Savage et al., 1999; Rees et 
al, 1999).
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In addition to the competition effects observed in the previous in vivo analyses, antigenic 
co-operation is likely to play a role in shaping the NT response (Creusot et al., 2003a). 
Antigenic co-operation in the form of CD4—CD8+ T cell co-operation studies have yielded 
important information. There is clear evidence, for example, that class I and class II 
epitopes need to be presented on the same APC for the generation of CTL immunity 
(Bennett et al., 1997). Activation of APC expressed CD40 by CD4+ T cell expressed 
CD40L appears to be the main trigger in licensing the APC to stimulate CD8+ T cell 
proliferation (Schoenberger et al., 1998; Ridge et al., 1998) although this mechanism of 
CD8+ T cell activation has been questioned (Bourgeois et al., 2002). CD4+ T cells also 
assist CD8+ immunity by secretion of cytokines such as IL-2, which promote the 
responsiveness of the CD8+ T cells and augment CTL activation (Wodarz and Jansen, 
2001). Numerous studies have documented the importance of CD4+ T cells in the 
maintenance of the CD8+ T cell response during chronic viral infection (Matloubian et al., 
1994; Cardin et al, 1996; Belz et al., 2002; Kostense et al., 2002). In addition to the CD4- 
CD8+ T cell co-operation models mentioned here, there is also evidence suggesting the 
existence of CD4-CD4+ (Gerloni et al., 2000; Creusot et al. 2003a) and CD8-CD8+ 
(Sherritt et al, 2000) T cell co-operation in vivo.
In this chapter, the effects of antigenic competition and co-operation on the NT and OVA 
immune responses following PMDD are investigated. The analysis is predominately 
focused on the CD8+ NT response but the effect of NT and OVA co-immunisation on the 
resulting OVA response is considered also. Each of the analyses incorporate another aspect 
of PMDD co-immunisation which arose from the in vitro in vivo correlation studies, 
namely, the effect of OVA intracellular localisation on resulting immune response (see 
section 6.4.2.1).
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7.2. Objective
To investigate the role of antigenic competition and co-operation in shaping the NT and 
OVA immune responses following co-immunisation of NT plasmid with cytoplasmic ally 
localised or secreted OVA encoding plasmid. Investigations include
• The effect of T cell memory on the resulting NT and OVA responses.
by pre-immunisation with pVACl .NT or pVACl .OVA only, 
by dose response of the co-immunised plasmid (i.e. pVACl.OVA).
• The effect of antigen linkage on the resulting NT and OVA responses.
73. Results
The nomenclature used to denote plasmid composition of the DNA cartridges used in this 
chapter is described in Table 7.1.
7.3.1. Effect of T cell memory
The effect of T cell memory on NT and OVA responses was investigated in two ways. 
Firstly, a pre-existing NT or OVA immune response was established in C57BL/6 mice by 
immunising with pVACl.NT or pVACl.OVA only. These mice were then immunised with 
groups containing NT/empty, NT/OVAc or NT/OVAs plasmid (referred to as groups 1, 2 
and 3, respectively). Secondly, mice were primed and boosted with cartridges containing 
different amounts of OVAc or OVAs plasmid combined with a constant amount of NT 
plasmid. For the first set of experiments, CD8+ NT and CD8+ and CD4+ OVA responses 
were assessed while for the repeat experiments, both CD8+ and CD4+ NT and OVA 
responses were monitored.
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Cartridge composition
Group name Theoretical loading (ng DNA / cartridge)
1 50 ng pVAC 1 .NT + 450 ng pVACl
2 50 ng pVACl.NT + 450 ng pVACl.OVAc
2
UL
50 ng pVACl.NT + 450 ng pVACl.OVAc (unlinked DNA cartridge)
2.1 50 ng pVACl.NT + 50 ng pVACl.OVAc + 400 ng pVACl
2.2 50 ng pVACl.NT + 5 ng pVACl.OVAc + 445 ng pVACl
3 50 ng pVACl.NT + 450 ng pVACl.OVAs
3
UL
50 ng pVACl.NT + 450 ng pVACl.OVAs (unlinked DNA cartridge)
3.1 50 ng pVACl.NT + 50 ng pVACl.OVAs + 400 ng pVACl
3.2 50 ng pVACl.NT + 5 ng pVACl.OVAs + 445 ng pVACl
4 50 ng pVACl.NT + 450 ng pVACl.RNG
5 50 ng pVACl.NT + 450 ng pVACl.HPV
Table 7.1. Nomenclature used to denote amount of influenza nucleoprotein encoding 
plasmid, ovalbumin encoding plasmid and control plasmid DNA in cartridge preparations 
for all in vitro and in vivo experiments presented in chapter 7.
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1a immunisation: pV AC 1 .NT Is* immunisation: pVACl
A
u. 400
1a immunisation: pV AC 1 .NT 1 st immunisation: pV AC 1 Is* immunisation: pVACl.NT 1st immunisation: pVACl
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Response to CD8 NT peptide; NT366_374 Response to CD4 NT peptide; NT 413^ 35
Figure 7.1. NT specific EFN-y producing CD8+ and CD4+ T cells detected by ELISPOT. 
Mice were primed with pVACl.NT or pVACl and boosted on day 28 with cartridges 
containing NT/empty (group 1), NT/OVAc (group 2) or NT/OVAs (group 3). Spleens were 
collected for analysis at day 7 PB. Initial and repeat experiments are shown in panels A and 
B, respectively. For ELISPOT analysis, results are reported as mean of individual means ± 
SEM of 3 mice/group. Stars on top of groups represent Student’s T-test comparison with 
corresponding group (** p < 0.01).
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Figure 7.2. OVA specific IFN-y producing CD8+ and CD4+ T cells detected by ELISPOT. 
Mice were primed with pVACl.NT or pVACl and boosted on day 28 with cartridges 
containing NT/empty (group 1), NT/OVAc (group 2) or NT/OVAs (group 3). Spleens were 
collected for analysis at day 7 PB. Initial and repeat experiments are shown in panels A and 
B, respectively. For ELISPOT analysis, results are reported as mean of individual means ± 
SEM of 3 mice/group. Stars on top of groups represent Student’s T-test comparison with 
corresponding groups (* p < 0.05, ** p < 0.01).
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7.3.1.1. Effect of a pre-existing NT response on NT and OVA responses
Mice were immunised with pVACl.NT or pVACl and boosted 28 days later with groups 1, 
2 or 3 (Figure 7.1). In the initial experiment (row A), results show a much higher level of 
NT specific IFN-y secretion associated with groups which were primed with pVACl.NT 
compared with groups primed with pVACl. In the pVACl and the pVACl.NT primed 
mice, similar CD8+ NT responses were obtained in all three groups. In the repeat 
experiment, greater CD8+ NT responses were also obtained in the pVACl.NT primed mice 
(Figure 7.1, row B). However, unlike the initial experiment, the group immunised with 
NT/OVAc (i.e. group 2) yielded a significantly greater level of IFN-y secretion than the 
group immunised with pVACl.NT only (i.e. group 1). The IFN-y response to the NT CD4 
peptide in the repeat experiment for the pVACl.NT primed groups showed a similar trend 
to the CD8 peptide analysis. Group 1 yielded less IFN-y than group 2 while groups 2 and 3 
recorded similar levels of IFN-y production (i.e. -85, -190 and -225 IFN-y spots/million 
cells for groups 1, 2 and 3, respectively). The main conclusions from the data are that a 
single dose of OVA does not result in OVA having a suppressive effect on the NT 
response.
The CD8+ and CD4+ OVA specific responses are shown in Figure 7.2. As observed with 
the NT CD4+ and CD8+ responses, the repeat experiment (row B) yielded much lower 
levels of IFN-y secretion compared with the initial experiment. In both experiments, the 
CD8+ and CD4+ responses showed a similar trend. Additionally, the CD4+ responses were 
generally much smaller and more variable than the corresponding CD8+ responses. In the 
repeat experiment, there were significant differences in CD8+ and CD4+ response between 
the NT primed NT/OVAs boosted group and the pVACl primed NT/OVAs group. A 
similar result was obtained when the corresponding NT/OVAc groups were compared for 
the NT CD4+ response. These results suggest that the OVA response is not affected or 
suppressed by a pre-existing NT response, but rather that the NT response may help a weak 
OVAs response.
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7.3.1.2. Effect of a pre-existing OVA response on NT and OVA responses
Mice were primed with OVAs, OVAc or empty plasmid and boosted 28 days later with 
groups 1, 2 or 3. NT and OVA CD8+ and CD4+ IFN-y specific secretion was assessed at 
day 7 PB. CD8+ specific responses to NT were measured in the initial and repeat 
experiments while CD4+ specific responses were measured in the repeat experiment only 
(Figure 7.3). For both experiments, the presence of OVA memory (i.e. pVACl.OVAc and 
pVACl.OVAs primed groups) resulted in a significantly lower CD8+ specific IFN-y 
response in groups boosted with group 2 and group 3 compared with groups boosted with 
group 1. This is particularly well illustrated in the OVAc primed group 2 boosted groups in 
both experiments where the NT response was completely abrogated. As in Figure 7.1, the 
IFN-y CD4+ NT response measured in the repeat experiment was low and variable. 
Overall, the data demonstrates that priming and boosting with OVA (2 immunisations) 
results in a suppression of the NT response. Furthermore, pVACl.OVAc is more 
suppressive than pVACl.OVAs.
The corresponding CD8+ and CD4+ OVA responses are shown in Figure 7.4. Results 
revealed that for both CD8+ and CD4+ responses, the pVACl.OVAc primed, group 2 
boosted group yielded a much greater level of IFN-y secretion than the pVACl.OVAs 
primed, group 3 boosted group in both experiments. This data suggests that pVACl.OVAc 
is a more potent immunising plasmid than pVACl.OVAs. This experiment showed an 
usually high level of “background” OVA response in mice primed with pVACl and 
boosted with pVACl .NT which was not explained.
7.3.1.3. Effect of OVA dose response on NT and OVA responses
Mice were primed and boosted with cartridges containing variable amounts of OVAc or
OVAs plasmid combined with a constant amount of NT plasmid. NT CD8+ and OVA
CD8+ and CD4+ IFN-y specific secretion was monitored at day 7 PP and PB. For the NT
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response, results revealed that, in general, as the level of OVA in the immunising groups
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Figure 7.3. Assessing the effect of a pre-existing OVA response on the CD8+ and CD4+ 
NT response by IFN-y ELISPOT. Mice were primed with OVAc, OVAs or pVACl and 
boosted on day 28 with cartridges containing NT/empty (group 1), NT/OVAc (group 2) or 
NT/OVAs (group 3). Spleens were collected for analysis at day 7 PB. For ELISPOT 
analysis, results are reported as mean of individual means ± SEM of 3 mice/group. Initial 
and repeat experiments are shown in panels A and B, respectively. Stars represent Student’s 
T-test comparison with corresponding groups (* p < 0.05, ** p < 0.01, *** p < 0.001).
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Figure 7.4. Assessing the effect of a pre-existing OVA response on the CD8+ and CD4+ 
OVA response. Mice were primed with OVAc, OVAs or pVACl and boosted on day 28 
with cartridges containing NT/empty (group 1), NT/OVAc (group 2) or NT/OVAs (group 
3). Spleens were collected for analysis at day 7 PB and assessed for cytokine secretion 
using IFN-y ELISPOT. Results are reported as mean of individual means ± SEM of 3 
mice/group. Initial and repeat experiments are shown in panels A and B, respectively. Stars 
represent Student’s T-test comparison with corresponding groups (* p < 0.05, *** p < 
0 .001).
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decreased, the NT response increased (Figure 7.5). For the CD8+ PP data, this effect was 
only apparent in the OVAc containing groups (i.e. groups 2—2.2) in the repeat experiment. 
However, following boost, the magnitude of the NT response increased and the OVA dose 
response effect was observed in both OVAc and OVAs containing groups. When 
corresponding OVA groups were compared PB (i.e. groups 2 and 3, groups 2.1 and 3.1 
etc.), the level of IFN-y activity associated with the OVAs groups was generally observed 
to be greater than that obtained in the OVAc containing groups indicating that 
pVACl.OVAc was more inhibitory than pVACl.OVAs for the CD8+ NT response. 
Additionally, animals immunised with group 1 gave greater amounts of IFN-y secretion 
compared with any of the OVA containing groups. OVA therefore exerted an inhibitory 
effect on NT even when there is less OVA plasmid than NT plasmid in the immunising 
groups. Finally, at day 7 PB, the IFN-y specific CD8+ response obtained in groups 4 and 5 
(containing plasmid encoding HIV-Reverse Transcriptase, Nef and Gag protein fusion 
(HIV-RNG) and human papilloma virus E6 protein (HPV-E6), respectively) was greater 
than that obtained in the corresponding OVAc group but less than NT alone in both 
experiments. Like pVACl.OVAc, plasmids HIV-RNG and HPV-E6 encode cell retained 
antigen.
The corresponding CD8+ and CD4+ OVA specific responses are shown in Figure 7.6. 
Results demonstrated that, as the level of OVA plasmid in the immunising groups 
decreased, so did the OVAs response. The OVAc response did not show this trend but 
instead remained maximal at all concentrations. The level of CD8+ and CD4+ specific 
IFN-y secretion associated with the OVAc groups were generally greater than that 
associated with the corresponding OVAs groups in both experiments at the day 7 PB time- 
point.
Together, the NT and OVA analyses indicate that OVAc suppressed the NT response to a 
greater extent than OVAs. For both OVAs and OVAc, some inhibition of the NT response 
occurred even when there was less OVA plasmid than NT plasmid in the immunising 
groups. As the level of OVAs plasmid in the immunising groups decreased, so too did the
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resulting OVAs response. This did not happen for OVAc again suggesting that this plasmid 
is a strong immunogen.
7.3.2. Effect of plasmid linkage on NT and OVA responses
In these experiments, “linked” DNA cartridges refers to the presence of the NT and OVA 
encoding plasmids on the same gold particles, in the same cartridge and delivered to the 
same immunisation site (i.e. the standard DNA cartridges used in all PMDD experiments 
thus far). “Unlinked” DNA cartridges refer to the presence of the NT and OVA encoding 
plasmids on different gold particles, in different cartridges and delivered to different 
immunisation sites. The preparation of linked and unlinked DNA cartridges is described in 
section 2.5.2 and represented in Figure 2.4.
CD8+ specific responses to linked and unlinked DNA cartridges are shown in Figure 7.7. 
Mice were primed and boosted with groups 1, 2 or 3 (linked or unlinked) along with groups 
containing pVACl.OVAc only or pVACl.OVAs only and NT specific IFN-y secretion was 
measured at day 7 PP and PB. Results revealed that at day 7 PP, groups primed with linked 
and unlinked plasmid gave similar levels of IFN-y. However, after boost, the groups 
immunised with the linked DNA (groups 2 and 3) yielded less IFN-y secretion than the 
corresponding unlinked DNA groups. Unlinked OVA did not induce suppression of NT in 
any group. As before, OVAc was a stronger suppressor of NT than OVAs. Finally, animals 
immunised with the linked group 1 gave significantly greater amounts of IFN-y secretion 
compared with the linked groups 2 or 3 in both experiments.
The corresponding CD8+ and CD4+ OVA specific responses are shown in Figure 7.8. 
Generally, PB results from the linked data revealed that the OVAc containing groups 
elicited stronger IFN-y responses than the OVAs containing groups. The OVAc only group 
yielded a significantly greater level of CD8+ and CD4+ specific IFN-y secretion compared 
with the OVAs only group in the repeat experiment. For the CD8+ responses, the group 2 
and the group 3 linked groups showed similar IFN-y activity to the corresponding OVA
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Figure IS .  Effect of OVA dose response on the CD8+ NT response. Mice were primed 
and boosted (day 28) with cartridges containing variable amounts of OVAc or OVAs 
combined with a constant amount of NT. Spleens were collected for analysis at day 7 PP 
and PB and assessed for cytokine secretion using IFN-y ELISPOT. For ELISPOT analysis, 
results are reported as mean of individual means ± SEM of 3 mice/group. Initial and repeat 
experiments are shown in panels A and B, respectively. Stars represent Student’s T-test 
comparison with corresponding groups (* p < 0.05, ** p < 0.01). ND: not done.
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Figure 7.6. Effect of OVA dose response on the CD8+ and CD4+ OVA response. Mice 
were primed and boosted (day 28) with cartridges containing variable amounts of OVAc or 
OVAs combined with a constant amount of NT. Spleens were collected for analysis at day 
7 PP and PB and assessed for cytokine secretion using IFN-y ELISPOT. For ELISPOT 
analysis, results are reported as mean of individual means ± SEM of 3 mice/group. Initial 
and repeat experiments are shown in panels A and B, respectively. Stars represent Student’s 
T-test comparison with corresponding groups (* p < 0.05). f  ELISPOT performed on 
splenocytes which were frozen on day of spleen harvest and thawed at a later date for 
analysis. ND; not done.
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only groups in the initial experiment and in the case of group 2, greater activity than the 
OVAc only group in the repeat experiment after boost. This suggests that the presence of 
NT may positively influence the OVA response. Finally, for the CD8+ response, the OVAc 
linked group showed a significantly higher level of IFN-y secretion compared with the 
corresponding unlinked group in the repeat experiment. In summary, the data indicates that 
OVA suppression of the NT response requires plasmid linkage. In contrast, the OVA 
response itself is not negatively affected by plasmid linkage. Indeed, delivering NT and 
OVA plasmids in a linked manner may benefit the OVAc response.
7.4. Discussion
The interaction between the NT and OVA immune responses was examined by measuring 
the CD8+ and CD4+ responses to both antigens. For NT, the response to the CD8 and CD4 
immunodominant epitopes (Db restricted amino acid residues 366-374 and I-Ab restricted 
amino acid residues 413-435, respectively) were measured. For OVA, responses to the CD8 
immunodominant epitope (Kb restricted amino acid residues 257-264) and the CD4 
immunodominant epitope (I-Ad restricted amino acid residues 323-339) were measured. A 
number of different immunisation strategies were used which included priming with either 
pVACl.NT or pVACl.OVA prior to co-immunisation, performing prime boost 
experiments with cartridges containing pVACl.NT combined with variable amounts of 
pVACl.OVA and studying the effect of antigen linkage on NT and OVA responses. 
Results from these studies suggest that depending on the experimental conditions, both sets 
of immune responses can compete and co-operate with each other. However, the dominant 
interaction observed is suppression of the NT response by the OVA response.
7.4.1. Interclonal T-cell competition
7.4.1.1. Competition under conditions of pre-existing immunity 
From the experiments performed, there are many lines of evidence indicating that the OVA
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Figure 7.7. Effect of antigen linkage on the NT CD8+ response. Mice were primed and 
boosted (on day 28) with cartridges containing linked or unlinked NT/empty (group 1), 
NT/OVAc (group 2) or NT/OVAs plasmid (group 3) as well as groups containing OVAs 
and OVAc plasmid only. Spleens were collected for analysis at day 7 PP and PB and 
ELISPOT was used to determine IFN-y specific activity. Results are reported as mean of 
individual means ± SEM of 3 mice/group. Initial and repeat experiments are shown in 
panels A and B, respectively. Stars represent Student’s T-test comparison with 
corresponding groups (* p < 0.05, ** p < 0.01).
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Figure 7.8. Effect of antigen linkage on the OVA CD8+ and CD4+ response. Mice were 
primed and boosted (on day 28) with cartridges containing linked or unlinked NT/empty 
(group 1), NT/OVAc (group 2) or NT/OVAs plasmid (group 3) as well as groups 
containing OVAs and OVAc plasmid only. Spleens were collected for analysis at day 7 PP 
and PB and assessed for cytokine secretion using IFN-y ELISPOT. Results are reported as 
mean of individual means ± SEM of 3 mice/group. Initial and repeat experiments are 
shown in panels A and B, respectively. Stars represent Student’s T-test comparison with 
corresponding groups (* p < 0.05, ** p < 0.01). f  ELISPOT performed on splenocytes 
which were frozen on day of spleen harvest and thawed at a later date for analysis.
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and the NT immune responses compete. Firstly, OVA suppression of the NT response was 
examined in mice which had a pre-existing NT or OVA response established. Others have 
demonstrated that a pre-existing CTL response to one of the epitopes encoded by a 
polyepitope DNA construct suppressed the expansion of the CTL responses to other 
encoded epitopes, restricted by different MHCs (Palmowski et al., 2002). In contrast, there 
is evidence which demonstrates that a pre-existing CTL response when present in large 
numbers enhances the priming of other CTL populations restricted by different MHC genes 
(Sherritt et al., 2000). Here, OVA inhibition of the NT response occurred in mice which 
had a pre-existing OVA response (Figure 7.3). This was especially evident in the 
pVACl.OVAc primed NT/OVAc boosted groups in both experiments where the CD8+ NT 
response was completely abrogated. In contrast, when NT was delivered with empty vector, 
a strong NT response was raised. This result is consistent with the findings of many groups 
(Ge et al., 2004; Rodriguez et al., 2002; Chen et al., 2000c).
Antigenic competition was also observed in the OVAs primed NT/OVAs boosted groups 
but to a lesser extent than that obtained in the OVAc groups. This difference may be 
because pVACl.OVAc is a much more potent plasmid than pVACl.OVAs and is capable 
of producing more OVA antigen for presentation. This view is supported by the greater 
CD8+ and CD4+ OVA responses obtained in the OVAc primed NT/OVAc boosted group 
compared with the OVAs primed NT/OVAs boosted group (Figure 7.4.) Alternatively, this 
result may reflect the fact that the OVAs and NT proteins are predominately presented on 
different DC.
Competition between the OVA and NT responses could occur at the level of the DC 
(processing/presentation) or at the level of T cell response. As both pVACl.NT and 
pVACl.OVAc encode predominately cell retained antigen and considering the idea that 
both plasmids end up in the same DC through direct transfection, it is possible that 
competition for class I processing occurs within the DC (Dick et al., 1994; Eggers et al.,
1995). However, it is noteworthy that OVA suppression of the NT response was much 
stronger after two OVA immunisations. In the case of OVAc, this led to total abrogation of 
the NT response. In mice with a pre-existing NT response, a single dose of either OVAs or
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OVAc (in the form of NT/OVA boost) had no suppressive effect on the NT response 
(Figure 7.1). This together with the results from the in vitro data presented in the previous 
chapter argues against processing and presentation as the major source of NT/OVA 
antigenic competition.
Therefore, it is more likely that competition between the NT and OVA CD8+ T cells occurs 
at the T cell level. Previous attempts to measure whether interclonal T cell competition 
occurs in vivo have yielded variable results. Some investigators have been successful in 
demonstrating this type of T cell competition (Kedl et al., 2002) while others have not 
(Probst et al., 2002; Smith et al., 2000). In the experimental scenario described in this 
chapter, the OVA memory CTL are present in the DC/T cell microenvironment at a much 
higher frequency than naive NT CTL. These cells may act to physically prevent the naive 
NT CTL from accessing contact sites on the DC. Alternatively, the OVA memory CTL 
may act directly to inhibit the naive NT CTL response. Possible inhibitory mechanisms 
include T cell suppression mediated by IFN-y (Rodriguez et al., 2002), down modulation of 
specific antigen from the DC surface (Hwang et al., 2000; Huang et al., 1999) or antigen 
extraction from the DC surface (Kedl et al., 2002).
There is also the possibility that the memory OVA response and naive NT response 
compete for non-specific factors surrounding the DC/T cell cluster. These non-specific 
factors may include access to important activation and proliferation related cytokines such 
as IL-2 (Wodarz and Jansen, 2001), IL-7, IL-15 (Ge et al., 2004) and IL-12 (Eberl et al, 
1996) or to numbers of available DC. For the latter, there is also the likelihood that the 
number of DC available for stimulation in the secondary response is insufficient to sustain 
activation of the entire OVA memory CTL plus the naive NT CTL (Lanzavecchia et al., 
2002). Limiting numbers of available DC would favour the more abundant OVA response. 
This is possible considering the immunisation regimen used in these experiments. To this 
end, it would be interesting to introduce increasing numbers of NT pulsed DC into animals 
where the OVA T cell response was in vast excess and assess if this led to a concomitant 
improvement in the NT response.
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7.4.1.2. Prime-boost strategies favours OVA competition
The different immunisation strategies used also allowed the interaction between naive NT 
and OVA T cell responses and the interaction between memory NT and OVA responses to 
be examined. The results of these studies (Figures 7.1-7.6) are in agreement with the 
NT/OVAs in vivo dose response data described in the previous chapter (i.e. the presence of 
OVA results in a reduced NT response compared with immunisation with pVACl.NT 
only). There are three prominent features of the interaction between the NT and OVA 
responses under these conditions. Firstly, the NT response was greatest when pVACl.NT 
was delivered with empty plasmid compared with co-immunisation suggesting competition 
between the NT and OVA responses. Secondly, in the OVA dose response studies, both 
forms of OVA suppressed the NT response. There was also the indication that suppression 
occurred when less OVA than NT plasmid was used for immunisation (Figure 7.5) though 
this experiment needs to be repeated for confirmation of this. Furthermore, the NT response 
observed in NT/OVAc groups was less than that observed in the NT/OVAs groups, 
especially after boost. This provides further evidence that OVAc is more inhibitory than 
OVAs for the NT response. This difference may reflect the relative potencies of both 
plasmids at generating antigen. The OVAc plasmid is also more potent than the HPV-E6 
and HIV-RNG plasmids (all of which encode cell retained antigen) at inhibiting the NT 
CTL response. Alternatively, it may also indicate that NT/OVA competition is greatest 
when both antigens are presented on the same APC because OVAs is likely to be secreted 
and re-presented by neighbouring DC (Kedl et al., 2000; Kedl et al., 2002). Finally, 
decreasing the amount of OVA plasmid delivered in both cases led to a concomitant 
increase in the NT response. For OVAs, this data is complimented nicely by the OVA CTL 
and helper responses which showed a general reduction as the amount of plasmid delivered 
is decreased (Figure 7.6). The fact that this did not happen with OVAc provides further 
evidence that competition is greatest when NT and OVA are presented on the same APC.
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7.4.1.3. OVA suppression requires linkage
Delivering NT and OVA plasmid in a linked manner resulted in a reduction in the NT 
response compared with unlinked plasmid delivery (Figure 7.7). This result is in agreement 
with the previous data and provides further evidence for antigenic competition between the 
NT and OVA T cell responses following co-immunisation using a prime-boost strategy. 
The NT response in corresponding linked and unlinked NT/OVAc and NT/OVAs groups 
were generally similar after the primary immunisation suggesting that little if any 
intracellular competition occurs between the antigens (Wolpert et al., 1998). However, after 
boost, unlinking the NT and OVA plasmids resulted in a NT CTL response comparable to 
the NT/empty linked group. Delivering the plasmids in a linked fashion led to reduced NT 
responses indicating that OVA suppression requires antigen linkage. Delivering 
pVACl.NT to a different immunisation site from pVACl.OVA means that the NT CTL 
and helper responses do not have to compete with the OVA response for the non-specific 
factors involved in T cell activation and proliferation. This is especially important after 
boost where the OVA memory response is in vast excess and the non-specific factors (IL-2, 
IL-12, IL-7, IL-15, number of APC and accessibility to MHC and co-stimulatory molecules 
on the APC) may be limiting. While antigen linkage affects the NT response, it does not 
appear to reduce the OVA response. Although there is no experimental data on affinities, it 
may be that the affinity of the OVA TcR for the OVA epitope/MHC complex 
(SIINFEKL/Kb) exceeds that of the NT TcR for the NT epitope/MHC complex 
(ASNENMDAM/Db). If this were the case, the OVA response would dominate the NT 
response even if both antigens were expressed on the same APC. This may also explain the 
findings of the OVA dose response studies where OVA suppressed the NT response, even 
when less OVA than NT plasmid was used for immunisation (section 7.4.1.2).
7.4.2. Interclonal T cell co-operation
Although the NT/OVA interactions are predominately competitive, there is also evidence 
for T cell co-operation. When a pre-existing NT response was established in mice (Figures 
7.1 and 7.2), a greater OVA response was obtained in the NT primed, NT/OVAs boosted
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group compared with the pVACl primed, NT/OVAs boosted group. This difference 
reached significance in the repeat experiment. This indicates that the OVA response is not 
inhibited by a pre-existing NT response, but that this response may help the OVAs 
response. The mechanism which is responsible for this is unclear but probably involves the 
activation of, or enhancement of the activation of the OVA presenting DC by the pre­
existing NT Th response via the CD40-CD40L pathway (Foy et al., 1996). The memory 
NT Th cells may stimulate the DC directly leading to the activation of the OVA CTL 
response. This may be a likely mode of OVA T cell activation especially if the NT and 
OVA antigens are presented on the same DC following PMDD. Additionally, the NT Th 
response may provide help to the nai've OVA Th cells allowing those cells to activate the 
OVA CTL response (Gerloni et al., 2000). Alternatively, the memory NT specific CTL 
may themselves contribute to DC activation causing the OVA CTL response to be launched 
(Mintem et al., 2002). If the NT CTL precursor frequency is high, then these cells can 
induce general activation of DCs, even those which did not present the NT antigen (Ruedl 
et al., 1999). In this event, there would be no requirement for the NT and OVA antigens to 
be expressed on the same DC. The second line of evidence supporting T cell co-operation is 
the greater OVA response obtained in the linked NT/OVAc group compared with the 
corresponding unlinked NT/OVAc group after boost (Figure 7.8). It appears as if under 
these immunisation conditions (9:1 ratio of pVACl.OVA to pVACl.NT), the OVA 
response benefits most when NT antigen is available in the same DC/T cell cluster as OVA 
antigen. The mechanisms responsible for the NT/OVA co-operation may be those 
previously discussed.
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7.5. Conclusions
In this chapter, the role of antigenic competition and co-operation in shaping the NT and 
OVA immune responses following co-immunisation was investigated. Results suggested 
that, under these conditions, the interaction between the NT and OVA immune responses 
was predominately a competitive one. The main findings were that
• The OVA response suppresses the NT response but this inhibition requires at least 
two doses of OVA (e.g. a prime-boost immunisation strategy).
• OVA suppression may occur even when animals were immunised with less OVA 
than NT plasmid.
• Suppression requires antigen linkage.
• Suppression is not reciprocated by the NT response.
Although much less prominent, there was also evidence that NT/OVA T cell co-operation 
occurred and that this also required antigen linkage.
The experimentally contrived conditions generated here may not mimic an in vivo situation. 
However, this data does provide evidence that T cell responses directed against antigens of 
different specificity can simultaneously interact in a positive and negative manner. The 
outcome is a reflection of the balance between these opposing forces. It also highlights the 
implications when two antigens are presented on the same or different DC. For 
vaccinologists interested in PMDD technology, it demonstrates ways of steering the 
immune response to a desired outcome. These include simple procedures like manipulating 
the design of the delivery strategy to more complicated interventions like altering the 
plasmid construct to produce secreted or cell retained antigen. For a technology like PMDD 
which is currently struggling to reach the levels of efficacy required for prophylaxis and 
especially therapy, it is important to optimise these parameters.
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8.1. Introduction
The research performed in this thesis addresses issues surrounding PMDD on two different 
levels. Firstly, the development of an in vitro system incorporating PMDD as the means of 
plasmid delivery along with performing parallel in vivo/in vitro studies provided a means to 
dissect gene gun immunisation into its individual component parts. The comparative 
similarities and differences observed serve to highlight the technical aspects of the 
technology which contribute to the overall efficacy of the delivery system in vivo. 
Secondly, issues surrounding dual plasmid immunisation were assessed. The interactions 
between the immune responses formed by two different antigens following plasmid co­
delivery were investigated using different immunisation strategies. Insights into the nature 
of these immune interactions and the mechanisms of regulation are provided. The impact of 
this work on the design of future vaccine strategies is discussed.
8.2. Technical aspects of particle mediated-DNA delivery and in vivo implications
8.2.1. Requirement for improved transfection efficiency
Many investigators have cited the need for improved DNA vaccine potency in prophylactic 
or therapeutic models (Reyes-Sandoval and Ertl, 2001). Related to this requirement is the 
need for an increased level of transfection in vivo after PMDD. Evaluation of the 
parameters associated with PMDD in vitro (see chapter 3) suggests that mostly, it is the 
intrinsic transfectability of the cell itself which dictates transfection efficiency of the target. 
The effect of many different ballistic variables on transfection efficiency was examined and 
only the delivery pressure was observed to be of notable importance. This is consistent with 
the views of many investigators who report optimal delivery pressures varying from 100- 
1350 psi, depending on the cell line transfected (Novakovic et al., 1999; Murphy and 
Messer, 2001). Significantly, there was evidence of an interactive relationship between the 
different ballistic variables for each cell line examined. These findings are similar to those 
of other investigators (Klein et al., 1987; Heiser et al., 1994) and serve to reinforce the need
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for these conditions to be empirically defined for each device used and each cell line 
transfected.
The general rules which govern PMDD in vitro can be extrapolated to the in vivo delivery 
of DNA. Intra-dermal gene gun delivery results in the transfection of both somatic 
bystander cells and the resident DCs in the skin, the Langherhans cells. The preponderance 
of reports suggests that the direct inoculation of the latter is the predominant mechanism 
which leads to DC antigen loading and immune response induction (Timares et al., 2003; 
Porgador et al. 1998). However, only a small number of DCs are present in the transfected 
area of skin and consequently, the majority of cells transfected are bystander keratinocytes. 
This leads to the type 2 profile commonly associated with gene gun vaccination (Feltquate 
et a l , 1997). In order to increase the number of directly transfected DC, many strategies 
have been employed to improve targeting to or increase expression within DCs as outlined 
in section 1.4.1.5. Indeed, some of these approaches such as the use of the DC specific 
fascin gene promoter have resulted in the propagation of type 1 immunity characterised by 
IFN-y producing Th cells and the production of IgG2a antibodies (Sudowe et a l, 2003). 
Combining strategies that focus transgene expression and antigen production within DC 
with PMDD transfection conditions which are specifically optimal for DC would further 
enhance CD8+ T cell mediated immunity. Although, PMDD transfection of murine BMDC 
in vitro was not successful in these studies, there is much evidence supporting direct 
inoculation to murine or human DC in vivo (Condon et a l, 1996; Larregina et a l, 2001). 
Indeed, DC specific promoters in conjunction with reporter genes may be directly 
employed to elucidate the optimal conditions for PMDD to such cells in situ.
8.2.2. Impact of antigen dose
The role of antigen dose in shaping the immune response was investigated by firstly 
varying the DNA dose administered and secondly by varying the amount of protein 
transcription in the context of a constant DNA plasmid dose. Although the in vitro analysis 
is limited by lack of sensitivity, both the immunisation and promoter dose response studies 
presented in chapter 5 (co-delivery of pVACl.NT and empty plasmid) demonstrated a
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broadly positive correlation between level of antigen presented and activity of the 
responding CD8+ T cell line. This data is consistent with the in vivo immunisation dose 
response curves (under conditions of single and dual immunisation), especially the post 
primary data and with the findings of other groups who investigated this relationship in 
vitro (Pihlgren et al., 1996) and in vivo (Murata et al., 1996; Kundig et al., 1996).
The correlation observed in the in vitro promoter dose studies is in agreement with 
investigators who have addressed the role of antigen dose in vivo. By employing a 
recombinant vaccinia virus system which generated a wide range of OVA SIINFEKL 
surface epitope expression, Wherry and colleagues assessed the influence of antigen density 
(during primary immunisation) on CD8+ T cell priming (1999) and on the magnitude of the 
memory response (2002). In both studies, the level of antigen density was observed to be 
proportional to the CD8+ T cell response. Interestingly in both cases, this relationship 
broke down when excessive levels of epitope were presented (~6 x 104 epitopes/cell). 
Likewise, Bullock et al. (2000) obtained similar results following immunisation of mice 
with DCs presenting different densities of epitopes derived from human tyrosinase and 
glycoprotein 100. Again, the magnitude of the responding CD8+ T cell population was 
greatest when a less than maximal antigen density was used for activation.
However, there are certain characteristics of the in vivo antigen dose response that the in 
vitro assay fails to represent. For example, the immunisation dose response curves 
described in chapter 5 exhibits a linear type relationship at the PP time-points and at day 7 
PB. At day 14 PB, this shifts to a predominately threshold type profile. This change may be 
explained by epitope density based selection of high affinity T cells in the memory 
response. Bullock et al. (2003) demonstrated that variations in cell surface epitope density 
led to the generation of CD8+ T cells with different avidities. At lower epitope densities, 
antigen specific T cells with higher TcR affinities were preferentially selected. Others have 
also documented a reciprocal relationship between the magnitude of the responding 
population and TcR avidity with changing antigen levels (Wherry et al., 2003). Although 
TcR affinity was not measured in vivo or in vitro in the present study, the threshold type 
curve obtained at the final PB time-point may be representative of a qualitatively
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heterogeneous response where the avidity of the responding population generated at lower 
antigen levels compensates for lack of magnitude obtained when greater levels of antigen 
are available for presentation. One prediction of this model would be that higher levels of 
antigen would allow more low avidity T cells to enter into the response and therefore 
encourage a higher degree of intraclonal competition. In contrast, T cells with high affinity 
TcR created as a consequence of low level antigen expression would be much more 
dominant in their inhibition of other antigenic specific T cells allowing only high avidity T 
cells to preferentially expand into an effector population.
Alternatively, a much simpler but less likely explanation may be that there is a finite 
resource of cytokines and growth factors available in the immune micro-environment to 
support an immune response. Following delivery of a single plasmid, the resulting CD8+ T 
cell population expands until this supply becomes exhausted. The response obtained at 
lower antigen levels may represent CD8+ T cells which have undergone more divisions 
than cells stimulated by a higher antigen dose. While this reasoning fits well with the data 
of Pertmer et al. (1995), it does not explain why the antigen dose-response curves are 
relatively linear at the PP and day 7 PB time-points. Irrespective of the mechanism 
responsible, the apparent similarities and differences between the in vitro and in vivo data 
suggest that the antigen dose-response relationship under conditions of single plasmid 
immunisation is not always linear. Importantly for gene gun delivered DNA vaccines, there 
may be an optimal antigen density that results in the generation of a quantitatively and 
qualitatively effective immune response.
8.2.3. Does intracellular antigenic competition occur in vivol
There are many factors which may contribute to antigenic competition within the APC in 
vivo. Eggers et al. (1995) and Niedermann et al. (1996) demonstrated the dependency of 
epitope generation on the cleavage preference of the proteasome. Levitsky and colleagues 
(1997) documented a role for mechanisms involved in transport of immunogenic peptides 
to the cell surface. Additionally, there is also evidence that the peptide affinity for MHC 
class I (Chen et a l, 1994; van der Most et al., 1996) and stability of these complexes
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(Levitsky et al., 1996) influences the immunodominance of certain peptide antigens and 
subsequently the resulting T cell response.
The in vitro results presented in chapter 6 suggested that the presence of the OVA plasmid 
had no effect on the magnitude or sensitivity of the NT response, irrespective of whether 
the OVA was retained in the cell in which it was synthesised or whether it was secreted. 
Consistent with this was the finding that the lowest dose of plasmid capable of eliciting an 
NT specific response in single and dual immunisations in vivo was the same (0.5 ng). 
Additionally, evidence from the in vivo co-immunisation studies (see chapter 7) indicated a 
requirement for more than one immunisation for OVA suppression of NT. Under 
conditions of pre-existing OVA immunity, a second dose of OVA led to a large reduction 
or total abrogation of the NT response. When a pre-existing NT response was present, a 
single dose of OVA had no effect on the NT response. Collectively, these data suggest that 
in the present system at least, intracellular antigenic competition is not functionally 
important and the source of antigenic competition happens at the T cell level (see section 
8.3). This hypothesis is in agreement with Wolpert et al. (1998) and Grufman et al. 
(1999b), both of whom attribute interactions between the responding T cell populations and 
not APC associated mechanisms as the cause of interclonal competition. From a vaccine 
perspective, this is an important observation and lends support to the approach of delivering 
multiple plasmid vectors (especially co-delivery of plasmids encoding molecular adjuvants 
such as IL-2, EL-12 or GM-CSF with the plasmid encoding the antigen of interest) as a 
feasible vaccination strategy.
8.2.4. Professional and non professional cells present epitopes differently
The disparities observed in vitro and in vivo throughout this work may in part be due to the 
differential processing and presentation of the NT immunodominant epitope (D restricted 
ASNENMDAM peptide) by a fibroblast cell line in vitro and DCs in vivo. Of special 
relevance to this work is the research by Butz and Bevan (1998b) who investigated the 
presentation of Db LCMV peptides by MC57 cells and a DC line (JawsII). They found that 
when virus infected MC57 cells were used to re-stimulate spleen cells, the responding CTL
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lines failed to react to the two Db restricted immunodominant epitopes but was lytic for 
targets expressing the normally subdominant epitope. In contrast, LCMV infected JawsII 
cells stimulated CTL lines reactive against the immunodominant but not subdominant 
epitopes. Together, the data suggested that different cell types process protein in 
quantitatively different ways. This difference was ascribed to either a deficiency in 
proteolytic activities within MC57s resulting in a much reduced level of immunodominant 
epitope generation and/or the presence of mechanisms favouring the processing of the 
subdominant epitope. Heterogeneity of antigen processing and presentation to CD4+ T 
cells by different presenting cell lines was also reported in the hen egg-white lysozyme 
model (Gapin et al., 1998). Moreover, others have demonstrated that the same antigen can 
be processed differently by two genetically identical antigen-presenting cell lines (Michalek 
et al., 1989).
The possibility that there are differences in NT protein processing between MC57s in vitro 
and professional APC in vivo would partially explain the lack of sensitivity of the RAG1.F5 
splenocytes in vitro. Arguing against this hypothesis however is the similar APCrcytokine 
spot ratios obtained when PMDD transfected and peptide pulsed MC57s were compared 
(see chapter 4) which suggest that this cell line is relatively proficient at peptide processing 
and presentation. Irrespective of whether or not there is a problem with presentation of 
immunodominant epitopes within MC57s, it does highlight an important mechanism in vivo 
which delivery of DNA vaccines by gene gun can exploit. While DC play an important role 
in focusing the immune response towards a few select epitopes, peptide presentation by a 
variety of APC types ensures priming of CTL against subdominant epitopes. This leads to a 
more diverse T cell repertoire important in the elimination of chronic infection (van der 
Most et al., 1996). Gene gun delivery of plasmid which results in multiple cell types 
transfected provides an opportunity to avail of this immune mechanism.
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8.2.5. Limitations of the in vitro model
The main limitation of the in vitro model was lack of sensitivity. This was especially 
evident from the dose response studies where the sensitivity was -100 fold less than that 
obtained in vivo. This large difference may be attributed to a number of factors associated 
with either the presenting or responding cells used. One explanation may be the differential 
processing capabilities of MC57 cells and APC in vivo as noted previously. Alternatively, 
fibroblasts as non professional presenting cells possess no co-stimulatory molecules which 
are not only important for T cell priming but also play a role in the maintenance of a highly 
effective memory response (Ludewig et al., 1999). The requirement for co-stimulatory 
molecules may be critical in this in vitro model considering the absence of CD4+ T cell 
help as well as the usual compliment of cytokines and growth factors normally available in 
vivo.
The relative lack of sensitivity in vitro may be a consequence of the culturing process used 
to generate the responder CD8+ T cell population. There is the possibility that the 
concentration of peptide used for stimulation and the time interval of stimulation during the 
culturing process was too high and sub-optimal, respectively (500 nM peptide for 7 days). 
Alexander-Miller and colleagues (1996) demonstrated that, in vitro, culturing cells in high 
concentrations of peptide resulted in low avidity CTLs with much reduced lytic capacity in 
vivo. Moreover, the same author showed that such populations were more susceptible to 
AICD by TNF-a receptor II mediated apoptosis (Alexander-Miller et al., 1998). Defining 
the peptide concentration that is too high or that is optimal for high avidity CTL generation 
is an empirical exercise specific to each CTL line. Presumably, it is dependent on factors 
such as peptide affinity for MHC I and the diversity of the T cell repertoire from which the 
CTL is derived. Because, activated T cells from the RAG1.F5 transgenics were used as 
responders in the in vitro studies, the culturing conditions used should not have affected the 
avidity of these cells. However, these conditions may have contributed to the production of 
less responsive RAG1.F5 T cells which would help explain the lack of sensitivity of the in 
vitro model. Indeed, it is most likely that the sensitivity issues associated with the in vitro 
model are due to most or all of the shortcomings discussed.
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Overall, the in vitro model proved to be relatively limited in its ability to predict in vivo 
responses. The data from the single and dual immunisation dose correlation studies 
indicated that the in vitro model was useful in determining the early stage primary response 
in vivo. After boost however, this relationship deteriorated. These results provide an insight 
into the differing factors which influence the in vivo immune response at the different 
stages. Early on in the immune response, the most important factor which affects the 
expansion of the naive NT specific CD8+ population is the level of antigen presented to 
these cells by APCs. Therefore, it is not surprising to find that the in vivo response is most 
analogous to the in vitro model at this stage as the latter is a two cell system responsive 
mostly to the level of antigen administered.
After boost, the in vivo response is influenced by both the quantity of antigen presented and 
the quality of the recall response generated during priming. It is characterised by the 
maturation of the memory response which selects for high avidity T cells. Additionally, due 
to the presence of competitive interactions at the T cell level (especially under conditions of 
dual plasmid immunisation), the NT response may be operating under limiting conditions. 
The poor correlations obtained when the in vitro and the PB in vivo data are compared 
(following single plasmid immunisation) are a reflection of the shift from the mechanisms 
that dominate the primary response to those that dictate the memory response in vivo and 
the failure of the in vitro model to account for these. In order to generate an in vitro assay 
which is more representative of the primary and secondary phases of the immune response 
in vivo, the minimal requirement would be the use of professional APCs together with 
CD4+ T cell help and a source of cytokines for T cell activation and proliferation. Issues 
such as intracellular competition and the effect of T cell avidity on interclonal T cell 
competition may be investigated more appropriately if T cell specific for the second 
immunodominant peptide (i.e. SIINFEKL) was also evaluated.
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83. Interclonal competition is functionally relevant in dual plasmid immunisation
Because the number of T cells in the mammalian immune system at any one time increases 
due to ongoing production of new cells from the thymus or expansion during infection, 
there are an array of homeostatic mechanisms which maintain the sizes of the overall naive 
and memory T cell repertoires at a constant level. Such control mechanisms exist at many 
different levels and stages of the T cell lifecycle and help to guard against the onset of auto­
immune diseases and the generation of excessive responses to foreign antigens which may 
result in immune pathology. For example, CD8+ memory cell turnover is predominately 
governed by cytokines such as the positive contribution of IL-15 (Fehniger et al., 2001) and 
EL-7 (Schluns et a l , 2000) and the negative impact of EL-2 (Ku et al., 2000) and IFN-a 
(Varga et al., 2001). Following encounter with antigen, the expansion of CD8+ effector 
cells are kept in balance by a number of mechanisms. These include T cell deletion 
(Critchfield et al., 1994), anergy induction following suboptimal activation (Mondino et al.,
1996) and effect of inhibitory receptors such as CTLA-4 (Doyle et al., 2001). In addition, 
the T cell response is further regulated by the competitive actions of the T cells themselves 
(Troy and Shen, 2003). Proliferating cells may compete with each other by direct inhibition 
of neighbouring cells (Kedl et al., 2002) or by competition for limiting resources such as 
growth factors and cytokines (Ge et al., 2004).
In chapters 6 and 7, the nature of the interaction between CD8+ T cells of different 
specificity was investigated following dual plasmid immunisation. Under the immunisation 
conditions used, this interaction was found to be predominately competitive. The results 
obtained highlight important aspects of dual or multi-plasmid immunisation which may 
underpin vaccine efficacy in vivo.
8.3.1. Competition occurs at the T cell level
There was no evidence to indicate that the suppression of the NT response by OVA was as 
a consequence of antigenic competition within the APC. In contrast, there were many lines 
of evidence which pointed towards the T cell level as the source of competition. These
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findings are in agreement with many investigators who have studied both intraclonal and 
interclonal T cell competition (Sandberg et al, 1998; Grufman et a l, 1999a). Indeed, the 
mechanisms responsible for intraclonal T cell competition have been documented 
comprehensively. Early observations from host versus graft responses to MHC antigens 
(Clark et a l, 1981) through to more recent studies using both viral (Butz and Bevan, 
1998a) and non-viral (Kedl et a l, 2002) models implicate the T cell-APC interface as the 
zone in which competition takes place. Many investigators have demonstrated that the 
simple expedient of introducing more antigen expressing APC results in the reduction of 
intraclonal competition effects (Wolpert et a l, 1998; Sandberg et a l, 1998). Competition of 
this kind is orchestrated by the T cells with the highest affinity for the MHC-peptide 
complex. As discussed in chapter 7, these cells may inhibit the response to other antigen 
specific T cells by a number of mechanisms including APC killing (Grufman et al, 1999a) 
or down-regulation (Kedl et a l, 2002) or internalization of antigen (Huang et a l, 1999) 
from the APC surface. Irrespective of the means by which competition occurs, the end 
result is that low affinity T cells are effectively starved of the appropriate levels of antigen 
required for activation. In this respect, the occurrence of T cell affinity maturation may be 
regarded as a natural by-product of the process of intraclonal T cell competition.
Whether interclonal CD8+ T cell competition exists or not is uncertain. Chen and 
colleagues (2000c) demonstrated this phenomenon in an influenza model. This is further 
supported by the work of Kedl et a l  (2002) who observed competition between the CD8+ 
T cell responses to the dominant and subdominant ovalbumin epitopes following transfer of 
OT1 T cells. Other investigators however, have concluded that this type of competition 
does not exist (Butz and Bevan, 1998a; Probst et a l, 2002). This apparent contradiction 
suggests that interclonal CD8+ T cell competition may occur but only under certain 
experimental conditions and in specific experimental models. In the studies where 
interclonal competition has been observed, there is a requirement that both antigens are 
presented on the same APC. This is in agreement with the results from the experiments in 
which a pre-existing OVA response was created and in the prime-boost experiments. Both 
approaches demonstrated greater suppression of the CD8+ NT response by OVA CD8+ T 
cells when NT plasmid was co-delivered with plasmid encoding cell retained OVA
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compared with secreted OVA. In addition, the antigen linkage experiments also support this 
requirement. A prominent feature of all of the experiments in chapter 7 is that the NT 
CD8+ response was greatest when NT plasmid was delivered with empty plasmid 
compared with OVAs or OVAc plasmid (linked or unlinked). Collectively, this suggests 
that T cells of different specificity may not only compete for the limited space available at 
the T cell-DC interface but in the local environment surrounding the DC-T cell cluster for 
soluble factors such as EL-2, IL-7 and IL-15.
Although not examined in this study, the role of regulatory T cells in suppressing the 
activation and proliferation of the NT CD8+ response (and the OVA CD8+ response also) 
must also be considered. Many reports have demonstrated that depletion of this T cell 
subset results in much increased responses to foreign antigen. Suvas and colleagues (2003) 
showed that by removing CD4+ CD25+ T cells prior to HSV infection, the CD8+ T cell 
effector and memory response to the immunodominant peptide was increased by a factor of 
up to fourfold. The effect of CD4+ CD25+ T cells on the response to foreign antigen has 
also been observed in bacterial (Xu et al., 2003; Belkaid et al., 2002) and tumour models 
(Shimizu et al., 1999). Regulation may be mediated through the secretion of inhibitory 
cytokines such as IL-10 (Barrat et al., 2002) or TGF-(3 (Chen et a l, 1998). Their 
constitutive expression of CD25 allows these cells to compete effectively for IL-2 thus 
limiting the expansion of other antigen specific T cells. Additionally, CD4+ CD25+ T cells 
also express CTLA-4 allowing them to compete for co-stimulatory molecule engagement at 
the DC-T cell interface (Read etal., 2000). The latter mechanism may be a more significant 
issue in situations where intraclonal T cell competition is a feature of the immune response, 
while competition for IL-2 around the DC-T cell cluster may have more of a bearing on the 
competition between T cells of different antigen specificity. Regardless of the mechanisms 
responsible for interclonal T cell competition, the results from chapter 7 demonstrate that 
CD8+ T cell competition is functionally relevant and can occur even when standard 
vaccination strategies such as a PMDD prime-boost approach are employed.
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8.3.2. Importance of TcR avidity
Data from the OVA dose response and antigen linkage experiments suggest that the OVA 
response may have a competitive advantage over the NT response due to the greater affinity 
of the OVA TcR for MHC/peptide than the NT TcR. This hypothesis gains support from a 
number of sources who have demonstrated the link between TcR affinity and efficacy of 
the resulting response. Using MHC I tetramers to stain CD8+ T cells specific to an 
immunodominant L.monocy to genes peptide, Busch and Palmer (1999) were the first group 
to show that the affinity of T cells for antigen increases with the number of rounds of 
expansion in vivo. Similar results were obtained by Savage et al. (1999) who revealed a 
narrowing of the T cell repertoire in the secondary response compared with the primary 
response and linked this to the selective loss of T cells which dissociated most rapidly from 
the MHC/peptide complex. The dominance of influenza specific CD8+ T cells was 
attributed to their greater affinity for antigen in humans (Lawson et al., 2001). This effect 
was also observed by Rees et al. (1999) with CD4+ T cells. Interestingly, in the latter 
study, the authors demonstrated an inverse relationship between T cell affinity and antigen 
dose (i.e. the lower the dose, the higher the affinity) in the secondary but not primary 
phases of the response.
While the relationship between the competitive ability of a T cell and its dependence on 
affinity for antigen has direct implications for intraclonal T cell competition, it may also 
impact on interclonal T cell competition. Although Kedl et al. (2002) observed interclonal 
T cell competition between high affinity transferred OT1 T cells and endogenous T cells of 
a different specificity, they observed this phenomenon to be much less efficient and require 
almost a log more transferred cells than was needed to demonstrate intraclonal competition. 
These findings may provide an explanation for the effect observed in the OVA dose 
response study in chapter 7 where OVA suppression occurred when less OVA than NT 
encoding plasmid was delivered. If so, it is possible that T cell avidity has functional 
implications in modulating the quality and quantity of the immune response to different 
antigens following dual plasmid immunisation.
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8.4. Lessons for future vaccination strategies
The results from the human PMDD vaccine trials performed to date (see section 1.4.1.8) 
portend a technology which is likely to struggle to reach the levels of efficacy required to 
confer prophylactic or therapeutic protection. The work presented in this thesis highlights 
aspects of PMDD that may be exploited in order to increase chances of a successful 
vaccination strategy. Initially, consideration must be given to the type of immune response 
that is required for protection or clearance of a particular pathogen before designing an 
appropriate vaccine strategy. Induction of the incorrect type of immunity (type 1 versus 
type 2) could lead to an exacerbation of pathogenesis which is undesirable. Delivering the 
appropriate antigen in a manner which modulates the response towards the desired 
phenotype is important. The inherent ability of PMDD to transfect many different cell types 
in vivo provides the means to launch cellular and humoral immunity simultaneously. If 
there is a specific requirement for a type 1 response, then targeting the class I pathway by 
using optimal PMDD conditions for DC transfection as well as DC specific promoters may 
be used. As previously discussed, defining the optimal balance between antigen dose and T 
cell avidity is critical for developing vaccine approaches which selectively induce high 
affinity T cells.
Important consideration must also be given to the role of interclonal T cell competition in 
the development of vaccine strategies. The research performed here suggests that 
competition of this nature has functional relevance following dual plasmid immunisation. 
Consistent with other investigators, the data also suggests a requirement of T cell 
competition for co-expression of epitopes on the same antigen presenting cell (Rodriguez et 
a l , 2002; Kedl et al., 2002). The natural bias of an immune response for a relatively small 
number of immunodominant epitopes may be alleviated by the simple expedient of 
separating the plasmids encoding the different antigens or epitopes onto different gold 
beads. This would allow for greater dispersal of epitopes amongst available APC and 
restrict competition to non specific components of the immune response such as access to 
cytokines and growth factors. This may benefit many different types of DNA vaccine
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approaches but presumably is of particular relevance to multivalent or polyepitope 
vaccines.
An alternative approach would be delivery of the antigens responsible for the dominant and 
subdominant epitopes in separate immunisation phases. This idea is not only supported by 
the results in chapter 7 (i.e. experiments in which a pre-existing OVA or NT response was 
created) but also by the findings of many other groups (Schirmbeck et al., 2002; Santra et 
al., 2002). Palmowski and colleagues (2002) demonstrated that a pre-existing response to 
one of the immunodominant epitopes encoded in the polyepitope vaccine dominated the 
CTL response to the other epitopes in subsequent immunisations. Moreover the same 
author also showed that a broad CTL response could be achieved by restricting the use of 
polyvalent constmcts to the initial immunisation and using separate constructs for 
subsequent boosting. Furthermore, pre-immunisation with a subdominant antigen can 
greatly reduce the response to an otherwise immunodominant dominant antigen 
(Schirmbeck et al., 2002). These approaches provide evidence that there are tangible ways 
of effectively counteracting the contribution of interclonal T cell competition, if necessary.
PMDD is an attractive approach for generating antigen specific immunotherapy. Indeed, it 
may at some point in the future prove to be the most effective method for conferring 
prophylactic or therapeutic protection in man. Before this happens, a number of important 
issues such as optimisation of potency, co-induction of systemic and mucosal immunity, 
plasmid design and appropriate delivery regimens have to be optimised for the pathogen in 
question. Fortunately, DNA vaccines are safe with no evidence for significant levels of host 
genome integration. Furthermore, they are relatively inexpensive to manufacture. The rapid 
progression of PMDD vaccination from its inception just over a decade ago to its current 
place in human clinical trials provides hope that this technology can play a decisive role in 
the prevention and treatment of a wide range of human diseases.
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